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A proteomic and genomic investigation into the role of lamin A 
in colorectal cancer cell motility - Clare Ruth Foster 
 
Lamins are type V intermediate filament proteins found at the nuclear envelope. Expression 
of lamin A in colorectal cancer (CRC) tumours is correlated with poor prognosis and 
expression of lamin A in CRC cell lines promotes greatly increased cell motility. The aim of 
this study was to identify proteins that promote cell motility in response to lamin A 
expression and to investigate lamin A regulated changes in gene/protein expression and 
cytoskeletal organisation that might underpin the increased cell motility. 
The effects of lamin A expression were studied using quantitative proteomic and genomic 
methods using cells from the colorectal cancer cell line SW480 which had been transfected 
with GFP-lamin A (SW480/lamA) or GFP as a control (SW480/cntl). A biochemical 
fractionation technique was optimised for the preparation of cytoskeletal fractions which 
were analysed by 2D DIGE (2D difference in-gel electrophoresis) to reveal accurate and 
reproducible changes in the representation of proteins within the cytoskeleton in 
SW480/lamA cells compared to controls. The majority of proteins identified were either 
components of the actin/intermediate filament cytoskeleton, protein chaperones or 
translation initiation/elongation factors. Interestingly, tissue transglutaminase 2, a protein 
which modifies elements of the cytoskeleton and is associated with cancer progression, was 
highly over-represented in the cytoskeleton fraction of SW480/lamA cells.  
Ingenuity Pathway Analysis was used to analyse genome-wide Affymetrix microarray 
analysis of SW480/cntl and SW480/lamA cell lines. A highly significant interaction network 
was identified which clustered together genes linked to cancer, cellular movement and 
cellular growth and proliferation. Epithelial markers such as CDH1 were down-regulated and 
mesenchymal markers such as FN1 were up-regulated in cells expressing GFP-lamin A, 
which suggested that lamin A over-expression may lead to an epithelial-mesenchymal 
transition (EMT). As A-type lamins are known to modulate downstream effects of TGFβ 
signalling, and TGFβ is an inducer of EMT, changes in genes involved in TGFβ signalling were 
investigated. Knockdown of lamin A using siRNA led to decreased expression of TGFBI and 
SNAI2 followed by reduced cell motility. 
The data suggest that expression of lamin A in CRC cells causes changes in the organisation 
of the actin cytoskeleton and in TGFβ signalling, potentially involving an epithelial to 
mesenchymal transition, leading to increased cell motility and an increased risk of death 
from cancer. 
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CHAPTER ONE   
Introduction 
1.1. Colorectal cancer  
The word cancer originated with the Greek physician Hippocrates (460-370BC), who 
referred to tumours as karkinos, the Greek word for crab, which translates into Latin as 
cancer. Hippocrates believed that cancer was caused by an excess of black bile, and this 
belief was commonplace for over a thousand years. It was subsequently thought that 
cancer was caused by abnormalities in the lymphatic system, chromic irritation or trauma. 
In the past century there have been vast improvements in our knowledge of tumour 
development, which we now understand involves a series of genetic changes causing a 
normal cell to become cancerous. In their seminal paper, Hanahan and Weinberg described 
the six hallmarks of cancer that describe the properties of most, if not all, malignant cells: 
self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion and 
metastasis, limitless replicative potential, sustained angiogenesis and the evasion of 
apoptosis (Hanahan and Weinberg, 2000). In 2011, Hanahan and Weinberg added two 
further hallmarks to this list: the preprogramming of energy metabolism and the evasion of 
immune destruction (Hanahan and Weinberg, 2011). 
Worldwide, the most commonly diagnosed cancers are lung cancer (1.61 million cases), 
breast cancer (1.38 million cases) and colorectal cancer (CRC) (1.23 million cases) (Ferlay et 
al., 2010b). CRC is the second most common cancer in females and the third most common 
cancer in males. Men are more likely to develop CRC than women; the overall sex ratio of 
the age standardised rates is 1.4:1 (Ferlay et al., 2010b). Incidence rates vary in different 
countries, with 60% of CRC occurring in developed regions, and countries that have 
experienced a rise in prosperity, such as Japan, have shown increased rates of CRC (Key, 
2002). The highest rates of CRC are in Western Europe and Australia/New Zealand, and the 
lowest rates are in Africa (excluding Southern Africa) and South-Central Asia (Figure 1.1) 
(Ferlay et al., 2010b).  
CRC is the fourth most common cause of cancer deaths worldwide.  Mortality rates are 
generally lower in women compared to men and are highest in Central and Eastern Europe 
(20.3 per 100,000 males and 12.1 per 100,000 females) and lowest in Middle Africa (3.5 per 
100,000 males and 2.7 per 100,000 females) (Ferlay et al., 2010b). In the UK, deaths from 
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CRC decreased between 1995-2008 from 27.5 to 21.9 per 100,000 population in men and 
18.8 to 14.4 per 100,000 population in women (Bray et al., 2002; Ferlay et al., 2010a). 5 year 
survival in England increased from 44.8% (males) and 46.6% (females) in 1990-1994 to 
51.8% (males and females combined) in 2000-2002 (Sant et al., 2003; Verdecchia et al., 
2007). The increased survival rates are thought to be due to improvements in treatment, 
diagnosis and knowledge of cancer genetics (Sant et al., 2003; Schurer and Kanavos, 2010; 
Sengupta et al., 2008). Rates of CRC survival vary across England, with a 6% difference 
between areas with the highest and lowest 5 year survival rates, compared to only a 3% 
range for breast cancer, which may be due to differences in service delivery, stage at 
diagnosis, communication issues or cultural differences (Charatan, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Estimated age-standardised incidence and mortality rates (per 100,000 
population) for CRC (adapted from Ferlay et al., 2010b)   
1.1.1. Hereditary CRC  
CRC exists in a sporadic form and in inherited forms such as familial adenomatous polyposis 
(FAP), hereditary nonpolyposis CRC (HNPCC) and hamartomatous polyposis syndromes. 
Sporadic CRC accounts for approximately 75% of all CRC cases and mostly arises in those 
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aged 60 years or above as it is the result of accumulation of genetic alterations. Young-
onset CRC is usually linked to familial syndromes and genetic predisposition. The lifetime 
risk of those over 50 with no personal or family history of CRC is 5-6%; in those with 
first/second degree relatives with CRC, this can increase to 20%; and in those with 
hereditary CRC syndromes the lifetime risk is 80-100% (Rustgi, 2007).  
HNPCC, also known as Lynch syndrome, is an autosomal dominant condition which causes 
2-5% of CRCs and is a genetically heterogeneous disease (Fearon, 2011). Patients have 
germline mutations in DNA mismatch repair (MMR) genes, with the majority of known 
HNPCC mutations being found in the genes MSH2 and MLH1. Tumours from HNPCC patients 
also often contain alterations in microsatellite sequences, a condition known as 
microsatellite instability (MSI). There is a more rapid transition from adenomatous lesion to 
carcinoma compared to sporadic cancers, as affected cells accumulate mutations swiftly 
due to the impaired DNA repair mechanism. HNPCC patients have an 80% lifetime risk of 
developing CRC, and have often developed tumours by the age of 40. HNPCC also increases 
the risk of other cancers such as gastric, ovarian, endometrial, renal and hepatobiliary 
cancers. 
FAP is also an autosomal dominant syndrome which causes 0.5-1% of CRCs and affects 
approximately 1 in 10,000 births (Fearon, 2011; Lipton and Tomlinson, 2006; Rustgi, 2007). 
Germline mutations in APC, typically frameshift or nonsense mutations, lead to premature 
truncation of protein synthesis. FAP is characterised by hundreds to thousands of adenomas 
in the colon and rectum which usually start to appear in the patient’s second decade of life. 
It is almost certain that one of the polyps will transform into CRC by the time the patient 
reaches the age of 40.  Hence, endoscopic screening from the age of 10 is recommended, 
and typical treatment for FAP involves the removal of the colon. 
Other conditions which increase CRC risk include hamartomatous polyposis syndromes, 
comprising a number of different syndromes which predispose the patient to developing 
hamartomatous polyps, ulcerative colitis and Crohn’s disease.  
1.1.2. Risk Factors  
Many cases of CRC are caused by environmental factors, and incidence rates could decrease 
if changes were made to diet and lifestyle (WCRF/AICR, 2007). A recent World Cancer 
Research Fund/American Institute for Cancer Research (WCRF/AICR) continuous update 
report examined the effects of diet and physical activity on CRC risk, based on a systematic 
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review of over 1000 papers (Norat, 2010; WCRF/AICR, 2011). They reported that there is 
‘convincing’ evidence that regular physical activity and consumption of food containing 
dietary fibre decrease the risk of colon cancer, and that consumption of red and processed 
meat, excess body fatness, abdominal fatness and the factors that lead to greater adult 
attained height, or its consequences, increase the risk of CRC (Norat, 2010; WCRF/AICR, 
2011). The evidence also showed that it was ‘probable’ that foods containing garlic, milk 
and calcium decrease the risk of CRC. 
1.1.2.1. Factors that decrease the risk of CRC  
There is strong evidence that physical activity reduces the risk of colon cancer, however 
there is no conclusive evidence for an effect of physical activity on rectal cancer (Norat, 
2010; WCRF/AICR, 2011). The mechanisms by which physical activity decreases the risk of 
colon cancer are currently unknown. However, several ideas have been suggested, involving 
gut transit time, immune function, chronic inflammation, levels of insulin and insulin-like 
growth factors, genetics and obesity (Harriss et al., 2007).  
The finding that fibre intake decreases CRC risk was first shown in the 1970s (Burkitt, 1971). 
There are a number of theories which may explain the protective effect of dietary fibre. It is 
thought that the physical properties of fibre may be important including its absorption of 
water as it passes through the digestive system. Also, the fermentation of fibre by the 
colonic microflora can produce butyrate, which is known to stimulate apoptosis (Avivi-
Green et al., 2000; Hague et al., 1993).  
It is probable that consumption of foods containing garlic reduces the risk of CRC (Norat, 
2010; WCRF/AICR, 2011). Garlic contains allyl sulphur compounds, which can protect 
against cancer via a number of different mechanisms, including inhibition of carcinogen-
induced DNA adduct formation, blocking cellular growth, proliferation and angiogenesis, 
inducing differentiation and apoptosis and enhancing carcinogen-detoxifying enzymes (Ngo 
et al., 2007). Garlic also contains kaempferol, selenium, vitamins A and C, arginine and 
fructooligosaccharides which protect against cancer (Ngo et al., 2007). It is also probable 
that milk and calcium consumption reduces the risk of CRC (Norat, 2010; WCRF/AICR, 2011). 
Calcium sequesters CRC-promoting bile acids in the colon and can induce differentiation, 
increase apoptosis and decrease proliferation of epithelial cells (Bernstein et al., 2005; 
Lupton et al., 1996; Whitfield et al., 1995). 
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Other factors which may reduce the risk of CRC include non-steroidal anti-inflammatory 
drugs (NSAIDs), hormone replacement therapy and estrogen. 
1.1.2.2. Factors that increase the risk of CRC  
There are many potential CRC risk factors including consumption of red/processed meat 
and alcohol, body and abdominal fatness, adult attained height, smoking, infectious agents, 
radiation, industrial chemicals, some medications and unsaturated fat. Some of the risk 
factors with the most convincing evidence are discussed below. 
There are several mechanisms by which consumption of red and processed meat may lead 
to CRC. High temperatures used during cooking of meat can result in the formation of 
heterocyclic amines, which are potent carcinogens (Sugimura et al., 2004). Processed meat, 
often defined as meat preserved by smoking, curing, salting or adding preservatives, often 
contains large amounts of salt, nitrite and nitrates. Degradation products of amino acids can 
react with nitrite and nitrate, forming N-nitroso compounds. Haem iron in the diet can also 
increase the amount of carcinogenic N-nitroso compounds and can lead to the production 
of free radicals (Cross et al., 2003; Nelson, 2001).  
High body and abdominal fatness increase the risk of CRC. Body fatness is commonly 
measured using the body mass index (BMI), however this is a crude measure of obesity and 
the pattern of fat distribution is thought to be more important in some circumstances. 
Abdominal fatness, measured by the waist circumference and/or waist to hip ratio, in 
particular increases insulin resistance (Despres, 1993), which can lead to increased insulin 
production and an increased risk of colon cancer (Trevisan et al., 2001).  Obesity in general 
stimulates the inflammatory response which can lead to cancer, as the adipose tissue of 
obese individuals recruits macrophages, which secrete pro-inflammatory signal molecules 
and cytokines (Fantuzzi, 2005). 
Adult attained height is associated with risk of several different cancers, with taller people 
being at increased risk (Gunnell et al., 2001). Height may act as a biomarker for another 
exposure, since it is dependent on many factors, including genetic influences, childhood 
diet/health/mental well being, the timing of puberty, circulating hormone levels and 
prenatal environmental factors (Gunnell et al., 2001). Height may also affect cancer risk as it 
is possible that the larger the number of cells in a body, the higher the chance of malignant 
transformation (Albanes and Winick, 1988).   
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There is also convincing evidence that consumption of alcohol increases risk of CRC in 
males, and it probably also increases risk in females (Norat, 2010; WCRF/AICR, 2011). This 
may be due to higher alcohol consumption in men compared to women, differences in 
choices of drink, hormone-related differences in alcohol metabolism or susceptibility to 
alcohol. Ethanol is carcinogenic as it can inhibit DNA methylation, interact with retinoid 
metabolites and produce toxic metabolites such as acetaldehyde (Seitz and Stickel, 2007). 
The link between smoking and lung cancer is well known. An association between CRC and 
smoking has been disputed, but a recent systematic review showed that both past and 
current smokers have increased risk of CRC (Liang et al., 2009). Cigarette smoke contains at 
least 80 mutagenic carcinogens and is a source of oxidative stress. Smoking can increase 
tumour growth by inducing angiogenesis and suppressing cell-mediated immunity (O'Byrne 
et al., 2000).  
1.1.3. Anatomy of the colon and rectum  
The colon is about 150cm long and it absorbs water and salts and propels unabsorbed 
faecal waste towards the rectum. It is divided into several different segments (Figure 1.2). 
The rectum is the terminal portion of the large intestine and serves as a temporary storage 
site for faeces. It is approximately 15 cm long.  
 
Figure 1.2: Anatomic subsites of the colon (Greene, 2002)  
Cancers arising on the left and the right side of the colon have different biological and 
clinical properties (Benedix et al., 2010; Bufill, 1990). Right sided tumours arise proximal to 
the splenic flexure (caecum, ascending colon, transverse colon), and left sided tumours 
originate distal to the splenic flexure (descending colon, sigmoid colon, rectum) (Figure 1.2). 
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Since the 1980s, the percentage of right-sided colon cancers (RCC) has been increasing, and 
the percentage of left-sided (LCC) and sigmoid colon cancers has been decreasing (Jass, 
1991; Levi et al., 1993; Meguid et al., 2008; Obrand and Gordon, 1998). The reason for this 
change is not known, although hypotheses include the effects of changes in screening, 
genetic/environmental epidemiology and an increasingly elderly population (Meguid et al., 
2008). RCCs are more common in women than in men, can cause pain, bleeding and 
anaemia and have a worse prognosis than LCCs (Benedix et al., 2010; Meguid et al., 2008).  
The intestinal wall comprises several layers (Figure 1.3): the mucosa (a simple columnar 
epithelium which forms millions of crypts), lamina propria (the basement membrane), 
muscularis mucosa (a thin layer of smooth muscle), submucosa (loose connective tissue), 
muscularis propria (containing circular and longitudinal smooth muscle), subserosa and 
serosa. 
 
Figure 1.3: Layers of the colon showing a tumour invading the submucosa (Greene, 2002) 
The mucosa consists of millions of crypts comprising goblet cells, columnar cells, endocrine 
cells and undifferentiated stem cells. Stem cells reside at the bottom of the crypt, where 
they can communicate with pericryptal myofibroblasts which are niche cells adjacent to the 
crypt (Figure 1.4). The stem cells are interspersed with CD24+ cells, thought to be the 
colonic equivalent of Paneth cells in the small intestine, which express signals needed for 
stem cell maintenance in culture (Sato et al., 2011).  Slightly higher up the crypt are the 
transit amplifying cells and committed progenitor cells. Cells undergo differentiation as they 
migrate from the base of the crypt towards the lumen. Epithelial cell turnover is rapid, and 
differentiated cells are shed at the surface of the colon.  
Over 95% of CRCs are adenocarcinomas, which originate in the mucosa, usually from benign 
growths or adenoma. Types of adenocarcinomas include mucinous tumours and signet ring 
8 
 
tumours, which are relatively rare. Other types of CRC including carcinoids, sarcomas and 
lymphomas are rarer and are treated differently to adenocarcinomas and squamous cells 
cancers. CRC as discussed in this thesis refers to adenocarcinomas. 
 
Figure 1.4: Anatomy of the colon crypt (adapted from Gatenby et al., 2010) – Stem cells and 
CD24+ cells at the base of the colonic crypt and differentiated cells at the top of the crypt are 
separated by transient amplifying/committed progenitor cells. 
 
1.1.4. Carcinogenesis 
In cancer, gene defects are either found in oncogenes, leading to increased or novel gene 
functions, or in tumour suppressor genes (TSGs), leading to loss of gene function. Both 
alleles of a TSG must be mutated for the gene to lose function – this is known as the two hit 
hypothesis (Knudson, 1971). Gene defects are found in many types of inherited and 
sporadic CRCs, although no germline oncogenic mutations have so far been discovered. 
Mutations in a small number of TSGs are found in many CRC cases.  
Carcinogenesis in the colon occurs when the balance between proliferation, differentiation, 
migration and apoptosis is lost, leading to hyperproliferation. Genetic alterations leading to 
CRC arise incrementally and occur stochastically, but accumulate in a non-random order. 
The classic model of colon cancer (Figure 1.5) shows a stepwise progression from adenoma 
to carcinoma (Fearon and Vogelstein, 1990).  
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Figure 1.5: Genetic model of colorectal carcinogenesis, adapted from Fearon and 
Vogelstein, 1990 (Pinto and Clevers, 2005) - Stepwise progression of CRC requires mutations 
in Wnt signalling pathway components for tumour initiation. Epigenetic events and mutations in 
genes such as K-ras and Smad4 are required for progression towards malignancy. 
The type of cells from which CRCs arise is still disputed. Some favour a ‘top down’ model in 
which tumours arise from dysplastic cells on the surface of the crypt and grow down into 
the crypt (Shih et al., 2001), whereas others prefer a ‘bottom up’ model in which tumours 
start in the stem cells at the base of the crypt (Preston et al., 2003). The presence of cancer 
stem cells (CSCs) has been reported in several subtypes of cancer, including colon (O'Brien 
et al., 2007), breast (Al-Hajj et al., 2003) and brain (Singh et al., 2004). The CSC model 
describes a hierarchical system in which only a small population of cancer cells, namely the 
CSCs, are able to initiate and maintain tumour growth. This contrasts with the stochastic 
theory in which every cancer cell is capable of initiating a tumour (Dick, 2003). CSCs 
maintain their aggressive properties as they are capable of self-renewal and differentiation 
(Dick, 2003).  
The classic model of CRC suggests that there are two main molecular pathways in CRC: 
chromosomal instability (CIN) and microsatellite instability (MIN), which have different 
pathological features. These pathways are also known as the ‘gatekeeper’ (CIN) and the 
‘caretaker’ (MIN) pathways (Kinzler and Vogelstein, 1996). CIN/gatekeeper pathway cancers 
account for most sporadic and FAP CRCs. The tumours contain chromosomal abnormalities 
including aneuploidy, inactivation of tumour suppressor genes (TSG) and loss of 
heterozygosity (LOH). This pathway features the disruption of genes that encode proteins 
which regulate growth such as APC, p53 and KRAS. MIN is involved in around 10-15% of 
sporadic CRCs and in most HNPCC cancers. These cancers demonstrate genetic or 
epigenetic abnormalities in DNA mismatch repair genes such as MMR genes. Alongside 
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mutations of the genes in the CIN pathway, mutations are found in genes such as TGFβIIR, 
IGF2R and BAX (Weitz et al., 2005). 
Some CRCs exhibit epigenetic changes, in addition to or instead of genetic abnormalities. An 
important epigenetic mechanism for CRC is widespread CpG island methylation, known as 
the CpG island methylator phenotype (CIMP) which involves hypermethylation of many 
tumour suppressor genes such as the MMR gene MLH1 (Curtin et al., 2011; Toyota, 1999). 
CIMP occurs in around 20-40% of CRCs and most cases of sporadic MIN feature CIMP 
silencing of MLH1 (Toyota, 1999).  
Vogelstein’s classic model of colon cancer (Figure 1.5) has been recently revised (Issa, 2008) 
to account for epigenetic changes and the finding that some CRCs exhibit neither CIN nor 
MIN (Georgiades et al., 1999). The new model (Figure 1.6) comprises three distinct 
pathways which display different clinicopathological features.  
 
 
Figure 1.6: Multiple pathways to CRC – adapted from Issa, 2008 - Sporadic CRC arises from 
at least three separate pathways. Pathway 2 is very heterogeneous and may arise from serrated 
as well as villous adenomas. It is not known whether or not the different pathways can originate 
in identical cells. 
Cancers arising from different pathways exhibit different prognoses and different responses 
to treatment. MSI tumours with no BRAF mutations have good prognoses whereas CIMP 
tumours with no MSI have poor prognoses (Issa, 2008). In the future, it may be possible to 
have a system of personalised therapy based on the molecular profile of the tumour; 
however the methods of detection of genetic/epigenetic alterations will have to be vastly 
improved before this can become a reality. 
1.1.4.1. APC and the canonical Wnt signalling pathway  
After the discovery that germline mutations in APC lead to FAP (Groden et al., 1991; Kinzler 
et al., 1991), somatic mutations in APC were shown to occur often in sporadic CRC (Powell 
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et al., 1992). 70-80% of sporadic CRCs contain inactivating APC mutations, most of which 
cause premature truncation of the APC protein. APC mutations are an early event in 
adenoma development (Powell et al., 1992). Mutations in other Wnt pathway components, 
such as CTNNB1 (encoding β-catenin) (Sparks et al., 1998), AXIN1 and AXIN2 (Salahshor and 
Woodgett, 2005) and TCF4 (Fukushima et al., 2001), are sometimes found in CRCs which 
lack APC mutations. 
APC is a negative regulator of Wnt signalling, as it can regulate the intracellular levels of β-
catenin (Munemitsu et al., 1995). In the absence of Wnt signalling, APC binds the scaffold 
protein Axin, promoting phosphorylation of β-catenin by casein kinase 1 and GSK3β. This 
targets β-catenin for ubiquitination and proteosomal degradation.  
In the canonical Wnt signalling pathway, when Wnt ligands are present, they interact with 
Frizzled and LRP5/6 co-receptor, inhibiting GSK3β and Axin. The APC-Axin complex is 
therefore disrupted and β-catenin cannot be marked for destruction. β-catenin then enters 
the nucleus, where is interacts with TCF/LEF transcription factors. This allows expression of 
Wnt target genes such as the proto-oncogenes CMYC and cyclin D1, growth factors such as 
FGF9 and FGF20 and Wnt pathway feedback regulators such as AXIN2 and Dickkopf-1. 
When APC is inactivated in cancer, β-catenin is no longer targeted for destruction, 
mimicking the constitutive activation of Wnt signalling. β-catenin can then complex with 
TCF/LEF transcription factors, turning on expression of Wnt target genes.  
Wnt/β-catenin signalling controls homeostasis of the crypt axis in the colon (Batlle et al., 
2002; van de Wetering et al., 2002). The TCF-4/β-catenin complex functions as a switch 
controlling proliferation versus differentiation. Proliferating crypt cells in normal tissue 
express genes known to be TCF-4/β-catenin target genes in CRC cells, whereas normal 
differentiated cells express genes repressed by TCF-4/β-catenin. There is also a gradient of 
β-catenin expression in the nucleus, which is low in cells at the base of the crypt, and high in 
cells at the top of the crypt (van de Wetering et al., 2002). 
1.1.4.2. Other genes involved in CRC carcinogenesis  
In a typical cancer it is thought that there are approximately 80 DNA mutations that alter 
amino acids, fewer than fifteen of which are likely to drive the initiation, progression or 
maintenance of the tumour (Wood et al., 2007). There are a small number of genes which 
are commonly mutated in CRC, known as ‘gene mountains’ and a much larger number of 
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genes which are mutated in a small proportion of tumours, known as ‘gene hills’.  Here, I 
discuss the genes which are most commonly mutated in CRC. 
KRAS, which encodes a member of the Ras family of small G proteins, is mutated in many 
cancers. Somatic mutations in KRAS are found in approximately 40% of CRCs and occur later 
in the development of CRCs than APC mutations (Fearon, 2011). Around 10% of <1cm 
adenomas contain KRAS mutations, compared to 50-60% of >1cm adenomas (Vogelstein et 
al., 1988). Somatic mutations in PIK3CA, the gene encoding the catalytic p110α subunit of 
PI3K, are found in 15-30% of CRCs (Samuels et al., 2004; Wood et al., 2007), leading to 
activation of PIK3CA activity (Carson et al., 2008). 20% of CRCs have somatic mutations 
inactivating FBXW7, a gene which encodes an F-box protein which regulates levels of cyclin 
E, c-Myc, c-Jun and Notch (Tan et al., 2008). This may therefore result in aberrant regulation 
of many different oncogenic proteins and pathways.  
p53 regulates genes which encode proteins with roles in promoting apoptosis, regulating 
cell cycle checkpoints and restricting angiogenesis. 75% of CRCs show LOH at 17p, the 
location of the p53 gene (Vogelstein et al., 1988). In the majority of tumours with 17p LOH, 
the other p53 allele is somatically mutated. Most p53 mutations are missense mutations, 
and some are nonsense and frameshift mutations (Fearon, 2011). As most adenomas lack 
mutations in p53 or 17p LOH, loss of p53 function is thought to be a late development in the 
adenoma-carcinoma transition (Baker et al., 1990). 
Other somatic mutations affect components of the TGFβ pathway. Over 70% of CRCs have 
LOH of 18q, which contains the genes for SMAD2 and SMAD4 (Vogelstein et al., 1988). 10-
15% of CRCs contain inactivating mutations in SMAD4, 5% of CRCs contain mutations in 
SMAD2 and 5% contain mutations in SMAD3 (Fearon, 2011; Wood et al., 2007). 25% of CRCs 
and more than 90% of MSI-high CRCs contain an inactivating mutation in TGFβIIR, which 
encodes the TGFβ type II receptor (Markowitz et al., 1995).  
1.1.5. Screening  
The aim of CRC screening is to detect cancer at an early stage when treatment is most 
effective. National screening programmes were introduced in England and Scotland 
between 2007 and 2010. Currently, individuals in England aged 60-74 and in Scotland aged 
50-74 are invited to take a Faecal Occult Blood test (FOBt) every two years, and people aged 
75+ can request a test kit. The FOBt is able to detect small amounts of blood in the stool. If 
the test is positive, patients are invited for further investigation, usually a colonoscopy. A 
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colonoscopy is used to diagnose CRC and polyps, which if present can be removed for 
further testing. The NHS is currently reviewing the evidence for the immunochemical FOBt 
(iFOBt), which can quantify the amount of blood present in a sample, and only identifies 
blood from the bowel. 
FOB screening is known to reduce the risk of dying from CRC (Scholefield et al., 2002) and a 
systematic review of four randomised control trials (Hardcastle et al., 1996; Kewenter et al., 
1994; Kronborg et al., 1996; Mandel et al., 1993), showed a 16% reduction in CRC mortality 
in populations offered screening and a 23% reduction in those actually screened (Towler et 
al., 1998).   
In April 2011, it was announced that the NHS bowel cancer screening programme would 
introduce flexible sigmoidoscopy screening over the next few years for those aged 55 and 
over. This procedure involves a visual examination of the rectum and sigmoid colon, in 
which two-thirds of CRC are located, using an endoscope. A recent study showed that 
flexible sigmoidoscopy screening reduces CRC incidence by 33% and mortality by 43% and 
that 489 people need to be screened to prevent one CRC death (Atkin et al., 2010).  
1.1.6. Classification  
The classification of cancer patients into different stages is used for several reasons: to give 
an indication of prognosis, to aid in planning the most effective course of treatment, to help 
evaluate the results of treatment and to facilitate information exchange and research into 
cancer. There are numerous staging systems in use for CRC but there is currently no general 
consensus on which system is the most appropriate for use. 
1.1.6.1. Dukes staging and modifications  
The earliest attempt at classification of CRC was the staging system of Cuthbert Dukes 
(Dukes, 1932). This consisted of three categories based on the extent of spread of the 
carcinoma and the involvement of local lymph nodes: 
A  Carcinoma is limited to the wall of the rectum, no extension into extrarectal tissues, 
no metastases in lymph nodes 
B Carcinoma has spread by direct continuity to the extrarectal tissues, no invasion of 
the regional lymph nodes 
C Metastases present in the regional lymph nodes 
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The Dukes system was based on observations of rectal cancers, however it was suggested 
that the system may be applied to all intestinal carcinomas (Dukes, 1932). Dukes stage C 
was later subdivided into C1 if only the regional lymph nodes contained metastases and C2 
if the apical lymph nodes contained metastases (Dukes, 1949; Dukes and Bussey, 1958).  
In 1949, the system was modified by Kirklin to include cancers of the colon (Kirklin et al., 
1949). Kirklin modified stage A to indicate tumours limited to the mucosa, and subdivided 
stage B into B1 (tumours extending into the muscularis propria) and B2 (tumours 
penetrating the muscularis propria). Stage C remained a single, non-divided stage. 
Later, in 1954, Astler and Coller extended Kirklin’s classification by separating Dukes C into 
C1 (tumour limited to the wall with positive lymph nodes) and C2 (tumour extending 
through all layers with positive lymph nodes) (Astler and Coller, 1954). Confusingly, these 
categories are not the same as Dukes’ C1 and C2 categories. The Astler and Coller system 
was further refined by Gunderson and Sosin in 1974, adding B3 (lesions adherent 
to/invading adjacent organs) and stage C3 (gross nodal disease with extension and invasion 
of adjacent organs) (Gunderson and Sosin, 1974). The system encompassing the 
modifications of the Dukes system described by Kirklin, Astler, Coller, Gunderson and Sosin 
is known at the Modified Astler Coller system (MAC).  
In 1967, Turnbull added a later stage to the Dukes classification, designated stage D, for 
patients with distant metastases or invasion of adjacent organs (Turnbull et al., 1967). 
Newland then further modified the system to include stages D1 (local tumour remaining 
after resection) and D2 (distant metastases) (Newland et al., 1981).  
The multitude of different modified Dukes classifications has led to difficulty comparing 
patients, especially given that authors often do not specify which system they are using 
(Raraty and Winstanley, 1998).  
1.1.6.2. TNM staging  
The American Joint Committee on Cancer (AJCC) system of classification for CRC uses the 
TNM (tumour-node-metastasis) system and is now in its seventh edition (Edge, 2009). TNM 
staging is widely used worldwide and is being continually improved based on new data 
(Gospodarowicz et al., 2004). The most recent edition of this staging system describes a 
total of nine stages for CRC (I, IIA, IIB, IIC, IIIA, IIIB, IIIC, IVA and IVB; Table 1.1). Patients are 
stratified using the depth of tumour penetration (T), number of positive lymph nodes (N) 
and extent of distant metastasis (M) (Table 1.2).  
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The TNM system is more detailed than the Dukes system, and takes into account more 
features of the cancer, which means patients can be compared more precisely. The TNM 
system can be used for preoperative clinical assessments, whereas Dukes staging is based 
on pathological findings following surgery (Dukes and Bussey, 1958; Eschrich et al., 2005). 
However, the Dukes system is still popular due to its simplicity. 
1.1.6.3. Molecular staging and prognostic biomarkers 
Dukes staging is very effective at predicting prognosis for those with stage A and D tumours. 
However, all the staging systems described above are limited in discriminating prognosis of 
intermediate stage patients (Dukes B and C). Molecular staging, based on the gene 
expression profile of the tumour, may be more effective in predicting long-term survival 
rates. For example, a cDNA classifier, based on microarray data from 43 genes, was 90% 
accurate (93% sensitivity and 84% specificity) at predicting 36-month overall survival of 
Dukes stage B and C patients. This was significantly better than Dukes staging (p = 0.0378) 
and discriminated patients into significantly different groups by survival time (p < 0.001) 
(Eschrich et al., 2005).  Consequently, molecular staging may be a useful technique to be 
applied in future. It would be beneficial to improve or create new staging systems as further 
prognostic factors are discovered, to allow clinicians to more accurately predict patient 
prognosis.  
A prognostic biomarker is a parameter that can be used to predict patient survival. As 
patients with tumours which are histologically identical can have different prognoses and 
different responses to chemotherapy, molecular biomarkers which more accurately predict 
patient survival would be invaluable for patient management. There are several features of 
colon cancer that may be useful as prognostic markers, including expression of lamin A, 
preoperative CEA (carcinoembryonic antigen) levels, MSI status, LOH at chromosome18q, 
expression of thymidylate synthase, p53 or Ki-67 and the presence of lymphovascular or 
perineural invasion (Allegra et al., 2003; Gill et al., 2004; Quah et al., 2008; Tejpar, 2007; 
Willis et al., 2008). However, none of these markers is yet recommended for use in a clinical 
setting (Zlobec and Lugli, 2008).  
Predictive biomarkers are used to discern patients that would benefit from adjuvant 
chemotherapy. Prognostic biomarkers do not necessarily also function as predictive 
biomarkers, for example the correlation between p53 expression and benefit of adjuvant 
chemotherapy is controversial (Ahnen, 1999; Allegra et al., 2003). 
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Stage T N M Dukes MAC 
0 Tis N0 M0 - - 
I T1 
T2 
N0 
N0 
M0 
M0 
A 
A 
A 
B1 
IIA T3 N0 M0 B B2 
IIB T4a N0 M0 B B2 
IIC T4b N0 M0 B B3 
IIIA T1-T2 
T1 
N1/N1c 
N2a 
M0 
M0 
C 
C 
C1 
C1 
IIIB T3-T4a 
T2-T3 
T1-T2 
N1/N1c 
N2a 
N2b 
M0 
M0 
M0 
C 
C 
C 
C2 
C1/2 
C1 
IIIC T4a 
T3-T4a 
T4b 
N2a 
N2b 
N1-N2 
M0 
M0 
M0 
C 
C 
C 
C2 
C2 
C3 
IVA Any T Any N M1a - - 
IVB Any T Any N M1b - - 
 
Table 1.1: Comparison of staging systems (Edge, 2009)  
 
 Primary Tumour (T) 
 
T0 
Tis 
T1 
T 
T3 
T4a 
T4b 
TX 
 
No evidence of primary tumour 
Carcinoma in situ: intraepithelial or invasion of lamina propria 
Tumour invades submucosa 
Tumour invades muscularis propria 
Tumour invades through the muscularis propria into pericolorectal tissues 
Tumour penetrates to the surface of the visceral peritoneum 
Tumour directly invades or is adherent to other organs or structures 
Primary tumour cannot be assessed 
 
Regional Lymph Nodes (N) 
 
N0 
N1 
N1a 
N1b 
N1c 
 
N2 
N2a 
N2b 
 
No regional lymph node metastasis 
Metastasis in 1-3 regional lymph nodes 
Metastasis in 1 regional lymph node 
Metastasis in 2-3 regional lymph nodes 
Tumour deposit(s) in the subserosa, mesentery or nonperitonealised pericolic 
or perirectal tissues without regional nodal metastasis 
Metastasis in 4 or more regional lymph nodes 
Metastasis in 4-6 regional lymph nodes 
Metastasis in 7 or more regional lymph nodes 
 
Distant Metastasis (M) 
 
M0 
M1 
M1a 
M1b 
 
No distant metastasis 
Distant metastasis 
Metastasis confined to 1 organ/site (e.g. liver, lung, ovary or non-regional node) 
Metastases in more than 1 organ/site or the peritoneum 
 
 
Table 1.2: Definitions of T, N and M in AJCC staging system (7th edition) (Edge, 2009)  
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However, LOH at chromosome 18q in microsatellite-stable cancers and mutation of the 
gene for the type II receptor for TGFβ in MIN cancers can act as both prognostic biomarkers 
and predictive markers of the benefit of adjuvant chemotherapy for stage III colon cancer 
(Watanabe et al., 2004).  
1.1.7. Treatment 
Surgical resection with curative intent is the main form of treatment for Stage I-III CRC, 
usually through traditional open surgery, though laparoscopic resection is also increasingly 
being used (Schurer and Kanavos, 2010). Laparoscopic surgery has many advantages over 
open surgery, including faster recovery, fewer systemic and wound complications and less 
pain (Noel et al., 2007). However, the MRC CLASICC (conventional versus laparoscopic-
assisted surgery in CRC) trial found that there was no difference in overall survival (OS) or 
disease-free survival (DFS) for CRC patients treated by laparoscopic or open surgery (Jayne 
et al., 2010). During surgery, it is important that lymph nodes are removed and identified, to 
reduce the chance of local recurrence from tumour in lymph nodes, and to aid patient 
management post-surgery. The larger the number of lymph nodes examined, the better the 
accuracy of staging, the more likely it is that patients are classified as node-positive and the 
higher the long-term survival rates. However, there is currently no consensus on the 
optimum number of nodes that should be removed.  
Some patients are offered adjuvant therapy following surgery, most commonly 
chemotherapy. For patients with Stage III colon cancer, adjuvant treatment such as 5-FU (5-
Fluorouracil) based adjuvant chemotherapy with oxaliplatin is known to improve DFS and 
OS (Andre et al., 2009). Stage I and II patients are often cured by surgery alone, with 5-year 
survival rates of 75-95%. However, it is important to be able to stratify stage II patients by 
risk, as some of these patients have similar relapse rates to stage III patients, and would 
benefit from adjuvant treatment. Adjuvant chemotherapy after surgical resection of the 
primary tumour increases survival by approximately 10% for patients with Stage III tumours, 
and by 4% for patients with Stage II tumours (Midgley et al., 2009).  
Use of post-operative chemotherapy for those with Stage II colon cancer is controversial. 
For patients who have been cured by surgical resection, chemotherapy is unnecessary and 
dangerous and should be avoided. Stage II tumours are heterogeneous and range from 
those with very early penetration into the bowel wall to aggressive tumours with 
involvement of adjacent organs. It has been suggested that Stage II patients with high risk 
features such as obstruction, perforation, inadequate lymph node sampling or T4 disease 
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should be considered for adjuvant chemotherapy, dependent on their age and co-
morbidities (Figueredo et al., 2008).  It is widely accepted that further high-risk features 
need to be identified which can aid in selecting patients who would benefit from 
chemotherapy and that more effective, less toxic therapies need to be found (Figueredo et 
al., 2008). There are a number of possible ways of identifying patients with high-risk 
features, including clinicopathologic characteristics, molecular biomarkers and genomic, 
proteomic or metabolomic profiling (Section 1.1.6.3). 
1.2. Lamins 
1.2.1. The nuclear envelope 
Lamins are type V intermediate filament proteins that bind together to form a filamentous 
meshwork encompassing the nucleoplasmic side of the nuclear envelope (NE). Lamins are 
also present in the nuclear matrix (see Section 1.2.4.3). The NE separates the nucleus from 
the cytoplasm in eukaryotic cells and is composed of an outer nuclear membrane (ONM) 
and an inner nuclear membrane (INM), which are fused at the site of nuclear pore 
complexes (NPCs). The ONM is continuous with the endoplasmic reticulum (ER) and is 
studded with ribosomes, whereas the INM is distinct from the ER and contains nuclear 
envelope transmembrane proteins (NETs) such as the lamina-associated polypeptides 
(LAPs) (Schirmer et al., 2003; Senior and Gerace, 1988) (Figure 1.7). NPCs control the 
exchange of components between the nucleus and the cytoplasm.  
The lamina was first discovered as a detergent and salt resistant component of the nucleus 
(Dwyer and Blobel, 1976; Pappas, 1956). Three genes are known to encode lamin proteins 
in human somatic cells: LMNA, encoding the A-type lamins and LMNB1 and LMNB2, 
encoding the B type lamins. A-type lamins (A, A∆10, C and C2) are alternatively spliced 
products of LMNA (Lin and Worman, 1993; Machiels et al., 1996). Lamins A and C are 
identical for the first 566 amino acids, following which lamin C lacks exons 11 and 12 and 
part of exon 10. Lamin C has 6 unique C terminal amino acids and lamin A has an extra 98 
amino acids at the C terminus. As its name suggests, lamin A∆10 lacks exon 10 (Machiels et 
al., 1996). Lamin A (70kDa) and lamin C (65kDa) are expressed in most differentiated cells 
(Broers et al., 1997) whereas lamin C2 is expressed only in the germline (Furukawa et al., 
1994). Lamin A∆10 is expressed in some tumour cell lines and normal cells (Machiels et al., 
1996).  
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Figure 1.7: The nuclear envelope (adapted from Chi et al, 2009) - The nuclear envelope 
contains nuclear pore complexes and NETs such as LBR, emerin, MAN1 and LAP2. The nuclear 
lamina encompasses the nucleoplasmic side of the nuclear envelope. 
B-type lamins, encoded by LMNB1 (lamin B1) (Lin and Worman, 1995) and LMNB2 (lamin B2 
and B3) (Biamonti et al., 1992; Furukawa and Hotta, 1993; Hoger et al., 1990) are essential 
for cell survival (Harborth et al., 2001). Lamins B1 (67kDa) and B2 (68kDa) are expressed in 
most cells, although lamin B2 is more ubiquitous than lamin B1 (Broers et al., 1997). Lamin 
B3 is only expressed in spermatocytes (Furukawa and Hotta, 1993). Gene targeting of lamin 
A in mouse models has shown that only B-type lamins are necessary for embryonic 
development, but A-type lamins are necessary for post-natal survival (Sullivan et al., 1999).   
1.2.2. Structure of lamins  
Lamin proteins have a tripartite structure typical of intermediate filament proteins (Fisher 
et al., 1986; McKeon et al., 1986). They consist of a globular NH2-terminal head domain, a 
central coiled-coil α-helical rod domain and a globular COOH-terminal tail domain. The 
central rod domain contains four α-helical subsegments (coils 1A, 1B, 2A and 2B) separated 
by short linker regions (L1, L12 and L2) (Conway and Parry, 1990).  
However, there are also some differences between IF proteins and lamins. The head 
domain is shorter than in other IF proteins (Fisher et al., 1986) and lamins contain a 42 
amino acid long insertion within coil 1B of the rod domain. The tail domain contains a 
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nuclear localisation signal (NLS) (Fisher et al., 1986; Loewinger and McKeon, 1988). A CaaX 
motif (where C represents cysteine, a represents any aliphatic residue and X represents any 
amino acid) is present in the tail domain of lamin A and B-type lamins, but not in lamin C, 
and is the site of posttranslational modifications (Fisher et al., 1986; Kitten and Nigg, 1991; 
McKeon et al., 1986; Vorburger et al., 1989). 
1.2.3. Assembly and post-translational modification of lamins 
Initially, lamins form parallel dimers via their coiled-coil domains. Two lamin dimers then 
associate in a polar ‘head to tail’ formation, in which the N- and C- terminal ends overlap by 
2-4nm (Aebi et al., 1986), following which they form antiparallel out of register associations 
(Strelkov et al., 2004; Stuurman et al., 1998). Both the head and tail domains of lamins 
contain cyclin dependent kinase 1 (CDK1) target sequences, and phosphorylation of these 
sequences is correlated with disassembly of lamin filaments during mitosis (Peter et al., 
1991; Peter et al., 1990; Ward and Kirschner, 1990). Phosphorylation of additional 
sequences in the head and tail domains may allow the correct assembly of lamin filaments 
(Collas et al., 1997; Stuurman, 1997). 
For lamin A and B-type lamins to be correctly localised at the INM, their COOH-terminal 
cysteine residues must undergo isoprenylation and methylation. Firstly, a 15-carbon 
farnesyl isoprenoid is added to the cysteine of the CaaX box, before the aaX sequence is 
removed and the cysteine is methylated. B type lamins also require LAP2β for their correct 
assembly into the nuclear lamina (Furukawa and Kondo, 1998; Yang et al., 1997). 
Once at the INM, lamin A undergoes further post-translational modifications, to progress 
from prelamin A to mature lamin A. The last 15 amino acids of prelamin A are cleaved by 
the zinc metalloproteinase Zmpste24, resulting in the loss of the isoprenylated cysteine 
residue (Bergo et al., 2002; Pendas et al., 2002).  
1.2.4. The role of lamins in the control of nuclear and cellular 
architecture  
Lamins anchor NETs at the INM. A-type and B-type lamins often, but not always, bind to 
different NETs, for example  A-type lamins bind emerin (Clements et al., 2000) and B-type 
lamins bind LAP2β (Furukawa and Kondo, 1998). Emerin interacts with MAN1 
(Mansharamani and Wilson, 2005) and emerin, LAP2β and MAN1 bind to BAF (barrier to 
autointegration factor) (Furukawa, 1999; Lee et al., 2001; Mansharamani and Wilson, 2005; 
Shumaker et al., 2001). Complexes of lamins and NETs are important for organising 
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peripheral chromatin, organising the cytoskeleton and anchoring nuclear pore complexes 
within the nuclear envelope. These processes are discussed in more detail in the following 
sections. 
1.2.4.1. The role of lamins in DNA binding and regulation of 
gene expression 
A network of lamins and lamin-binding proteins are involved in tethering chromatin to the 
nuclear envelope. A-type lamins can directly bind DNA (Stierle et al., 2003) however it is 
thought that most interactions between DNA and lamins occur indirectly, through lamin 
binding proteins. Both A-type lamins and the lamin-binding LEM (LAP2, Emerin, MAN) 
domain proteins bind BAF, which can bind DNA (Holaska et al., 2003; Zheng et al., 2000). 
BAF is involved in higher order chromatin structure, nuclear assembly and gene regulation 
(Haraguchi et al., 2001; Holaska et al., 2003; Segura-Totten et al., 2002). Lamins may play a 
role in organising heterochromatin, as some laminopathies and LMNA null nuclei show a 
dramatic loss of heterochromatin (Goldman et al., 2004; Scaffidi and Misteli, 2005; Sullivan 
et al., 1999). 
The nuclear lamina is thought to play a role in regulation of gene expression, particularly in 
the repression of genes. It has recently been shown that there are over 1,300 sites of 
interaction between the genome and the lamina, known as lamina-associated domains 
(Guelen et al., 2008), which typically display low gene expression levels. Artificial tethering 
of genes to the lamina can also lead to repression of gene expression (Reddy et al., 2008). 
Furthermore, A-type lamins can bind a number of transcriptional repressors including 
hypophosphorylated Rb (Mancini et al., 1994; Ozaki et al., 1994), BAF (Holaska et al., 2003) 
and SREBP1a and 1c (Lloyd et al., 2002) .  
1.2.4.2. Lamin function in the control of nuclear size and shape 
Most cells contain round or oval nuclei, but some specialised or diseased cells display 
altered nuclear shape. Abnormally shaped nuclei are often seen in cells with reduced lamin 
expression and in laminopathies (Capell and Collins, 2006; Liu et al., 2000; Sullivan et al., 
1999) and depletion of lamins leads to reduced nuclear size (Jenkins et al., 1993). Changes 
in nuclear shape can affect the rigidity of the nucleus and/or gene expression, and it has 
been suggested that these effects may be due to changes in lamin proteins (Webster et al., 
2009). 
  
22 
 
1.2.4.3. Lamins and the nuclear matrix 
A homologue of the cytoplasmic cytoskeleton, known as the nuclear matrix or 
nucleoskeleton, is present in the nucleus (Rando et al., 2000) and is thought to contain A-
type lamins, actin, myosin and spectrin-repeat proteins (Broers et al., 2005; Pederson and 
Aebi, 2005; Pestic-Dragovich et al., 2000; Young and Kothary, 2005). Many aspects of the 
nuclear matrix are not yet fully understood and its function as a structural, force-bearing 
structure is disputed (Misteli, 2007; Pederson, 2000).  
The suggestion that actin is present in the nucleus was once controversial, but now actin is 
known to be involved in several nuclear processes such as chromatin remodelling and gene 
splicing (Rando et al., 2000). Many papers have convincingly detected actin in the nucleus 
(Rando et al., 2000) and all isoforms of actin contain nuclear export sequences (Wada et al., 
1998). In the nucleus, phalloidin stainable F-actin filaments are not present, which may be 
due to the geometry of the interchromatin space (Pederson and Aebi, 2002). Instead, 80% 
of actin is free and 20% is found as oligomers or short polymers (McDonald et al., 2006).  
Actin binds both A- and B-type lamins (Fairley et al., 1999; Sasseville and Langelier, 1998; 
Simon et al., 2010). Lamin A tails also contain a unique actin binding domain in residues 
564-608 and they are capable of bundling F-actin in vitro (Simon et al., 2010). It is thought 
that lamins may suppress formation of F-actin in the nucleus through regulating actin 
polymers or sequestering G-actin, as nuclei of Drosophila muscle cells that lack the A-type 
lamin contain phalloidin-stainable fibres (Schulze et al., 2009; Simon et al., 2010).  
1.2.4.4. LINC complexes and the cytoskeleton  
It has recently been shown that the cytoskeleton is connected to the nucleus through LINC 
(linker of nucleoskeleton and cytoskeleton) complexes, formed through binding of KASH 
(Klarsicht/ANC-1/Syne homology) domain proteins such as nesprins to SUN (Sad1 and UNC-
84 homology) domain proteins (Starr and Han, 2003). The physical connection between the 
cytoskeleton and the nucleus is important for force transmission, cell migration and nuclear 
positioning. SUN1 and SUN2 bind to A-type lamins at the INM and interact with nesprins in 
the perinuclear space (Crisp et al., 2006; Haque et al., 2006; Padmakumar et al., 2005). 
Some nesprin isoforms bind lamin A and/or C (Libotte et al., 2005; Mislow et al., 2002) and 
A-type lamins are necessary for nesprin-2 localisation at the nuclear envelope (Libotte et al., 
2005). 
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Nesprins can connect to all three of the major components of the cytoskeleton. Nesprins-1 
and -2 giant isoforms bind to actin (Padmakumar et al., 2004; Zhen et al., 2002) and nesprin-
1 is thought to be an actin bundling protein (Padmakumar et al., 2004). Nesprins-1,-2 and -4 
can connect to microtubules through interacting with kinesin and/or dynein (Fan and Beck, 
2004; Roux et al., 2009; Schneider et al., 2011) whilst nesprin-3 associates with the IF 
cytoskeleton via plectin (Wilhelmsen et al., 2005). The lamin binding protein emerin also 
interacts with nesprins (Mislow et al., 2002; Wheeler et al., 2007) and nuclear and 
cytoplasmic actin (Fairley et al., 1999; Lattanzi et al., 2003) and it increases F-actin filament 
assembly by binding to and stabilising the pointed ends of F-actin (Holaska et al., 2004). 
Another recent discovery is that thick actin filament bundles organised into an ‘actin cap’ 
are located above the apical surface of the nucleus in some cells (Khatau et al., 2009; 
Khatau et al., 2010). Khatau et al. showed that the actin cap is connected to the NE through 
LINC complexes, plays a role in controlling nuclear shape and is structurally and functionally 
distinct from conventional actin fibres at the basal and dorsal surfaces of cells. The actin cap 
was lost in most LMNA-/- cells but no disorganisation of basal stress fibres was observed.  
LMNA-/- MEFs contain mislocalised LINC complex proteins (Crisp et al., 2006; Libotte et al., 
2005). These cells also have a lack of mechanical stiffness and disturbed actin, tubulin and 
vimentin-based filaments (Broers et al., 2004; Lammerding et al., 2004). Fibroblasts with 
disrupted LINC complexes have a loss of cellular mechanical stiffness similar to that in 
fibroblasts lacking A-type lamins (Stewart-Hutchinson et al., 2008), which demonstrates the 
importance of LINC complexes in the mechanical properties of the cell.  
1.2.5. Lamin expression and cell motility 
Several studies have shown that lamin A/C deficiency in mouse embryonic fibroblasts 
(MEFs) results in reduced cell migration and this is thought to be caused by deficient 
nuclear-CSK organisation and/or reduced CSK stiffness (Houben et al., 2009; Lee et al., 
2007). LMNA-/- MEFs displayed softening of the cytoplasm (Lee et al., 2007) and loss of 
nuclear reorientation during cell migration (Houben et al., 2009). Depletion of A-type lamins 
and/or emerin leads to deficient microtubule organising centre (MTOC) polarisation (Hale et 
al., 2008; Lee et al., 2007) and detachment of the MTOC from the nucleus (Hale et al., 2008; 
Houben et al., 2009; Lee et al., 2007; Salpingidou et al., 2007). It is important to note that A-
type lamin deficiency or mutation does not always lead to reduced cell motility (Emerson et 
al., 2009; Hale et al., 2008; Lu et al., 2009)  
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The link between A-type lamins and cell motility has also been studied in cancer cells. 
Previous work in our laboratory has shown that expression of lamin A in colon carcinoma 
promotes increased cell motility (Willis et al., 2008). In wounding assays, wound closure was 
seven times faster in cells transfected with GFP–lamin A compared with control cells 
transfected with GFP alone. Lamin A was shown to control a pathway in which up-regulated 
expression of T plastin, an actin bundling protein, led to down-regulated expression of the 
cell adhesion molecule E-cadherin, resulting in increased cell motility. Loss of E-cadherin 
and expression of plastins are often hallmarks of tumours, correlating with invasive and 
metastatic behaviour (Foran et al., 2006; Perl et al., 1998). The findings of Willis et al. may 
reveal a function of lamin A as a regulator of a pathway involving actin dynamics, cell 
adhesion and cell motility. It is possible that lamin A expression controls the reorganization 
of the cytoskeleton through its association with LINC complexes, causing alterations in cell 
migration.  
1.2.6. Lamins as a marker of colonic stem cells  
Our group has previously investigated A-type lamin expression in colonic crypts using 
immunohistochemistry (Figure 1.8). Strong lamin A/C expression was found in 
differentiated cells, whereas no A-type lamin expression was found in the proliferative 
region (Willis et al., 2008). Serial crypt sections revealed reciprocal expression of lamin A/C 
and the DNA replication protein PCNA (proliferating-cell nuclear antigen) at the crypt base. 
The cells in the putative stem cell niche were positive for lamin A, but not lamin C, revealing 
lamin A as a putative marker of colonic stem cells.  
 
1.3. Lamins and disease 
1.3.1. Laminopathies  
Abnormal structure or processing of LMNA lead to a wide range of degenerative diseases 
termed laminopathies (Broers et al., 2006). LMNA is one of the most highly mutated genes 
in the genome; to date over 200 different LMNA mutations have been discovered. Primary 
laminopathies are caused by mutations in LMNA, whereas secondary laminopathies are 
caused by mutations in FACE-1, which is involved in posttranslational processing of prelamin 
A.   
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Figure 1.8: A-type lamin expression in the colonic crypt (Willis et al., 2008)  
A Thin sections of normal colon stained with JoL2 (anti-lamin A/C), counterstained with Mayers 
Haemalum. Arrowheads show differentiated epithelium cells and arrows indicate the putative 
stem cell niche. Scale bars = 150 µm (left-hand panel) & 50 µm (right-hand panels).  
B, C Serial sections of normal colonic epithelium immunohistochemically stained with 133A2 
(anti-lamin A) (B) and RaLC (anti-lamin C) (C). Arrowheads indicate functional differentiated 
cells and arrows indicate cells within the proposed stem cell niche. Scale bars = 50 µm. 
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Some laminopathies affect specific tissues, i.e. striated muscles, peripheral nerves or 
adipose tissue. Others affect two or more tissue types, and some laminopathies cause 
premature ageing syndromes, such as progeria.  
1.3.2. Lamins and cancer  
Many of the cell processes that lamins are involved in are implicated in tumour progression, 
such as control of nuclear architecture, regulation of gene expression, apoptosis, 
senescence and chromatin organization and segregation (Broers et al., 2006). Therefore the 
effects of alterations of lamin expression or localization in tumour cells are particularly 
complex. As discussed above, A type lamins bind to a number of LEM domain proteins - 
LAP2α, MAN1 and emerin - which regulate growth regulators and can therefore be 
components of cancer pathways. Mutant emerin results in nuclear accumulation of β-
catenin and fibroblasts null for emerin show autostimulatory growth (Markiewicz et al., 
2006). LAP2α and A-type lamins have been shown to anchor unphosphorylated pRb, a 
growth suppressor, in the nucleus (Markiewicz et al., 2002). MAN1 antagonises TGFβ 
signalling by binding to Smad2 and Smad3 (Lin et al., 2005).  
The TGFβ superfamily contains TGFβs, bone morphogenic proteins (BMPs) and activins, 
which are known to regulate development, differentiation and homeostasis. The role of 
TGFβ in cancer was initially thought to be in the suppression of  tumours (Markowitz and 
Roberts, 1996), but it was later also found to have oncogenic activities (Wakefield and 
Roberts, 2002). In colon cancer, the function of TGFβ depends on the differentiation stage 
of the tumour, as it inhibits proliferation in the early stage of cancer and stimulates invasion 
at later stages of tumour progression (Hsu et al., 1994; Schroy et al., 1990).  
The canonical TGFβ signalling pathway is inherently simple, comprising three TGFβ-
receptors (TβR-I, -II and –III) and three latent transcription factors (Smad2, 3 and 4). TGFβ 
stimulates responsive cells by binding TβR-III, which presents TGFβ to TβR-II. TβR-II then 
activates TβR-I, which phosphorylates Smads 2 and 3.  Smads 2 and 3 subsequently 
associate with Smad4, and the Smad2/3/4 complex translocates to the nucleus where it can 
interact with transcriptional regulators to induce or repress TGFβ target genes. There are 
also numerous Smad-independent pathways in which TGFβ-signalling can occur. TGFβ is 
known to inhibit NFκB and to stimulate MAP kinases, small GTPases, protein tyrosine 
kinases and PI3K/AKT (Derynck and Zhang, 2003; Tian et al., 2011).  
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A-type lamins are known to modulate responses to TGFβ signalling in mesenchymal cells 
(Van Berlo et al., 2005). Van Berlo et al. showed that A-type lamins regulate the 
phosphorylation and de-phosphorylation of R-SMADs (receptor-regulated SMADs) and that 
A-type lamins are essential for inhibition of proliferation by TGFβ. MAN1, a lamin A-
interacting protein, is also known to regulate TGFβ signalling through binding to R-SMADs 
(Lin et al., 2005; Osada et al., 2003).  
1.3.2.1. Lamins as diagnostic biomarkers  
Numerous studies have tried to elucidate the relationship between lamin expression and 
cancer subtype by investigating the changes in lamin expression in malignant cells and 
tissue sections. Expression levels of lamins are often but not always aberrant in tumours.  
As B-type lamins are necessary for cell survival (Harborth et al., 2001), at least one B-type 
lamin is always present in a malignant cell. Abnormal expression levels are present in some 
tumour subtypes: expression is usually found to be reduced (Broers et al., 1993; Moss et al., 
1999), but increased lamin B1 expression has also been shown in prostate cancer and in 
hepatocellular carcinoma (HCC) (Coradeghini et al., 2006; Lim et al., 2002; Sun et al., 2010). 
The presence of B-type lamins in most normal and tumour cells renders them poor 
diagnostic biomarkers for many cancer subtypes. However, lamin B1 has the potential to be 
used as a diagnostic biomarker to detect HCC from an early stage, as it is overexpressed in 
early and late stage HCC when compared to non-malignant controls (p < 0.0001). Lamin B1 
mRNA was present in plasma of HCC patients and was found to detect early stage HCCs with 
a sensitivity of 76% and a specificity of 82% (Sun et al., 2010). 
As with B-type lamins, there is no simple overall pattern of A-type lamin expression in 
cancer and frequently no consistent patterns are observed between cancer subtypes. Many 
studies show lamin A/C to be downregulated in tumour cells (Broers et al., 1993; Moss et 
al., 1999; Venables et al., 2001), but expression is also frequently positive or upregulated 
(Broers et al., 1993; Hudson et al., 2007; Tilli et al., 2003). Often expression levels can vary 
dramatically even within cancer subtypes, for example in colorectal and basal cell 
carcinomas, A-type lamin expression can be positive (Tilli et al., 2003; Venables et al., 2001; 
Willis et al., 2008), reduced (Moss et al., 1999; Venables et al., 2001) or negative (Moss et 
al., 1999; Venables et al., 2001; Willis et al., 2008) in tumour tissue.  
The presence of variable A-type lamin expression in most tumour subtypes suggests that in 
most cases, A-type lamins may not be useful as diagnostic biomarkers. Nevertheless, cell 
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type-specific lamin A expression may be valuable as a diagnostic biomarker for detecting 
some cancers such as skin cancer. In non-cancerous skin, lamin A is not expressed in basal 
layers of the epidermis. However, in the apparently normal epidermis covering squamous 
cell carcinoma (SCC) and basal cell carcinoma (BCC), lamin A was found to be present in the 
basal layer (Tilli et al., 2003). 
Lamin A/C has been shown to aberrantly localise to the cytoplasm in some lung carcinomas, 
colon adenoma and adenocarcinoma, pancreatic and gastric cancers (Broers et al., 1993; 
Moss et al., 1999; Willis et al., 2008) whilst lamin B1 was localised to the cytoplasm in some 
colon and lung cancers (Moss et al., 1999). Lamin C was localised to the nucleolus in BCC 
and adrenal cortex carcinoma (Tilli et al., 2003; Vaughan et al., 2001; Venables et al., 2001). 
A number of studies have shown that lamins are present in the nucleoplasm and nuclear 
matrix in addition to the nuclear envelope in non-tumour cells (Fricker et al., 1997; 
Goldman et al., 1992; Moir et al., 1994).  Therefore, the detection of lamins in the 
cytoplasm is more likely to function as a diagnostic marker than the detection of lamin C in 
the nucleolus.  
Research into the use of lamins as cancer biomarkers is still at an early stage and none are 
yet being used clinically. A and B-type lamins have limited use as diagnostic biomarkers in 
many cancers, due to their variable expression between and within cancer subtypes and the 
presence of at least one B-type lamin in every tumour and normal cell. 
1.3.2.2. Lamins as markers of tumour proliferation  
Proliferating epithelial cells contain low levels of A-type lamins (Broers et al., 1997) and 
overexpression of A-type lamin expression has been shown to inhibit cell proliferation 
(Ivorra et al., 2006).  However, data on the relationship between A-type lamins and 
proliferation in cancer cells is currently inconclusive. In BCC, highly proliferative cells were 
negative for expression of lamin A, whereas slow growing tumours were negative for 
expression of lamin C (Venables et al., 2001). Ki67 and lamin A/C expression were found to 
be mutually exclusive in about 80% of Hodgkin’s disease cells (Jansen et al., 1997). 
However, co-expression of lamin A and Ki-67 was found in 56% of proliferating SCC cells and 
in 62% of proliferating BCC tumour cells (Tilli et al., 2003). It appears that too little is known 
about the patterns of A-type lamin expression in proliferating tumour cells for it to be used 
as a marker for cell proliferation. 
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1.3.2.3. Lamins as markers of tumour differentiation 
In non-cancerous tissue, A-type lamins are generally only expressed in differentiated cells 
(Broers et al., 1997; Rober et al., 1989) and lamin B1 has been shown to be reduced in some 
differentiated cells (Broers et al., 1997; Machiels et al., 1997). The link between B-type 
lamin expression and differentiation appears to vary with tumour subtype.  B-type lamins 
were expressed in testicular germ cell tumours (TGCTs) regardless of the degree of 
differentiation (Machiels et al., 1997) whilst well differentiated SCCs showed reduced 
expression of lamins B1 and B2 compared to poorly differentiated tumours (Oguchi et al., 
2002). The presence of A-type lamins is often used to demarcate differentiated tumour 
cells. Down-regulation of A-type lamins in poorly differentiated tumours has been shown in 
many tumour subtypes such as SCC (Oguchi et al., 2002) and gastric carcinoma (Wu et al., 
2009b).  A study into TGCTs (Machiels et al., 1997) showed that differentiated non-
seminomas were positive for lamins A/C, only lamin C was expressed in embryonal 
carcinoma (EC), and poorly differentiated seminomas were negative for lamins A/C. It is 
understood that in general, the poorer the differentiation of tumour cells, the worse the 
prognosis. More work needs to be carried out to assess the potential for expression of 
lamin A/C to act as a prognostic biomarker by defining the degree of differentiation of 
tumour cells. 
1.3.3 The effect of A-type lamin expression on cancer prognosis 
The link between cancer prognosis and A-type lamin expression is complex. Some studies 
point to a lack of lamin A/C expression as a sign of poor prognosis. CpG island promoter 
hypermethylation, which silences LMNA and leads to loss of lamin A/C expression in nodal 
diffuse large B-cell lymphoma, has been correlated with a decrease in overall survival 
(P=0.0005) (Agrelo et al., 2005). Moreover, a recent study has revealed that patients with 
gastric carcinoma cells containing down-regulated lamin A/C expression have poorer 
prognosis compared with those expressing lamin A/C (P=0.034) and that lamin A/C 
expression is an independent prognostic factor (Wu et al., 2009a).  
However, in colorectal cancer, Willis et al. discovered that patients with CRC tumours 
expressing lamin A/C were almost twice as likely to die from the cancer compared with 
clinicopathologically identical patients with tumours showing negative expression of lamin 
A/C (Hazard ratio [HR] 1.85; 95% confidence interval [C.I.] 1.16–2.97, p=0.005) (Willis et al., 
2008). A-type lamins are therefore potential biomarkers of poor prognosis in CRC. It has 
been suggested that the poorer prognosis of CRC patients with lamin A expressing tumours 
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may be linked to the discovery that lamin A is a marker of colonic stem cells (Willis et al., 
2008) as cancer cells with characteristics of stem cells may be more aggressive (O'Brien et 
al., 2007).  
The results described above suggest that the effect of A-type lamin expression on cancer 
prognosis, and hence their use as prognostic biomarkers, may depend greatly on the 
subtype of cancer involved. 
1.4 Thesis aims and overview 
The central aim of this thesis was to further elucidate the mechanisms by which 
overexpression of lamin A in CRC cells causes increased cell motility, leading to a poor 
prognosis for patients. I sought to use quantitative proteomic and genomic techniques to 
assess the effect of lamin A expression on gene and protein expression and on the 
organisation of the cytoskeleton. The effects of lamin A expression were studied using cells 
from the colorectal cancer cell line SW480 which had been transfected with GFP-laminA 
(SW480/lamA) or GFP as a control (SW480/cntl). 
Chapter 2 describes the optimisation of a biochemical fractionation protocol in order to 
isolate cytoskeletal fractions. 2D DIGE was then used to analyse the effect of overexpression 
of lamin A on the representation of proteins within the cytoskeleton of CRC cells. 64 protein 
spots showed highly reproducible changes in representation and 29 of these spots were 
identified using mass spectrometry. The majority of proteins fell into three distinct 
categories and these proteins were either components of the actin and intermediate 
filament cytoskeleton, protein chaperones or translation initiation and elongation factors. 
Most interestingly, tissue transglutaminase 2, a protein associated with cancer progression 
which is known to crosslink elements of the cytoskeleton, was highly over-represented in 
the cytoskeleton fraction of SW480/lamA cells. The results suggested that changed protein 
cross-linking and folding in SW480/lamA cells may lead to changes in the organisation of the 
cytoskeleton, accounting for the increased cell motility. 
In Chapter 3, the data from a genome-wide Affymetrix microarray study comparing 
SW480/lamA cells with control cells were analysed using Ingenuity Pathways Analysis (IPA). 
Interaction networks showing known literature-curated interactions were produced. The 
most highly significant network produced by IPA clustered together molecules linked to 
cancer, cellular movement and cellular growth and proliferation. Epithelial markers such as 
CDH1 were down-regulated and mesenchymal markers such as FN1 were up-regulated in 
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SW480/lamA cells, which suggested that lamin A over-expression may lead to an epithelial-
mesenchymal transition. Further analysis of the dataset using IPA revealed that there was a 
statistically significant overlap between IPA lists of genes linked to EMT and the microarray 
dataset. 
Chapter 4 explores the effects of siRNA knockdown of lamin A in SW480/lamA cells. 
Transfection of si-lamin A resulted in a reduction of endogenous lamin A expression by over 
95% and a reduction of GFP-lamin A expression by over 50% by 120 hours after 
transfection. Cells transfected with si-lamin A were less motile than control cells, confirming 
that upregulation of lamin A in CRC cells causes increased cell motility.  As A-type lamins are 
known to modulate downstream effects of TGFβ signalling, and TGFβ is an inducer of EMT, 
changes in genes involved in TGFβ signalling were investigated. Knockdown of lamin A using 
siRNA showed that reduced cell motility was preceded by decreased expression of TGFBI 
and SNAI2. Therefore, expression of lamin A in CRC cells may cause increased cell motility 
cause through changes in TGFβ signalling, potentially involving an epithelial to 
mesenchymal transition. 
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CHAPTER TWO   
The effects of over-expression of lamin A on 
cytoskeleton organisation in CRC cells 
2.1. Introduction 
The aim of this study was to further understand the mechanisms behind the finding that 
SW480 CRC cells over-expressing lamin A exhibit increased cell motility (Willis et al., 2008). 
Willis et al. used wounding assays to investigate cell motility, and discovered that wound 
closure was seven times faster in cells transfected with GFP–lamin A compared with control 
cells transfected with GFP alone, when the percentage reduction in wound closure was 
measured over 12 hours. Expression of GFP-lamin A was found to cause up-regulation of 
the actin bundling protein T-plastin, and down-regulation of the cell adhesion molecule E-
cadherin. Loss of E-cadherin and increased expression of plastins are often hallmarks of 
tumours, correlating with invasive and metastatic behaviour (Foran et al., 2006; Perl et al., 
1998). These findings suggest that lamin A regulates a pathway involving actin dynamics, 
cell adhesion and cell motility.  
The nucleus is known to be connected to the cytoskeleton through LINC complexes, formed 
through binding of KASH domain proteins such as nesprins to SUN domain proteins (Starr 
and Han, 2003). SUN1 and SUN2 bind to A-type lamins at the INM and interact with 
nesprins in the perinuclear space (Crisp et al., 2006; Haque et al., 2006; Padmakumar et al., 
2005). Nesprins can bind A-type lamins (Libotte et al., 2005; Mislow et al., 2002), actin 
(Padmakumar et al., 2004; Zhen et al., 2002), plectin (Wilhelmsen et al., 2005), kinesin and 
dynein (Fan and Beck, 2004; Roux et al., 2009; Schneider et al., 2011). This provides a 
pathway by which signals can travel between the outside of the cell and the nucleus. Lamin 
A expression may therefore control the reorganisation of the cytoskeleton through its 
association with LINC complexes, causing alterations in cell migration. 
In addition to the link between A-type lamins and cell motility, there is a link between A-
type lamin expression in CRC cells and patient survival. Patients with CRC tumours 
expressing A-type lamins were found to be almost twice as likely to die from their disease 
compared with clinicopathologically identical patients whose tumours were negative for 
expression of A-type lamins (Hazard ratio [HR] 1.85; 95% confidence interval [C.I.] 1.16–
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2.97, p=0.005) (Willis et al., 2008). A-type lamins are therefore potential biomarkers for 
poor prognosis in CRC.  
The aim of this study was to investigate changes induced in the organisation of the 
cytoskeleton when lamin A is over-expressed in colon carcinoma cells. To do this, I used the 
model system that was used by Willis et al. The SW480 cell line was originally derived from 
a Broders’ grade 4, Dukes B primary colon adenocarcinoma taken from a 50 year old 
Caucasian male (Leibovitz et al., 1976). SW480 cells, which express endogenously low levels 
of lamin A were stably transfected with DNA constructs encoding either EGFP-lamin A 
(SW480/lamA) or EGFP (SW480/cntl) (Willis et al., 2008). SW480/cntl cells maintain low 
expression levels of lamin A, whereas SW480/lamA cells express both higher levels of 
endogenous lamin A and GFP-lamin A. 
In this study, the cytoskeleton was isolated using a biochemical fractionation method and 
subsequently 2D DIGE (2 dimensional difference in gel electrophoresis) was used to assess 
differences in protein expression. Elucidating the processes by which lamin A expression 
causes increased cell motility may help us to understand the finding that colorectal cancer 
patients expressing A-type lamins in the tumour are twice as likely to die. 
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2.2. Materials and Methods 
2.2.1. General chemicals and materials 
All chemicals and reagents used in this project were purchased from Sigma-Aldrich (Poole, 
UK), BDH Ltd. (VWR International Ltd., Leicestershire, UK) or Melford Laboratories Ltd. 
(Suffolk, UK) unless otherwise stated. All chemicals were Molecular Biology grade, except 
those from BDH, which were AnalaR® analytical grade. 
2.2.2. Mammalian cell culture 
Cell culture was performed in a containment level 2 tissue culture laboratory using strict 
aseptic techniques. All plasticware was supplied by Greiner Bio-One Ltd. (Gloucestershire, 
UK). 
2.2.2.1. Cell lines 
Cells used were from the colon carcinoma cell line SW480, kindly supplied by Dr. Naomi 
Willis, originally obtained from the European Collection of Cell Cultures (ECACC, Salisbury, 
Wiltshire, UK). This cell line was originally derived from a Broders’ grade 4, Dukes B primary 
colon adenocarcinoma taken from a 50 year old Caucasian male (Leibovitz et al., 1976). 
Cells had been stably transfected with DNA constructs encoding either EGFP-lamin A 
(SW480/lamA) or EGFP (SW480/cntl) (Willis et al., 2008). EGFP-lamin A full length was a gift 
from Dr M Izumi, Institute of Physical and Chemical Research, Saitama, Japan. 
2.2.2.2. Subculture 
Cells were cultured in L-15 (Leibovitz) medium with 2mM Glutamine (Invitrogen), 
supplemented with 100 units/ml penicillin and 100µg/ml streptomycin (Invitrogen), and 
10% foetal bovine serum (FBS) lot 057K3395. Cultures were grown in 75cm2 flasks, 
maintained at 37oC in a humidified environment without CO2. 
Once cells had reached 70% confluency, they were washed with Versene [137mM NaCl, 
2.7mM KCl, 8mM Na2HPO4, 1.5mM KH2PO4, 1.5mM EDTA pH 7.4] and detached from the 
flask with Versene containing 10% (v/v) trypsin at 37oC in a humidified atmosphere for 4 
minutes. They were then neutralised with medium and centrifuged (Eppendorf 5810R) at 
200g for 5 minutes. Supernatants were removed and cells were resuspended in medium 
and seeded into new flasks. SW480/cntl cells were split 1:2-1:4 and SW480/lamA cells were 
split 1:4-1:6.  
  
35 
 
2.2.2.3. Cryopreservation 
Cells were harvested and pelleted by centrifugation as described above. The supernatant 
was removed, cells were resuspended in 4ml phosphate buffered saline (PBS) and 
centrifuged (Eppendorf 5810R) at 200g for 5 minutes. The supernatant was removed and 
cells were resuspended in 90% (v/v) supplemented L-15 medium (Invitrogen) and 10% (v/v) 
dimethylsulphoxide (DMSO), added drop-wise. Cells were transferred to cryovials and 
placed in a Nalgene™ Cryo 1oC Freezing Container which was kept at -80oC for several days 
before being transferred to a -150oC freezer for long-term storage. 
To re-establish cell cultures, cells were thawed at 37oC and re-suspended in 4ml L-15 
medium (Invitrogen). Cells were then centrifuged (Eppendorf 5810R) at 200g for 5 minutes. 
The supernatant was removed and cell pellets were resuspended in 2ml medium before 
being transferred to T-25 cell culture flasks.  In subsequent passages, some cells were 
transferred to T-75 flasks and some were cryopreserved to replenish stores of stock cells. 
2.2.2.4. Cell counting 
Cell suspensions were applied to the chambers of an Improved Neubauer 
haemocytometer. A light microscope (Zeiss Telaval 31) was used to view the cells. Cells in 
the four corner squares were counted, excluding cells that touched the upper and left hand 
side edges of the squares. The mean number of cells per square was calculated, and this 
number was multiplied by 1.0x104 to give the number of cells per ml. 
2.2.3. Biochemical fractionation 
 
2.2.3.1. Initial protocol 
The cytoskeletal extraction protocol was modified from a protocol to extract the nuclear 
matrix (Dyer et al., 1997). Cells were grown to 70% confluency before being washed in 
versene, trypsinised and centrifuged as described in Section 2.2.2. Cells were resuspended 
and washed in PBS before centrifugation at 200g for 5 minutes (Eppendorf 5810R). For 
storage, cell pellets were snap frozen in liquid nitrogen and stored in a -80oC freezer. 
A sequential extraction was performed involving ice-cold buffers to produce four insoluble 
pellets and four supernatants (Table 2.1). 10µl protease inhibitor cocktail (Sigma) and 0.1ml 
of 100mM DTT were added freshly to every 1ml of each buffer. After each extraction step, 
soluble and insoluble fractions were separated by centrifugation (Sigma centrifuge) at 
1200g (4,000RPM) for 5 minutes at 4oC. 
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Table 2.1: Buffers used in biochemical fractionation 
Buffer name 
Buffer 
abbreviation 
Buffer composition 
Cytoskeleton 
buffer 
CSK 
10mM PIPES (piperazine-N,N’-bis(2-ethanesulphonic 
acid)) pH6.8, 10mM KCl, 300mM sucrose, 3mM MgCl2, 
1mM EGTA pH8.0 
Cytoskeleton 
buffer/ 
Triton X 
CSK/T 
10mM PIPES (piperazine-N,N’-bis(2-ethanesulphonic 
acid)) pH6.8, 10mM KCl, 300mM sucrose, 3mM MgCl2, 
1mM EGTA pH8.0, 0.5% (v/v) Triton X-100 
Digestion 
buffer 
Dig 
10mM PIPES (piperazine-N,N’-bis(2-ethanesulphonic 
acid)) pH6.8, 50mM NaCl, 300mM sucrose, 3mM 
MgCl2, 1mM EGTA pH8.0 
Digestion 
buffer/DNase 
Dig/DNase 
10mM PIPES (piperazine-N,N’-bis(2-ethanesulphonic 
acid)) pH6.8, 50mM NaCl, 300mM sucrose, 3mM 
MgCl2, 1mM EGTA pH8.0, 500 units/ml DNase I 
Extraction 
buffer 
Ext 
10mM PIPES (piperazine-N,N’-bis(2-ethanesulphonic 
acid)) pH6.8, 250mM ammonium sulphate, 300mM 
sucrose, 3mM MgCl2, 1mM EGTA pH8.0 
 
Briefly, cell pellets were thawed at 37oC, resuspended in 800µl CSK buffer and split into 4 
equal samples of 200µl. Samples were then centrifuged. The supernatants were collected 
into one tube, labelled S1 and one pellet was labelled P1. P1 and S1 were kept on ice until 
the end of the procedure. The remaining 3 pellets were then resuspended in 200µl CSK/T 
buffer and incubated for 5 min on ice. After centrifugation, all 3 supernatants were 
transferred into a tube labelled S2 and one pellet was kept and labelled P2. Both were kept 
on ice until the end of the procedure. Two pellets were then resuspended in 200µl Dig 
buffer, centrifuged, and the supernatants discarded before the pellets were resuspended in 
200µl Dig/DNase and incubated for 20min at room temperature. Samples were then 
centrifuged, supernatants were transferred into tube S3, one pellet was labelled P3 and 
both were kept on ice. The last sample was extracted with 200µl Ext buffer, incubated for 5 
min on ice and centrifuged. The supernatant was removed and labelled S4 and the pellet 
was labelled P4. 
Pellets were then incubated with 125µl ice-cold hypotonic buffer [10mM Tris-HCl pH7.4, 
10mM KCl, 3mM MgCl2, 0.1% (v/v) Triton X-100] plus 2µl DNase (5 units/µl) and 2µl 
protease inhibitor cocktail for 10 min on ice. 125µl 2x sample buffer [125mM Tris-HCl pH 
6.8, 2% (v/v) sodium dodecyl sulphate (SDS), 2mM dithiothreitol (DTT), 20% (v/v) glycerol, 
5% (v/v) β-mercaptoethanol and 0.25% (w/v) bromophenol blue] was then added to each 
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pellet tube, heated for 3min at 95oC and centrifuged for 30 seconds at 13000g in a bench 
top centrifuge (VWR). 
50µl 5x sample buffer [312.5mM Tris-HCl pH 6.8, 5% (v/v) SDS, 5mM DTT, 50% (v/v) 
glycerol, 12.5% (v/v) β-mercaptoethanol and 0.625% (w/v) bromophenol blue] was added 
to each supernatant tube, heated for 3 min at 95oC and centrifuged for 30 seconds at 
13000g in a bench top centrifuge  (VWR). 
All samples were snap frozen in liquid nitrogen and stored in a -80oC freezer. 
2.2.3.2. Final protocol 
The reasons for the changes made to the protocol are discussed in the results section of 
this chapter. 
SW480/lamA and SW480/cntl cells were grown to the desired confluency (40%, 70% or 
100% as described in the appropriate results section) before being washed in versene, 
trypsinised, counted and centrifuged as described above. Cells were resuspended and 
washed in 4ml PBS before centrifugation (Eppendorf 5810R) at 200g for 10 minutes. 
A sequential extraction (see Figure 2.1) was performed involving the ice-cold buffers 
described in Table 2.1 to produce four insoluble pellets and four supernatants. 10µl 
protease inhibitor cocktail and 100µl of 0.4M N-ethylmaleimide (NEM) were added freshly 
to every 1ml of each buffer. After each extraction step, soluble and insoluble fractions were 
separated by centrifugation at 1200g for 5 minutes at 4oC (Sigma centrifuge). 
Fractionation of both SW480/lamA and SW480/cntl cells was carried out simultaneously. In 
brief, an appropriate volume of CSK buffer was added to cell pellets so that 820µl of CSK 
buffer could be removed from each pellet tube for the biochemical fractionation 
procedure, with both tubes containing the same number of cells. Each sample was then 
split into 4 aliquots of 200µl and the tubes were centrifuged. The supernatants were 
collected into one tube, labelled S1. One pellet was labelled P1. After each step, the 
labelled pellets and supernatants were snap frozen in liquid nitrogen until the end of the 
procedure. The remaining 3 pellets were then resuspended in 200µl CSK/T buffer and 
incubated for 5 min on ice. After centrifugation, all 3 supernatants were transferred into a 
tube labelled S2 and one pellet was kept and labelled P2. The two remaining pellets were 
then resuspended in 200µl Dig buffer, centrifuged, and the supernatants discarded before 
the pellets were resuspended in 200µl Dig/DNase and incubated for 20min at room 
temperature. Samples were then centrifuged, supernatants were transferred into tube S3 
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and one pellet was labelled P3. The last sample was extracted with 200µl Ext buffer, 
incubated for 5 min on ice and centrifuged. The supernatant was removed and labelled S4 
and the pellet was labelled P4. 
Pellets were then thawed and incubated with 86µl ice-cold hypotonic buffer [10mM Tris-
HCl pH7.4, 10mM KCl, 3mM MgCl2, 0.1% (v/v) Triton X-100] plus 2µl DNase (5 units/µl), 10 
µl 0.4M NEM and 2µl protease inhibitor cocktail for 10 min on ice. Each P1 was 
homogenised with a Dounce homogeniser to extract the proteins using 10 gentle strokes of 
the pestle. 5µl was removed from each sample in order to calculate protein concentration. 
95µl 2x sample buffer [125mM Tris-HCl pH 6.8, 2% (v/v) SDS, 2mM DTT, 20% (v/v) glycerol, 
5% (v/v) β-mercaptoethanol and 0.25% (w/v) bromophenol blue] was then added to each 
pellet and all pellet samples were heated for 3min at 95oC and centrifuged for 30 seconds 
at 13000g in a bench top centrifuge (VWR). 
Supernatants were thawed and 5µl was removed from each sample in order to calculate 
protein concentration. Samples were incubated with 50µl 5x sample buffer [312.5mM Tris-
HCl pH 6.8, 5% (v/v) SDS, 5mM DTT, 50% (v/v) glycerol, 12.5% (v/v) β-mercaptoethanol and 
0.625% (w/v) bromophenol blue], heated for 3 min at 95oC and centrifuged for 30 seconds 
at 13000g in a bench top centrifuge (VWR). 
All samples were snap frozen in liquid nitrogen and stored in a -80oC freezer. 
2.2.4. Preparation of whole cell extracts 
Cells grown in T-75 cell culture flasks were washed in versene, trypsinised and centrifuged 
as described in Section 2.2.2. Cells were resuspended and washed in 4ml PBS before 
centrifugation at 200g for 10 minutes (Eppendorf 5810R). After the supernatant was 
removed, cells were snap frozen in liquid nitrogen and stored at -80oC. When required, cell 
pellets were thawed, resuspended in 500µl hypotonic buffer [10mM Tris-HCl pH7.4, 10mM 
KCl, 3mM MgCl2, 0.1% (v/v) Triton X-100] plus 2µl DNase (5 units/µl), 2µl protease inhibitor 
cocktail, 50µl 0.4M NEM and incubated on ice for 10 minutes.  5µl of each sample was 
removed in order to calculate protein concentration.  500µl 2x sample buffer [125mM Tris-
HCl pH 6.8, 2% (v/v) SDS, 2mM DTT, 20% (v/v) glycerol, 5% (v/v) β-mercaptoethanol and 
0.25% (w/v) bromophenol blue] was then added to each sample and tubes were heated to 
95oC for 3 minutes then centrifuged for a minute at 13000g in a bench top centrifuge 
(VWR).  
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Figure 2.1 Biochemical Fractionation Protocol 
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2.2.5. One-dimensional SDS-PAGE 
One-dimensional SDS-PAGE was performed following the procedure of Laemmli (Laemmli, 
1970) to separate proteins according to their molecular weights (Mr). Gels were cast using 
the Mini-Protean Electrophoresis System (BioRad). Firstly, a 1mm thick resolving gel was 
formed containing either 10% or 12% (v/v) poly-acrylamide [10/12% (v/v) ProSieve® 50 
acrylamide gel solution (Cambrex BioScience Wokingham, Ltd., UK), 375mM Tris-HCl pH 
8.8, 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate (Fisher Biosciences) and 0.04% 
(v/v) TEMED (N,N,N',N'-Tetramethylethylenediamine). Butan-1-ol was pipetted onto the 
top of the gel solution to ensure the top of the gel was flat.  After the gel had set, the 
butan-1-ol was poured off. The stacking gel solution was prepared, as for the resolving gel 
but containing 5% (w/v) acrylamide, 125mM Tris-HCl pH 6.8 and 0.1% (v/v) TEMED. The 
resolving gel solution was added to the top of the resolving gel and a Teflon comb was 
inserted to form wells. 
Gels were submerged in Tank buffer [25mM Tris pH 8.3, 192mM Glycine, 0.1% (v/v) SDS] 
and protein samples prepared for SDS-PAGE (Section 2.2.4) were added to wells, with an 
equal concentration of protein added to each well. 10µl of protein ladder - PageRulerTM 
Prestained Protein Ladder Plus (Fermentas) or Prestained SDS-PAGE Standards (BioRad) - 
was used for visualising molecular weights of proteins and to demonstrate transfer of 
proteins onto nitrocellulose membranes. 
Table 2.2: Composition of one-dimensional SDS-PAGE gels 
 
Final concentration 
Resolving Gel Stacking Gel 
ProSieve® 50 acrylamide gel solution 10% or 12% (v/v) 5% 
Tris-HCl pH 8.8 375mM - 
Tris-HCl pH 6.8 - 125mM 
SDS 0.1% (w/v) 0.1% (w/v) 
Ammonium persulphate 0.05% (w/v) 0.05% (w/v) 
TEMED 0.04% (v/v) 0.1% (v/v) 
 
SDS-PAGE was performed at 100V, 40mAmp for approximately 2 hours, until the samples 
had migrated to the bottom of the resolving gel. Proteins were then visualised using 
Coomassie Brilliant Blue (Section 2.2.7.5) or immunoblotting as described below.  
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2.2.5.1. Immunoblotting 
Proteins separated by SDS-PAGE were transferred from the gel onto nitrocellulose 
membrane (Protran®, grade BA85, Schleicher and Schuell Bioscience Inc., Keene, NH) in 
Transfer buffer [25mM Tris-HCl pH 9.2, 192mM Glycine, 0.1% (v/v) SDS, 20% (v/v) 
methanol] at 30V, 25mAmp for 16 hours at 4oC. 
Membranes were washed in 2x Blot Rinse buffer [10mM Tris pH7.4, 150mM NaCl, 1mM 
EDTA] containing 0.1% (v/v) Tween-20® (BRB/T) on an orbital shaker. Blocking was 
performed in Blocking buffer (BRB/T + 4% (w/v) non-fat dry milk) for 1.5 hours at room 
temperature on an orbital shaker. Membranes were incubated with primary antibody at 
room temperature for 1 hour on an orbital shaker. Primary antibody was diluted in BRB + 
1% (v/v) NCS at concentrations detailed in Table 2.3. Membranes were then washed 3 
times for 15min each time in 2XBRB/T on an orbital shaker before incubation with 
secondary antibody for 1hour at room temperature on an orbital shaker. Polyclonal HRP-
conjugated secondary antibody (Stratech Scientific Limited, UK) was diluted in BRB + 1% 
(v/v) NCS 1:2000. After incubation, membranes were washed three times for 15min each 
time in 2XBRB/T on an orbital shaker.  
500µl of enhanced chemiluminescence (ECL) reagent (Amersham Biosciences) was added 
to each membrane for 2 minutes. The chemiluminescence signal was detected using 
Hyperfilm™ ECL films (Amersham Biosciences) and a Compact X4 Automatic X-ray Film 
Processor (Xograph Imaging Systems Ltd., Gloucestershire, UK). 
Table 2.3: Details of primary antibodies used in immunoblotting  
Protein targeted/clone 
Host 
Species 
Dilution 
Manufacturer/
Reference 
Actin(AC-40) Mouse 
1:1000-
1:2000 
Sigma 
α-tubulin Mouse 1:1000 Sigma 
Lamin A/C (JoL2) Mouse 1:200 Dyer et al., 1997 
Keratin 18 Mouse 1:1000 Oncogene 
Vinculin (VIN-11-5) Mouse 1:500 Sigma 
 
2.2.6. Densitometry 
Differences in protein expression as determined by immunoblotting were quantified using 
densitometry. Developed X-ray films were scanned in a Fujifilm Intelligent Dark Box II 
(Fujifilm Medical Systems, Edison, NJ) directed by Fujifilm Image Reader LAS-1000 Pro Ver. 
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2.11 software. Intensities were quantified using Image J (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-
2009). 
2.2.7. Proteomics 
Equipment used for proteomic analysis was cleaned before use to remove keratins and 
other compounds that may interfere with proteomic analysis. All proteomic experiments 
were carried out in collaboration with Dr. J.W. Simon and Miss. J. Robson, Durham. 
2.2.7.1. Protein sample preparation 
 
2.2.7.1.1. Protein isolation 
Biochemical fractionation was performed on SW480/lamA and SW480/cntl cell extracts in 
the procedure described in Section 2.2.3.  However, instead of producing four pellets (P1-4) 
and four supernatants (S1-4) in each fractionation procedure, the sample was not split into 
four, and only P4 was produced. The supernatants were discarded. Each P4 was solubilised 
in 86μl lysis buffer [9M urea, 2M thiourea, 4% (w/v) CHAPS] plus 2μl protease inhibitor 
cocktail (Sigma), 2μl DNase (5 units/µl) and 10μl 0.4M NEM.  
2.2.7.1.2. Acetone precipitation 
Acetone precipitation is performed to remove any non-protein contaminants such as salt 
which may interfere with the 2D DIGE process. 1ml of ice-cold 80% (v/v) acetone was 
added to the cell pellet, which was then vortexed and incubated overnight at -20oC before 
centrifugation at 15,000g for 10minutes at 4oC in a bench top centrifuge (VWR). The 
supernatant was discarded and pellets were washed once more with ice-cold 80% (v/v) 
acetone before centrifugation at 15,000g for 10minutes at 4oC. After the supernatant was 
removed, the pellet was air dried for 1 minute. The pellet was resuspended in 500μl Tris-
urea labelling buffer [9M urea, 2M thiourea, 4% (w/v) CHAPS, 30mM Tris-HCl pH8.8] and 
vortexted for 1 hour. Samples were centrifuged for 10 minutes at 15,000g. All samples 
were stored at -20oC for short-term and -80oC for long-term storage. 
2.2.7.1.3. Modified Bradford Assay 
It is important to be able to accurately calculate protein concentration for 2D DIGE analysis 
so that identical amounts of protein can be added to each gel, to allow accurate 
comparisons. 
The Bradford assay is a colorimetric assay which utilises the fact that Coomassie Brilliant 
Blue G-250 undergoes an absorbance shift from 465nm to 595nm when it binds to 
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proteins. An increase in absorbance at 595nm is proportional to the amount of Coomassie 
Brilliant Blue that has bound to proteins, and hence the protein concentration. The protein 
concentration of an unknown sample can be calculated by comparing its absorbance value 
to those of samples of known protein concentration. However, basic reagents present in 
samples prepared for 2D DIGE analysis, such as urea and carrier ampholytes, can interfere 
with the binding of Coomassie Brilliant Blue to proteins. A modified assay has therefore 
been developed in which dilute acid is added to protein samples at the start of the 
procedure, neutralising the sample (Ramagli and Rodriguez, 1985). 
BSA (bovine serum albumin) standards in labelling buffer [9M urea, 2M thiourea, 4% (w/v) 
CHAPS, 30mM Tris-HCl pH8.8] ranging from 0-15μg were prepared from a stock solution of 
1μg/μl and made up to a final volume of 15μl in ddH2O. 2μl of protein samples in labelling 
buffer were also made up to a final volume of 15μl in ddH2O water. To each sample, 10μl 
0.1M HCl, 75μl ddH2O water and 900μl of 25% (v/v) Protein Assay Dye Reagent Concentrate 
(BioRad) was added. Samples were vortexed and left to stand for 15min at room 
temperature. Absorbance at 595nm was measured using a spectrophotometer (Thistle 
Scientific, UK) and the concentrations of unknown protein samples were calculated using 
the absorbance values of the BSA standards. 
2.2.7.2. Mini-format 1D SDS-PAGE 
1D SDS-PAGE was performed as described in Section 2.2.5 using 12% gels, with 20μg 
protein added to each well. 
2.2.7.3. Mini-format 2D SDS-PAGE 
 
2.2.7.3.1. Protein loading by in-gel rehydration 
7cm ImmobilineTM Dry strips (GE Healthcare) were used with linear pH gradients of pH3-10 
and pH4-7, as described in the results section. 125µl rehydration solution (50-100µg 
protein solubilised in 9M urea, 2M thiourea, 4% (w/v) CHAPS, 1% (w/v) DTT, 2% (v/v) IPG 
(immobilised pH gradient) buffer pH 3-10 or 4-7 (GE Healthcare), 0.002% (w/v) 
bromophenol blue) was added to each groove of an ImmobilineTM DryStrip reswelling tray 
(Amersham Biosciences). IPG strips were laid gel-side down on top of the rehydration 
solution, covered with 2ml paraffin oil and left to rehydrate overnight. 
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2.2.7.3.2. First dimension isoelectric focusing (IEF) 
IEF separates proteins according to their isoelectric points (pI). Briefly, hydrated strips were 
rinsed with ddH2O and placed gel side up on a Multiphor II Electophoresis System 
connected to an EPS 3501 XL Powers Supply (Amersham Biosciences) with the acidic end 
towards the anode. Electrode wicks were soaked with ddH2O and laid across each end of 
the IPG strips, making contact with the gels. Electrodes were placed on top of the wicks and 
paraffin oil was poured onto the strips. IEF was performed with a circulating water bath 
(Grant Instruments Ltd., Cambridgeshire, UK) maintaining the ceramic cooling plate at 20oC 
to ensure IPG strips did not overheat.  The electrophoresis programmes used are detailed 
in Tables 2.4 and 2.5. The current was maintained at 50µA/strip and the power at 5W. The 
Volt hours determined the length of the IEF run, and time was always in excess. 
Table 2.4: IEF programme (pH 3-10) 
 
Step Volts (V) Volt hours (Vh) 
1 200 10 
2 3500 2800 
3 3500 3700 
Total 6510 
 
Table 2.5: IEF programme (pH 4-7) 
 
Step Volts (V) Volt hours (Vh) 
1 200 10 
2 3500 2800 
3 3500 5200 
Total 8010 
 
2.2.7.3.3. IPG strip equilibration 
During strip equilibration, proteins are prepared for electrophoresis in the second 
dimension through reduction by DTT and binding to SDS. Iodoacetamide is used to alkylate 
the proteins’ thiol groups, in order to prevent their re-oxidation during electrophoresis. 
IPG strips were rinsed with ddH2O and incubated in 2ml equilibration buffer (6M urea, 30% 
(v/v) glycerol, 2% (w/v) SDS, 50mM Tris HCl pH 8.8, 0.002% (w/v) bromophenol blue) 
supplemented with 1% (w/v) DTT on an orbital shaker, at room temperature for 15minutes. 
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The DTT/equilibration buffer was poured off, and equilibration buffer supplemented with 
4.8% (w/v) iodoacetamide was poured onto the strips. This incubation was also carried out 
in the equilibration tray on an orbital shaker, at room temperature for 15minutes. 
2.2.7.3.4. Second dimension SDS-PAGE 
SDS-PAGE was performed as described in Section 2.2.5 using 12% resolving gels, with the 
following modifications: 
The space above the resolving gel was rinsed with ddH2O and the rinsed IPG strip was 
placed on top of the resolving gel, in the place of a stacking gel. 5µl PageRulerTM Prestained 
Protein Ladder Plus (Fermentas, York, UK) was loaded onto a small square of filter paper, 
which was placed next to the alkaline end of the IPG strip. Water was removed with 
blotting paper, and agarose sealing solution (1% (w/v) low melting point agarose, 0.002% 
(w/v) bromophenol blue in tank buffer [25mM Tris pH 8.3, 192mM Glycine, 0.1% (v/v) SDS] 
was poured on top of the strip. Proteins were then visualised using Coomassie Brilliant Blue 
or silver staining (Section 2.2.7.5). 
2.2.7.4. Large-format 2D SDS-PAGE 
 
2.2.7.4.1. Gel casting 
Plates were soaked in 1% (v/v) DeconTM overnight before use to remove any 
polyacrylamide or protein that may be attached. Plates were then rinsed in water, soaked 
in 1% (v/v) HCl for one hour, rinsed with water and allowed to air dry. Plates were wiped 
with 2-4ml of Bind-saline solution [80% (v/v) ethanol, 0.01% (v/v) PlusOne Bind-Silane 
(Amersham Biosciences), 0.2% (v/v) glacial acetic acid] so the gel would be immobilized 
onto the glass plate. An a2DE optimizer (Nextgen Sciences, Huntingdon, UK) was used to 
cast 10% homogenous large format gels with low fluorescence glass cassettes (260mm x 
200mm x 1mm). 
2.2.7.4.2. Reswelling IPG strips 
24cm IPG strips (pH4-7) (Amersham Biosciences) were rehydrated in an ImmobilineTM Dry 
Strip Re-swelling Tray (Amersham Biosciences). Rehydration solution (lysis buffer, 1% (w/v) 
DTT, 2% ampholytes pH4-7, 0.002% (w/v) bromophemol blue) in a final volume of 500µl 
was placed into grooves in the tray and the IPG strips were laid gel-side down on top of the 
solution. 3ml paraffin oil was added onto the top of each strip to prevent urea 
crystallization and evaporation and strips were left to re-swell overnight. 
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2.2.7.4.3. Protein loading using anodic cups 
Rehydrated strips were placed on the EttanIPGphor manifold tray (Amersham Biosciences), 
with the gel side facing up and the basic end at the cathode.  Electrode wicks (5 x 12mm) 
were soaked in water and blotted to remove excess liquid. The wicks were placed at either 
end of each IPG strip and electrodes were clipped on top of each wick. Anodic cups were 
placed on the anodic end of each strip. 70µl paraffin oil was placed in each cup to ensure 
no leaks were present and 70µl sample containing 200µg or 500µg protein was then 
pipetted underneath the oil into the cups. Paraffin oil was poured on top of the IPG strips. 
2.2.7.4.4. First dimension IEF 
IEF was performed as described in Section 2.2.7.3.2 but on an EttanTM IPGphorTM Isoelectric 
Focusing System (Amersham Biosciences). The samples were run overnight to a total of 
70kVh at 50µA per strip at 20oC using the programme outlined in Table 2.6. 
Table 2.6: IEF programme settings 
Step Step Type Time Volts (V) 
1 Gradient 10min 500 
2 Gradient 1hr20min 1000 
3 Gradient 1hr40min 4000 
4 Step ‘n’ Hold 10hr 6500 
5 Step ‘n’ Hold 60hr 1000 
 
2.2.7.4.5. IPG strip equilibration 
Strips were equilibrated as described in Section 2.2.7.3 but using 5ml of each buffer as 
opposed to 2ml. 
2.2.7.4.6. Second dimension SDS-PAGE 
An EttanTM DALTtwelve Large Format Vertical System (Amersham Biosciences) was used for 
second dimension SDS-PAGE. The butan-1-ol in the space above the resolving gel was 
washed away using ddH2O and the IPG strips were placed carefully onto the gel. The water 
was removed by blotting and agarose sealing solution (1% (w/v) low melting point agarose, 
0.002% (w/v) bromophenol blue in Tris-glycine SDS electrophoresis buffer) was poured 
onto the strips. 
7.5 litres of tank buffer [25mM Tris pH 8.3, 192mM Glycine, 0.1% (v/v) SDS] was added to 
the lower reservoir of the tank and 2.5 litres of 2x tank buffer was added to the upper 
reservoir. Electrophoresis was carried out at 5W per gel for 30 minutes followed by 17W 
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per gel for 4 hours at 25oC. After electrophoresis, gels were imaged by staining with SYPRO 
Ruby (Section 2.2.7.5). 
2.2.7.5. In-gel protein staining 
 
2.2.7.5.1. Coomassie Brilliant Blue R-250 
Gels containing proteins separated by SDS-PAGE were stained sequentially in three 
Coomassie Brilliant Blue solutions (see Table 2.7) to allow the gradual removal of 
background staining. Volumes used (100-500ml) were appropriate for the size of the gel. 
Solutions were heated in a microwave for 30 seconds before the gel was placed in the 
solution and left to incubate with on an orbital shaker overnight (solution 1) or for 1hr 
(solutions 2 and 3).  Gels were then washed with Destain solution (67.5% (v/v) until the 
background of the gel was transparent, with the protein bands stained blue. Gels were 
visualised using a Fujifilm Intelligent Dark Box II (Fujifilm Medical Systems, Edison, NJ) 
directed by Fujifilm Image Reader LAS-1000 Pro Ver. 2.11 software. 
Table 2.7: Composition of Coomassie Brilliant Blue solutions 
Component Coomassie Blue solution Destain 
Solution 1 2 3 
1.25% (w/v) Coomassie 
Brilliant Blue R-250 in ddH2O 
2% 0.25% 0.25% - 
Propan-2-ol 25% 10% - - 
Glacial Acetic Acid 10% 10% 10% 10% 
Glycerol - - - 10% 
 
2.2.7.5.2. PlusOne silver staining 
Gels were fixed in 250ml fixing solution [40% (v/v) methanol, 10% (v/v) glacial acetic acid] 
twice for 15 minutes each. This was poured off and 250ml sensitising solution [30% (v/v) 
methanol, 6.8% (w/v) sodium acetate, 0.2% (w/v) sodium thiosulphate] was added and 
incubated for 30 minutes. Gels were washed in deionised water three times for ten 
minutes each, then were incubated in 250ml of 0.5% (w/v) silver nitrate for 20 minutes. 
After brief washing with deionised water, gels were incubated in 250ml developing solution 
[2.5% sodium carbonate, 0.008% (w/v) formaldehyde] for approximately 4 minutes or until 
spots were visible. To stop the reaction, gels were transferred to 250ml of 1.46% (w/v) 
EDTA and incubated for ten minutes. Finally gels were washed in deionised water three 
times for five minutes each wash. Images were taken with a Fujifilm Intelligent Dark Box II 
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(Fujifilm Medical Systems, Edison, NJ) directed by Fujifilm Image Reader LAS-1000 Pro Ver. 
2.11 software. 
2.2.7.5.3. SYPRO Ruby 
Gels were fixed in 250ml fixing solution [40% (v/v) methanol, 10% (v/v) glacial acetic acid] 
twice for 30-60 minutes each and then incubated in SYPRO™ Ruby Protein Stain (Genomic 
Solutions Ltd., Huntingdon, UK) overnight in the dark. Gels were rinsed briefly with 
deionised water, then incubated twice in de-stain solution [10% (v/v) methanol, 6% (v/v) 
acetic acid) for 1-2hrs each. All steps were performed with gentle agitation. Images were 
taken by a Typhoon Variable Mode Imager (GE Healthcare/Amersham Biosciences). 
2.2.7.6. 2-Dimensional Difference in-Gel Electrophoresis 
2D DIGE enables a quantitative analysis of proteins from multiple samples to be compared 
on one 2D gel. 
2.2.7.6.1. CyDye Labelling 
Protein samples were prepared as described in Section 2.2.7.1. The pHs of the samples 
were adjusted to pH 8-9 if necessary with 1M NaOH. CyDye DIGE Fluor minimal dyes (GE 
Healthcare) that had been reconstituted with DMF (dimethylformamide) (≤0.005% H2O, 
≤99.8% pure) were used at a concentration of 0.04mM. For each sample, 1µl of Cy-5 dye 
was added to 50µg protein in 38µl Tris-urea labelling buffer. A pooled standard was 
prepared by mixing 50µg protein from each sample in a total volume of 380µl Tris-urea 
labelling buffer and adding 10µl Cy-3 dye.  After addition of the CyDye, samples were mixed 
by vortexing and left on ice in the dark. To quench the reaction after exactly 30 minutes, 
1µl of 10mM lysine was added to each individual sample and 10µl of 10mM lysine was 
added to the pooled sample. Samples were then mixed by vortexing and incubated on ice 
for 10 minutes. 
A 1D SDS-PAGE gel (Section 2.2.5) was run to evaluate the labelling efficiency. Gels were 
visualized using a Typhoon Variable Mode Imager (GE Healthcare/Amersham Biosciences). 
10µg of each Cy5-labelled sample was mixed with 10µg of Cy3-labelled pooled internal 
standard, 80µl ddH2O water, 400µl (80% v/v) acetone and 5µl 1.5M Tris pH8.8. Samples 
were incubated for an hour at room temperature then centrifuged (VWR) for 10 minutes at 
14,000g, at room temperature. The supernatant was removed and the pellets were air 
dried for 3 minutes. Samples were resuspended in lysis buffer supplemented with 1% (w/v) 
DTT and 2% (v/v) ampholytes (pH4-7) in a final volume of 70µl and vortexed for two hours. 
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2.2.7.6.2. Large-format 2DE of labelled protein samples 
This was performed as described in Section 2.2.7.4; however gels were run overnight at a 
total of 4W. This was increased to 17W per gel in the morning until the dye front had 
reached the base of the gel. 
2.2.7.6.3. DIGE gel imaging 
CyDye labelled proteins were visualized by a Typhoon Variable Mode Imager (GE 
Healthcare/Amersham Biosciences). The machine was switched on 30minutes before use 
to warm up, and the scanning surface was cleaned using lint-free tissue, 70% (v/v) ethanol 
and ddH2O. 
Immediately after SDS-PAGE, gels were rinsed with ddH2O, dried with tissue and scanned. 
Gels waiting to be scanned were kept in the dark. +3mm Gel Alignment Guides were used 
and gels were scanned at the +3mm focal plane whilst being pressed to prevent 
movement. Cy3 images were scanned using a 532nm laser and a 580nm BP 30 emission 
filter. Cy5 images were scanned using a 633nm laser and a 670nm BP 30 emission filter. 
Initial images were scanned at 500µm (pixel size) resolution and an appropriate 
photomultiplier tube voltage was chosen to avoid pixel saturation. Final images were 
acquired at 100µm (pixel size) resolution and were saved as .GEL files. Two images were 
produced per gel, and these were overlaid and saved as multi-channel dataset (.ds) files. 
2.2.7.6.4. Image analysis 
Only four replicates of SW480/lamA were used in the analysis as the principle components 
analysis showed that one of the replicates was anomalous. Gel images were processed 
using Progenesis Samespots (Nonlinear Dynamics, UK). Gel images were aligned in 
automatic model then checked manually. An Anova test was performed, and spots with a 
p-value of <0.05 and a power of >0.7 were chosen to be identified by mass spectrometry. 
This list of 64 spots was further reduced to a list of 29 spots which were confirmed by eye 
to be likely to contain sufficient protein for mass spectrometry analysis.  
2.2.7.7. Mass spectrometry 
Trypic digestion of proteins was performed on a ProGest Workstation (Genomic Solutions 
Ltd.) using a ProGest robot according to the ProGest long trypsin digestion protocol. 
Protein spots were removed from the gel and placed in a 96 well microtitre plate 
containing microscopic holes to allow positive liquid displacement during reagent changes. 
Gel plugs were equilibrated in 50µl of 50mM ammonium bicarbonate, reduced and 
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alkylated with 10mM DTT and 100mM iodoacetamide and destained and dessicated with 
acetonitrile. 
50mM ammonium bicarbonate containing 5% (w/v) trypsin (Promega) was used to 
rehydrate the gel plugs and digest the proteins for 12 hours at 37oC.  Extraction of the 
proteins was performed with 50% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid into a 
final volume of 50µl. Peptide extracts were freeze-dried and resuspended in 10µl 0.1% (v/v) 
formic acid. 
Matrix-assisted laser-desorption/ionization time-of-flight/time-of-flight (MALDI-ToF-ToF) 
mass spectrometry was performed on a 4800 Plus MALDI TOF/TOF Analyser (Applied 
Biosystems, Warrington, UK). 
1µl of matrix solution [saturated α-cyano-4-hydroxy-cinnamic acid in 50% (v/v) acetonitrile, 
0.1% (v/v) trifluoroacetic acid and 10mM ammonium acetate] was spotted onto the MALDI 
target. 1µl peptide solution was then added to each position and left to dry for 1 hour. 
TOF-MS analysis was performed using automated data acquisition and processing with the 
Applied Biosystems 4000 series Explorer software (v3.5) using reflector mode, 1000 total 
laser shots per spectrum, the mass range 700-4000 m/z and a laser intensity of 3300V. 
Spectra were then noise-corrected, peak de-isotoped and internally calibrated using the 
trypsin autolysis peaks 842.5100 and 221.1046 m/z.  The eight most abundant precursor 
ions per spectra then underwent fragmentation and MS-MS analysis using a 1kV CID 
fragmentation method, with 4000 laser shots per spectra and a laser intensity of 3800 over 
the mass range. 
2.2.7.7.1. Protein Identification 
GPS Explorer software (v3.6, Applied Biosciences) generated peak lists of ion masses from 
the MS and MS-MS spectra for each sample. Combined lists of MS and MS-MS data were 
matched to theoretical trypsin digests of proteins from the NCBInr database 
(www.ncbi.nlm.nih.gov) using the MASCOT software (v2.2, Matrix Science) at a mass 
accuracy of 50ppm. The search included the parameters: digestion enzyme trypsin, single 
missed cleavage allowed, variable modifications of carboxymethyl cystein and oxidized 
methionine and fragment ion tolerance of 0.2Da. 
Results were ranked by the MOWSE score (Pappin et al., 1993) which uses the number of 
peptide matches, the number of fragment ion matches, the matching accuracy and a 
weighting for large peptide fragment matches. 
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2.2.8. Wounding assays 
Differences in cell motility were measured using scratch wound assays. SW480/lamA and 
SW480/cntl cells were seeded at 7.5x105 cells per well in a 12 well plate. Once cells reached 
100% confluency, the cell media was removed and wounds were made using a 10µl pipette 
tip (Star Lab, UK). The cell media was changed two times to remove floating cells. The 
wound area was visualized using a live cell imaging phase contrast microscope (Zeiss) at 
X10 magnification. Images were captured every 15minutes for 24 hours in identical wound 
locations. Three wound locations were chosen per well. 
The width of the wound at the start (0hr) and end (24hr) of the experiment was measured 
six times for each wound at 100µm intervals using Axiovision Rel. 4.8 (Zeiss). The mean 
distance the cells moved in 24hours was calculated and standard errors were calculated 
from the biological replicates. A paired student t-test was used to test for statistical 
significance.  
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2.3. Results 
 
2.3.1. Confirmation that SW480/lamA cells contain higher 
levels of GFP-lamin A and endogenous lamin A than SW480/cntl 
cells 
SW480/lamA and SW480/cntl cells are used as a model system to investigate the effect of 
lamin A expression on colorectal cancer cells (Willis et al., 2008). To confirm that the cells 
were still expressing the expected levels of lamin A, protein levels were analysed by 
immunoblotting and densitometry (Figure 2.2). SW480/lamA cells contained GFP-lamin A, 
lamin A and lamin C, whereas SW480 cells contained only lamin A and lamin C, as expected. 
Expression of endogenous lamin A was over 30% higher in the presence of GFP-lamin A. 
When the expression levels of both endogenous lamin A and GFP-lamin A were taken into 
account, SW480/cntl cells contained 65% less lamin A than SW480/lamA cells.  
 
 
 A                                 B                               C 
 
 
 
 
 
Figure 2.2: SW480/lamA cells contain higher levels of GFP-lamin A and endogenous 
lamin A than SW480/cntl cells 
A Whole cell extracts of SW480/lamA and SW480/cntl cells were resolved on a 10% SDS-PAGE 
gel, transferred to nitrocellulose and probed with Jol2 (anti-lamin A/C) antibody. Actin antibody 
was used as a loading control.  
B Densitometric analysis of endogenous lamin A expression in SW480/lamA cells relative to 
SW480/cntl cells. Images were taken with Fujifilm Intelligent Dark Box II and relative densities 
were measured with Image J software. Error bars represent standard errors. 
C Densitometric analysis of GFP-lamin A plus endogenous lamin A expression in SW480/lamA 
cells relative to SW480/cntl cells, as above. Error bars represent standard errors. 
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2.3.2. Confirmation that SW480/lamA cells are more motile 
than SW480/cntl cells 
Willis et al. demonstrated that SW480/lamA cells are more motile than SW480/cntl cells 
using scratch wounding assays (Willis et al., 2008). To confirm that SW480/lamA cells were 
still more motile than SW480/cntl cells, scratch wounding assays were performed. Cells 
were grown in 6-well plates and wounded with a 10μl pipette tip. The mean distance 
moved by cells in 24 hours was calculated from phase-contrast images. SW480/lamA cells 
were shown to be more motile than control cells (Figure 2.3). There was a statistically 
significant difference between the distance moved by SW480/lamA and SW480/cntl cells in 
24 hours (p<0.05) using a paired t-test. SW480/lamA cells moved 20% further than 
SW480/cntl cells in 24 hours. 
 
A                                                      B 
 
 
 
 
 
 
 
Figure 2.3: SW480/lamA cells are more motile than SW480/cntl cells 
A  Representative phase-contrast images of the start and end time points of the cell wounding 
assay. Cells were grown in 12-well plates and wounded with a 10μl pipette tip. Scale bars = 
20μm.  
B  The mean distance moved by cells in 24 hours in scratch-wounding assays as calculated from 
phase-contrast images. In each experiment, three wound locations were chosen for each of 
three biological replicates and images were taken every 15 minutes for 24 hours. Error bars 
represent the standard error calculated from the biological replicates. There is a statistically 
significant difference between the distance moved by SW480/lamA and SW480/cntl cells in 24 
hours (* = p<0.05) using a paired t-test. SW480/lamA cells moved 20% further than 
SW480/cntl cells in 24 hours. 
* 
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2.3.3. Optimisation of biochemical fractionation protocol 
To discover why expression of lamin A in colorectal cancer cells leads to increased cell 
motility, the cytoskeletons of SW480/lamA and SW480/cntl cells were investigated. A 
protocol to isolate the cytoskeleton in these cell lines was optimised, so that the 
differences in cytoskeletal protein expression could be determined using 2D DIGE. The 
advantage of running the cytoskeletal fraction on 2D gels rather than the whole cell extract 
is that the interpretation of results should in principle be easier, as the gel should be less 
crowded, allowing for higher resolution of proteins. The cytoskeleton was chosen for 
analysis as previous studies had implicated cytoskeleton proteins as determinants of 
altered cell motility in SW480/lamA cells (Willis et al., 2008). 
The aim of the biochemical fractionation process was to isolate the cytoskeleton with a 
high yield and as few non-cytoskeletal proteins present as possible. It is important that the 
cytoskeleton is as structurally and functionally intact as is possible, with the minimum of 
protein denaturation. However, it must be noted that it is impossible to isolate the 
cytoskeleton in a completely natural state, as the cellular environment changes 
dramatically in a fractionation process and proteins may adhere to the cytoskeleton during 
homogenisation. 
The original protocol used was an extraction protocol modified from Dyer et al (1997) 
(Section 2.2.3.1). Cells were grown to 70% confluency before undergoing a sequential 
extraction with CSK, CSK/TritonX-100 to remove membrane lipids and the soluble 
components of the cell, Dig/DNase to digest chromatin, and a final extraction with 0.25M 
ammonium sulphate to terminate DNase digestion (Fey et al., 1986; Zhai et al., 1987). The 
last insoluble fraction (P4) should contain the cytoskeleton and the nuclear matrix.  
The first problem encountered was that in some immunoblots, two protein bands were 
seen very close together where just one band was expected, for example in Figure 2.4A 
there appears to be a double band for lamin C in the lanes containing P3 and P4. This may 
have been due to oxidation of the proteins, despite the presence of DTT in the buffers. 
Subsequently, DTT was replaced by 0.04M NEM in every 1ml of buffer in an attempt to 
prevent oxidation. This appeared to be much more effective (Figure 2.4B) as there were no 
double bands seen in subsequent immunoblots. The pellets and supernatants were also 
snap frozen in liquid nitrogen once they had been produced, to reduce the risk of protein 
degradation during the remainder of the procedure.  
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In some immunoblots, there was little or no detection of some proteins in the first 
insoluble fraction, P1 (Figure 2.4A). P1 is a whole cell extract therefore the proteins are not 
as effectively extracted in this fraction compared to the other fractions. Subsequently, to 
ensure efficient protein extraction, P1 was homogenised using a Dounce homogeniser 
before the addition of 2x sample buffer. The immunoblot in Figure 2.4B shows that bands 
in P1 representing A-type lamins became much more prominent; therefore it appeared 
that homogenising P1 was successful in extracting the proteins.  
To further reduce the number of variable factors in the experiments, fractionation of both 
SW480/lamA and SW480/cntl cells was performed at the same time. The fractionation 
procedure was carried out immediately after cell harvesting. To allow comparisons to be 
made between the solubility of proteins in cells in confluent and non-confluent states 
(Section 2.3.4), cells were seeded on day 1 and extracted from flasks of both cell lines at 
the same time on day 2 (subconfluent cells) and day 4 (confluent cells). Cells were counted 
and the same number of cells was used for all four fractionations.  
                 A 
 
 
             B 
 
 
 
 
 
 
Figure 2.4: Optimisation of biochemical fractionation protocol 
A Pellets and supernatants from biochemical fractionation of SW480/cntl cells were resolved 
on 10% SDS-PAGE gels, transferred to nitrocellulose and probed with Jol2 (anti-lamin A/C) 
antibody. DTT was added to samples to reduce protein oxidation, however double bands for 
lamin C can be seen in P3 and P4 fractions (arrows). 
 
B Pellets and supernatants from biochemical fractionation of SW480/cntl cells were resolved 
on 10% SDS-PAGE gels, transferred to nitrocellulose and probed with Jol2 (anti-lamin A/C) 
antibody. NEM was added to samples to reduce protein oxidation and P1 was homogenised with 
a Dounce homogeniser to allow more efficient extraction of proteins. 
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2.3.4.  Confluent and subconfluent SW480 cells show 
differences in solubility of α-tubulin, β-actin and lamin C      
Cell density is known to affect protein expression, cytoskeletal dynamics, cell motility, cell 
signalling and cell-cell/cell-matrix interactions. With this in mind, biochemical 
fractionations were performed on cells that had been harvested when subconfluent (40-
50% confluent) or confluent (95-100% confluent). 
Figure 2.5 shows that, as expected, A-type lamins were present after each extraction step. 
Small amounts of lamin A and C were visible in some of the soluble fractions, particularly 
after ammonium sulphate extraction (S4). The ratio of lamin C: lamin A was greater in the 
insoluble fractions of subconfluent cells than in confluent cells. 
Actin was present in all of the soluble and insoluble fractions studied. In SW480/cntl cells, 
there was less insoluble actin in subconfluent than in confluent cells. In SW480/lamA cells, 
there was less actin in the soluble fraction S2 of subconfluent cells than of confluent cells. 
α-tubulin was present in all of the insoluble fractions of both confluent and subconfluent 
cells. A small amount of α-tubulin was visible in the first soluble fraction (S1) of confluent 
cells and very little/none was seen in subconfluent cells. No differences were observed in 
expression of α-tubulin between the two cell lines. 
It is therefore important to ensure the cells are harvested when at the same confluency 
when preparing pellets for 2D DIGE analysis. 70% confluency was selected for further 
analysis, as this was the confluency used in previous experiments in our lab to analyse 
differences between SW480/lamA and SW480/cntl.  
2.3.5. Cells expressing GFP-lamin A show changes in protein 
expression 
The levels of retention of lamin A, lamin C and α-tubulin were broadly similar in SW480/cntl 
and SW480/lamA fractions (Figure 2.5). GFP-lamin A was present in SW480/lamA cells and 
not in SW480/cntl cells as expected. 
In confluent cells, there was less insoluble actin in P1-3 of SW480/lamA cells compared to 
SW480/cntl cells. The profiles of actin retention were broadly similar in subconfluent cells, 
although there appeared to be more soluble actin in SW480/cntl compared to SW480/lamA 
in the first two fractionation steps.   
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2.3.6. Confirmation that insoluble fraction P4 contains the 
detergent/high salt resistant cytoskeleton 
The immunoblots in Figure 2.5 show that A-type lamins, actin and α-tubulin are all present 
in the insoluble fraction P4 in both SW480/lamA and SW480/cntl cells. Figure 2.6 shows 
that  keratin 18 is also present in P4 in both cell types. These results together demonstrate 
that the final insoluble pellet contains the detergent and high salt resistant 
nucleo/cytoskeletal (N/CSK) proteins .  
To confirm that some proteins had been removed in the fractionation process, the 
expression of the membrane-bound protein vinculin was analysed using immunoblotting 
(Figure 2.6). Vinculin was mostly solubilised in the Triton X-100 extraction, as it is primarily 
present in the soluble fraction S2. A small amount of vinculin was still present in the 
insoluble pellet P4. Although vinculin is localised to the plasma membrane, it may be 
present in small amounts in P4 as it is known to bind to actin (Jockusch and Isenberg, 
1981).  
The final insoluble pellet P4 was therefore used in 2D DIGE analysis to investigate the effect 
of over-expression of lamin A in SW480 colorectal cancer cells on protein expression 
(Section 2.3.8). 
 
 
Figure 2.5: The effect of cell confluency and expression of lamin A on protein expression 
in colorectal cancer cells 
Pellets and supernatants from biochemical fractionation of SW480/lamA and SW480/cntl cells 
were resolved on 12% SDS-PAGE gels and transferred to nitrocellulose. Blots were probed with 
Jol2 (anti-lamin A/C) (A-D), anti-actin (E-H) or anti-α-tubulin (I-L) antibodies. ‘Confluent’ cells 
were harvested at 95-100% confluency and ‘subconfluent’ cells were harvested at 40-50% 
confluency. 
 
  
 SW480/cntl                         SW480/lamA 
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2.3.6. Confirmation that insoluble fraction P4 contains the 
detergent/high salt resistant cytoskeleton 
The immunoblots in Figure 2.5 show that A-type lamins, actin and α-tubulin are all present 
in the insoluble fraction P4 in both SW480/lamA and SW480/cntl cells. Figure 2.6 shows 
that keratin 18 is also present in P4 in both cell types. These results together demonstrate 
that the final insoluble pellet contains the detergent and high salt resistant 
nucleo/cytoskeletal (N/CSK) proteins.  
To confirm that some proteins had been removed in the fractionation process, the 
expression of the membrane-bound protein vinculin was analysed using immunoblotting 
(Figure 2.6). Vinculin was mostly solubilised in the Triton X-100 extraction, as it is primarily 
present in the soluble fraction S2. A small amount of vinculin was still present in the 
insoluble pellet P4. Although vinculin is localised to the plasma membrane, it may be 
present in small amounts in P4 as it is known to bind to actin (Jockusch and Isenberg, 
1981).  
The final insoluble pellet P4 was therefore used in 2D DIGE analysis to investigate the effect 
of over-expression of lamin A in SW480 colorectal cancer cells on cytoskeleton organisation 
(Section 2.3.8). 
 
 
 
 
 
 
Figure 2.6: The membrane-bound protein vinculin is lost from detergent/high salt 
resistant N/CSK during biochemical fractionation of SW480 colorectal cancer cells, 
whereas keratin 18 remains mostly insoluble 
Pellets and supernatants from biochemical fractionation of SW480/lamA and SW480/cntl cells 
were resolved on 12% SDS-PAGE gels and transferred to nitrocellulose. Blots were probed with 
anti-vinculin (A, B) or anti-keratin 18 (C, D) antibodies. Cells in blots A and B were harvested at 
90-100% confluency and cells in blots C and D were harvested at 70-80% confluency. 
 
   
 SW480/cntl                                       SW480/lamA 
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2.3.7. Optimisation of 2D electrophoresis (2-DE) 
2-DE (O'Farrell, 1975) allows the separation of a complex mixture of proteins in two 
dimensions. Proteins are first separated by their isoelectric points (pI) using isoelectric 
focusing and then according to their molecular weights using SDS-PAGE. 2-DE can be used 
to detect differences in protein expression between different samples and can also detect 
post- and co-translational modifications. 
To prepare samples for 2-DE, proteins were precipitated with 80% (v/v) acetone and re-
solubilised in lysis buffer [9M urea, 2M thiourea and 4% (w/v) CHAPS]. A modified Bradford 
assay was used to determine protein concentration (see Section 2.2.7.1). It is important to 
accurately quantify the amount of protein in each sample, particularly in 2D DIGE analysis, 
so that identical amounts of protein can be added to each gel to allow quantitative 
comparisons between samples. 
IPG strips of different lengths were used in the 2-DE analysis. Initially, mini-format 2-DE gels 
were run with 7cm IPG strips, to quickly screen the samples in order to identify the correct 
pH range to be used and to ensure the biological replicates were reproducible. Large-
format 2-DE gels were run with 24cm IPG strips for 2D DIGE analysis and to make 
preparative gels, from which samples were taken for mass spectrometry analysis. The 
longer IPG strips allow higher loading capacity and detection of more protein spots, 
therefore allowing easier identification of proteins. 
Firstly, detergent/high salt resistant N/CSK, isolated from SW480/lamA and SW480/cntl 
cells were analysed using broad range (pH 3-10) IPG strips. 50μg of protein was loaded 
using in-gel rehydration into 7cm IPG strips. Proteins were resolved in the first dimension 
using isoelectric focusing. IPG strips were equilibrated and proteins were resolved in the 
second dimension using 12% mini-format SDS-PAGE gels. The resolved proteins were 
visualised using Coomassie Blue. 
A number of proteins resolved well on the 2D gels. Most proteins appeared to be acidic and 
resolved within a pH range of 4-7. (Figure 2.7: A, B) To improve protein resolution and 
minimise the possibility that different proteins may migrate to the same position on the 2-
DE gel, the same samples were run as described above, but using narrow range IPG strips 
(pH4-7) (Figure 2.7: C, D) Protein spots seen on both pH3-10 and pH4-7 gels were more 
clearly separated on pH 4-7 gels, demonstrating increased resolution. 
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Figure 2.7: Optimisation of 2-DE protocol  
Detergent/high salt resistant N/CSKs were isolated from SW480/lamA and SW480/cntl cells. 
Samples were acetone precipitated and resolubilised in lysis buffer. 
A, B: 50μg of protein was loaded using in-gel rehydration into 7cm pH 3-10 IPG strips. Proteins 
were resolved in the first dimension using isoelectric focusing and in the second dimension 
using 12% mini-format SDS-PAGE gels. The resolved proteins were visualised using Coomassie 
blue staining. Images show mini-format gels run with replicate samples from SW480/cntl cells 
(A) and from SW480/lamA cells (B). 
C, D: 2-DE was performed as described above, with pH4-7 IPG strips and 100μg protein. Images 
show mini-format gels run with replicate samples from SW480/cntl cells (C) and from 
SW480/lamA cells (D). 
  
 SW480/cntl                         
SW480/lamA 
 SW480/cntl                         
SW480/lamA 
SW480/lamA 
SW480/lamA 
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It is important to study biological replicates to increase confidence that any differences 
found between samples are due to a genuine biological difference. Proteomic analysis of 
the differences between SW480/lamA and SW480/cntl requires the biological replicates to 
be highly reproducible so that quantitative comparisons can be made. To ensure the 
protein profiles of biological replicates were reproducible, detergent/high salt resistant 
N/CSKs were isolated from SW480/lamA and SW480/cntl cells in six independent 
experiments. A 12% 1D SDS-PAGE gel was run with 20μg protein from each of the biological 
replicates from both cell types and stained using Coomassie blue (Figure 2.8). This showed 
that the biological replicates were reproducible and that the determination of 
concentration using the modified Bradford assay was accurate. It was also evident that 
there is very little obvious difference between the two samples and therefore a 
quantitative approach such as 2-D DIGE would be necessary to accurately determine the 
differences. 
 
 
 
Figure 2.8: 1D gel shows reproducibility of samples for 2D DIGE  
Detergent/high salt resistant N/CSKs were isolated from SW480/lamA and SW480/cntl cells in 
five further independent experiments. Samples were acetone precipitated and re-solubilised in 
lysis buffer. 20μg protein was added to each well of a 12% SDS-PAGE gel which was stained 
with Coomassie Blue after electrophoresis. 
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Each biological replicate was then run on a mini-format 2-DE gel to discover if the 2D gel 
profiles were reproducible (Figure 2.9). 100μg of protein was loaded using in-gel 
rehydration into 7cm pH 4-7 IPG strips. Proteins were resolved in the first dimension using 
isoelectric focusing. IPG strips were equilibrated and proteins were resolved in the second 
dimension using 10% mini-format SDS-PAGE gels. The resolved proteins were visualised 
using Coomassie Blue. The images show that the biological replicates are reproducible. 
It was thought that a 10% gel might increase the separation of high molecular weight 
proteins; however the visible protein spots were closer together on the 10% gels than in 
the 12% gels. Hence, 12% gels were used in subsequent experiments. 
As the 1D gel (Figure 2.8) revealed many high molecular weight proteins not seen on the 
mini 2D gels (Figure 2.9), a large format 2D gel was run and stained with SYPRO Ruby to 
discover whether or not the profile was more complicated than it appeared with 
Coomassie blue staining. 200μg of protein was loaded using anodic cups into 24cm pH 4-7 
IPG strips. Proteins were resolved in the first dimension using isoelectric focusing. IPG strips 
were equilibrated and proteins were resolved in the second dimension using 12% large 
format SDS-PAGE gels (Figure 2.10). These gels revealed that more high molecular weight 
protein spots were visible than on the mini-format 2D gels stained with Coomassie blue. 
 
 
 
 
 
 
Figure 2.9: 2D mini-format gels confirm reproducibility of replicate samples of 
detergent/high salt resistant N/CSKs and demonstrate that a pH range of 4-7 is 
appropriate for 2D DIGE 
Detergent/high salt resistant N/CSKs were isolated from SW480/lamA and SW480/cntl cells in 
six independent experiments. Samples were acetone precipitated and resolubilised in lysis 
buffer. 100µg of protein was loaded using in-gel rehydration into 7cm pH 4-7 IPG strips. 
Proteins were resolved in the first dimension using isoelectric focusing and in the second 
dimension using 10% mini-format SDS-PAGE gels.  
The resolved proteins were visualised using Coomassie blue staining. Images show mini-format 
gels run with replicate samples from SW480/cntl cells (A, C, E, G, I, K) and from SW480/lamA 
cells (B, D, F, H, J, L). 
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Figure 2.10: 2D large-format gels stained with SYPRO Ruby 
Detergent/high salt resistant N/CSKs were isolated from SW480/lamA and SW480/cntl cells in 
six independent experiments. Samples were acetone precipitated and resolubilised in lysis 
buffer. 200ug of protein from the third replicate of each cell type was loaded using in-gel 
rehydration into 24cm pH 4-7 IPG strips. Proteins were resolved in the first dimension using 
isoelectric focusing and in the second dimension using 10% large-format SDS-PAGE gels. The 
resolved proteins were visualised using SYPRO Ruby staining. Images show large-format gels 
run with replicate 3 from SW480/cntl cells (A) and from SW480/lamA cells (B). 
 
2.3.8. 2D difference in-gel electrophoresis (2D DIGE) 
2D DIGE (Unlu et al., 1997) allows differences in protein expression between samples to be 
accurately detected by labelling samples with CyDyes before electrophoresis. CyDyes are 
mass and charge matched so that identical proteins labelled with any CyDye will migrate to 
identical locations on a 2D gel. An internal standard is included on every gel to remove the 
effects of inter-gel variation, and is produced by mixing together aliquots of all the samples 
in the experiment. This allows quantitative comparisons to be made between gels, based 
on the ratio of the protein abundance in the sample compared to the standard. Statistical 
methods can then be employed to analyse changes in protein abundance between 
different samples. 
Six biological replicates were originally produced, but replicate 2 from both SW480/lamA 
and SW480/cntl cells was discarded as the cells had been isolated at a slightly lower cell 
density than the other five replicates. 
SW480/lamA SW480/cntl 
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Figure 2.11: Samples for 2D DIGE analysis labelled with Cy3 and Cy5 
Detergent/high salt resistant N/CSKs isolated from SW480/lamA and SW480/cntl cells were 
labelled with Cy5 and a pooled internal standard was labelled with Cy3. 4μg of each labelled 
sample was run on a 12% SDS-PAGE gel and visualised with a Typhoon Variable Mode Imager. 
 
For each sample, 1µl of CyDye was added to 50µg protein (prepared as for 2-DE) in 38µl 
Tris-urea labelling buffer. SW480/lamA and SW480/cntl samples were both labelled with 
Cy5, and the pooled internal standard was labelled with Cy3. CyDye labelling was confirmed 
by running 4μg of each labelled sample on a 12% SDS-PAGE gel (Figure 2.11). 
Samples were loaded using anodic cups into 24cm pH 4-7 IPG strips. Proteins were resolved 
in the first dimension using isoelectric focusing. IPG strips were equilibrated and proteins 
were resolved in the second dimension using 12% large format SDS-PAGE gels. Gels were 
scanned using a Typhoon Variable Mode Imager and the images were processed using 
Progenesis Samespots. Gel images were aligned in automatic model then checked 
manually. Only four replicates of SW480/lamA were used in the final 2D DIGE analysis as 
the principle components analysis showed that one of the replicates (replicate 1) was 
anomalous. An Anova test was performed, and spots with a p-value of <0.05 and a power 
of >0.7 were chosen to be identified by mass spectrometry. This list of 64 spots was further 
reduced to a list of 29 spots which were confirmed by eye to be likely to contain sufficient 
protein for mass spectrometry analysis (Figure 2.12). 
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Figure 2.12: 2D DIGE reveals differences in protein abundances of detergent/ high salt 
resistant N/CSK from SW480/lamA and SW480/cntl cells 
2D DIGE gel comparing detergent/ high salt resistant N/CSK from SW480/lamA and 
SW480/cntl cells. Arrows represent protein spots selected for analysis by MALDI-ToF-ToF 
  
Protein over-represented in N/CSK from SW480/lamA cells 
Protein under-represented in N/CSK from SW480/lamA cells 
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In order to identify the protein present in each spot, 2-DE preparative gels were run with 
500μg protein. Protein samples were loaded using anodic cups into 24cm pH 4-7 IPG strips 
and proteins were resolved in the first dimension using isoelectric focusing. IPG strips were 
equilibrated and proteins were resolved in the second dimension using 12% large format 
SDS-PAGE gels. The 29 protein spots identified by 2D DIGE analysis were removed from the 
gel using a Genomic Solutions ProGest robot and subjected to tryptic digestion. MALDI ToF-
ToF analysis was performed on the samples and combined lists of MS and MS-MS data 
were matched to theoretical trypsin digests of proteins from the NCBInr database 
(www.ncbi.nlm.nih.gov) using the MASCOT software (v2.2, Matrix Science) at a mass 
accuracy of 50ppm. The proteins identified are detailed in Figures 2.13 and 2.14. Proteins 
identified with a MOWSE score higher than 82 were considered significant. 
Eight proteins were over-represented in the cytoskeletal fraction of SW480 cells expressing 
lamin A: transglutaminase 2, β-actin, eIF2α, EF-1γ, vimentin, actinin α4, histone cluster 2 
H4b and eIF5A. Five proteins were under-represented in the cytoskeletal fraction of 
SW480/lamA cells: Hsp60, nucleophosmin, EF-1δ, mortalin and EF-Tu.  
Many of the proteins (transglutaminase 2, Hsp60, vimentin, nucleophosmin, actinin α4, 
mortalin and eIF5A) migrated as a train of two or three distinct spots with similar Mr but 
differing pI values. The largest number of mobility forms was observed for β-actin which 
was identified in a train of seven spots. The spots found in trains of mobility forms were 
discovered to have very similar fold change values, with a range of no more than 0.2.  
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Figure 2.13: 2D DIGE and MALDI-ToF-ToF mass spectrometry reveal differences in 
protein abundances of detergent/ high salt resistant N/CSK from SW480/lamA and 
SW480/cntl cells 
2-D DIGE gel comparing detergent/ high salt resistant N/CSK from SW480/lamA and 
SW480/cntl cells, annotated to show the identities of the proteins determined by MALDI-ToF-
ToF 
  
Protein over-represented in N/CSK from SW480/lamA cells 
Protein under-represented in N/CSK from SW480/lamA cells 
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Tables 2.8-2.10 reveal the identities of the proteins highlighted in the 2D DIGE experiment, their 
MS only and MOWSE scores and their fold changes 
 
 
Table 2.8: Protein spots from Figure 2.11A identified using mass spectrometry 
Spot 
no. 
Gene 
symbol 
Gene name 
MS only 
protein 
score 
MOWSE 
score 
Fold 
change 
1 TGM2 Transglutaminase 2 63 108 3.3 
2 TGM2 Transglutaminase 2 88 180 3.5 
3 TGM2 Transglutaminase 2 73 102 3.3 
4 ACTB Beta actin 170 766 1.6 
5 ACTB Beta actin 183 592 1.6 
6 ACTB Beta actin 212 791 1.6 
7 ACTB Beta actin 190 680 1.5 
8 ACTB Beta actin 136 398 1.5 
9 ACTB Beta actin 132 273 1.5 
10 ACTB Beta actin 203 656 1.4 
11 HSPD1 
Heat shock 60kDa protein 1 
(chaperonin) 
81 148 1.5 
12 HSPD1 
Heat shock 60kDa protein 1 
(chaperonin) 
164 345 1.5 
13 EIF2S1 
Eukaryotic translation initiation factor 
2, subunit 1 alpha, 35kDa  
56 1.4 
14 EEF1G 
Eukaryotic translation elongation factor 
1 gamma 
173 446 1.4 
15 VIM Vimentin 373 422 1.3 
16 VIM Vimentin 174 233 1.4 
17 NPM1 Nucleophosmin 60 166 1.3 
18 NPM1 Nucleophosmin 118 164 1.4 
19 ACTN4 Actinin, alpha 4 401 722 1.2 
20 ACTN4 Actinin, alpha 4 374 683 1.2 
21 ACTN4 Actinin, alpha 4 383 698 1.2 
22 EEF1D 
Eukaryotic translation elongation factor 
1 delta 
145 294 1.7 
23 HIST2H4B Histone cluster 2, H4b 
 
117 2.1 
24 HSPA9 Heat shock 70kDa protein 9 (mortalin) 335 701 1.5 
25 HSPA9 Heat shock 70kDa protein 9 (mortalin) 348 701 1.7 
26 TUFM 
Tu translation elongation factor, 
mitochondrial  
166 1.6 
27 EIF5A 
Eukaryotic translation initiation factor 
5A  
166 1.6 
28 EIF5A 
Eukaryotic translation initiation factor 
5A  
127 1.6 
29 EIF5A 
Eukaryotic translation initiation factor 
5A  
215 1.6 
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Table 2.9: Proteins over-represented in N/CSK of SW480/lamA cells 
Spot 
Number(s) 
Gene 
Symbol 
Protein Name 
MOWSE 
score 
Fold change 
1-3 TGM2 Transglutaminase 2 
102 - 
180 
3.3-3.5 
4-10 ACTB β-actin 
273 - 
791 
1.4-1.6 
13 EIF2S1 
Eukaryotic translation initiation 
factor 2, subunit 1 alpha, 35kDa 
56 1.4 
14 EEF1G 
Eukaryotic translation 
elongation factor 1 gamma 
446 1.4 
15-16 VIM Vimentin 
233 - 
422 
1.3-1.4 
19-21 ACTN4 Actinin, α4 683-722 1.2 
23 HIST2H4B Histone cluster 2, H4b 117 2.1 
27-29 EIF5A 
Eukaryotic translation initiation 
factor 5A 
127-215 1.6 
  
 
   
Table 2.10: Proteins under-represented in N/CSK of SW480/lamA cells 
Spot 
Number(s) 
Gene 
Symbol 
Protein Name 
MOWSE 
score 
Fold change 
11-12 HSPD1 
Heat shock 60kDa protein 1 
(chaperonin) 
148 - 
345 
1.5 
17-18 NPM1 Nucleophosmin 164-166 1.3 
22 EEF1D 
Eukaryotic translation 
elongation factor 1 delta 
294 1.7 
24-25 HSPA9 
Heat shock 70kDa protein 9 
(mortalin) 
701 1.5-1.7 
26 TUFM 
Tu translation elongation 
factor, mitochondrial 
166 1.6 
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2.4. Discussion 
The aim of this study was to investigate the changes induced in the insoluble cytoskeleton 
when lamin A is over-expressed in colon carcinoma cells, leading to increased cell motility. 
We used biochemical fractionation to isolate a cytoskeletal fraction from SW480/lamA and 
SW480/cntl cells and then performed 2D DIGE to analyse the changes in abundance of 
proteins in this fraction. It is important to note that we were not comparing differences in 
protein expression between the two cell types, rather the changes in abundance of 
proteins associated with the cytoskeleton. Previous studies have used quantitative 
proteomics to investigate changes in cancer cell motility; however this is the first study to 
focus on a cytoskeletal fraction. 
Proteomic analysis using 2D DIGE requires the biological replicates to be highly 
reproducible so that quantitative comparisons can be made, in order to increase 
confidence that any differences found between samples are due to a genuine difference in 
protein abundance. Immunoblots comparing protein expression in confluent and 
subconfluent cells revealed that there were differences in the solubility of A-type lamins 
and α-tubulin. Hence, cells were always harvested when 70% confluent, to keep the cell 
density constant between biological replicates. 2D gels resolving the proteins present in the 
last insoluble pellet (P4), which contained cytoskeletal-related proteins, were shown to be 
highly reproducible. In conclusion, we were very satisfied that the methodologies used 
were reliable and the biological replicates produced were reproducible. 
Spots present on all the 2D DIGE gels were subjected to an Anova test and 64 spots had a p-
value of <0.05 and power of >0.7 and were considered to be significantly differentially 
expressed.  29 out of the 64 spots were considered likely to contain sufficient protein for 
mass spectrometry analysis and these spots were analysed by MALDI ToF-ToF. The strict 
statistical criteria used to define proteins that were differentially expressed gives further 
confidence in the reliability of the data.  
We found that most of the 29 spots analysed represented multiple isoforms of a set of 13 
proteins. If this is also true of the 35 spots not subjected to MALDI ToF-ToF analysis, it is 
possible that as few as 30 salt and detergent resistant proteins are needed to modify the 
cytoskeleton in order to promote increased cell motility. Many of the proteins 
(transglutaminase 2, Hsp60, vimentin, nucleophosmin, actinin α4, mortalin, eIF5A and β-
actin) migrated as a train of between two and seven distinct spots with similar Mr but 
differing pI values. Interestingly, the spots found in trains of mobility forms were 
72 
 
discovered to have very similar fold change values, with a range of no more than 0.2. This 
gives further confidence that the fold changes identified are reliable. The gel mobility 
isoforms may represent post-translational modifications such as phosphorylation and 
acetylation (Anderson et al., 2010; Coulonval et al., 2003; Halligan et al., 2004).  
MALDI ToF-ToF analysis identified eight proteins that were over-represented in the 
cytoskeletal fraction of SW480 cells expressing lamin A: transglutaminase 2, β-actin, eIF2α, 
EF-1γ, vimentin, actinin α4, histone cluster 2 H4b and eIF5A. Five proteins were identified 
that were under-represented in the cytoskeletal fraction of SW480/lamA cells: Hsp60, 
nucleophosmin, EF-1δ, mortalin and EF-Tu. Twelve out of these thirteen proteins fall into 
three distinct categories: components/modifiers of the CSK, protein chaperones and 
translation initiation/elongation proteins. 
eIF5α, EF-1γ and EF-1δ are all involved in translation elongation and EF-1γ and EF-1δ are 
both subunits of the elongation factor 1 complex (Riis et al., 1990; Saini et al., 2009). EF-Tu 
is involved in protein synthesis in mitochondria, where it drives the cycle of peptide 
elongation and eIF2α is a subunit of eIF2, which catalyses the first regulated step of protein 
synthesis initiation (Sonenberg and Dever, 2003).     
Most of these proteins have known roles in cancer. eIF5A is a regulator of p53, p53-
dependent apoptosis and TNF-alpha-mediated apoptosis and over-expression of eIF5A has 
been shown to induce apoptosis in colon cancer cells (Taylor et al., 2007). eIF2α is over-
expressed in many tumour types, including gastrointestinal carcinoma (Lobo et al., 2000; 
Rosenwald et al., 2001; Wang et al., 2001; Wang et al., 1999). High levels of Ef-1γ have 
been seen in many tumour types, including colon tumours, compared to their normal 
counterparts (Chi et al., 1992; Lew et al., 1992; Mathur et al., 1998). Over-expression of EF-
1γ mRNA in gastric and oesophageal carcinomas was correlated with tumour 
aggressiveness (Mimori et al., 1996; Mimori et al., 1995). EF-1δ mRNA and/or cDNA 
expression was higher in some cancer cells and tumours compared to their normal 
counterparts (Kolettas et al., 1998; Ogawa et al., 2004; Shuda et al., 2000). EF-1δ mRNA 
expression was correlated with lymph node metastases and poorer prognosis in 
oesophageal cancer (Ogawa et al., 2004). However, the effect of EF-1δ in colon carcinoma 
has not yet been studied and the effects of EF-1δ on tumours may be cell-type specific. 
Down-regulation of EF-Tu is associated with human colonic epithelial ageing (Yi et al., 
2010).  Although high levels of EF-Tu were found in tumour tissue compared to normal 
tissue (Koch et al., 1990), little is known about the role of the protein in cancer.  
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The changes seen in the retention of translation factors may reflect an association between 
transcriptional machinery and the cytoskeleton or the nuclear matrix. The cytoskeleton is 
known to be a site for targeted protein synthesis, and EF1α co-localises with F- and β-actin 
mRNA at cell protrusions of crawling cells (Bassell and Singer, 1997; Bassell et al., 1994; Liu 
et al., 2002; Singer, 1992; Yang et al., 1990). The findings might reflect the hypothesis that 
there is a trans-cellular network which physically links the interior of the nucleus via the 
lamins and the cytoskeleton to the extracellular matrix, allowing signalling between the 
outside of the cell and the interior of the nucleus.  
Histone cluster 2 H4b was over-represented in the cytoskeletal fraction of SW480 cells 
expressing lamin A. Histone cluster 2 H4b has only recently been found at the protein level 
(Jufvas et al., 2011) and its function is as yet unknown. Lamins have been shown to bind to 
histones (Mattout et al., 2007; Taniura et al., 1995), therefore the change in the abundance 
of histone cluster 2 H4b may reflect changes in the organisation of chromatin associated 
with lamin A expression. 
Three of the five proteins that were under-represented in the cytoskeletal fraction of 
SW480/lamA cells (Hsp60, mortalin and nucleophosmin) are protein chaperones. All three 
are implicated in cancer (Cappello et al., 2005a; Dundas et al., 2005; Lim and Wang, 2006) 
and are known to bind to CSK proteins or influence CSK dynamics and organisation 
(Kuwabara et al., 2006; Sandsmark et al., 2007; Staubach et al., 2009).  
Nucleophosmin (B23) is a nucleolar phosphoprotein that shuttles between the nucleus and 
the cytoplasm. It has been suggested that nucleophosmin can act as both an oncogene and 
a tumour suppressor gene (Lim and Wang, 2006). It regulates tumour suppressors such as 
p53 and ARF (Gjerset, 2006). The role of nucleophosmin in regulation of the cytoskeleton 
and cell motility is also complex. It is involved in regulating centrosome duplication (Okuda 
et al., 2000; Tokuyama et al., 2001) and maintaining the correct organisation of the 
microtubule network (Wang et al., 2010). HeLa cells lacking nucleophosmin were found to 
have a disrupted microtubule network, with less polymerised tubulin (Wang et al., 2010). 
Recently, knockdown of nucleophosmin has been shown to cause distortion of α-tubulin 
and β-actin structure, resulting from defects in centrosomal microtubule nucleation (Amin 
et al., 2008). Nucleophosmin is a regulator of actin cytoskeleton dynamics. In astrocytes, 
increased expression of nucleophosmin led to decreased actin stress fiber formation and 
inhibition of nucleophosmin shuttling caused increased cell motility (Sandsmark et al., 
2007). It is possible that the decreased association of nucleophosmin with the cytoskeleton 
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in SW480/lamA cells is linked to increased actin dynamics or increased actin stress fibre 
formation, which is often found in invasive cells (Miettinen et al., 1994; Zavadil et al., 
2001). 
Hsp60 is a molecular chaperone found mostly in the mitochondria, but also in the cytosol, 
cell surface, extracellular space and peripheral blood (Cappello et al., 2008). Many studies 
have investigated the role of Hsp60 in cancer. Hsp60 levels are often increased in colorectal 
tumours when compared to normal cells and tissues (Cappello et al., 2003; Cappello et al., 
2005a; He et al., 2007; Mori et al., 2005). Elevated Hsp60 levels were found to correlate 
with high tumour grade and high occurrence of lymph node metastases in large bowel 
carcinomas (Cappello et al., 2005a). However, Hsp60 expression is not always elevated in 
cancer cells (Cappello et al., 2005b; Lebret et al., 2003) and Hsp60 may both promote and 
prevent apoptosis in tumour cells (Chandra et al., 2007; Kirchhoff et al., 2002; Lin et al., 
2001; Samali et al., 1999; Xanthoudakis et al., 1999). In HUVECs (human umbilical vein 
endothelial cells) treated with digoxin to induce apoptosis, lamin A was up-regulated and 
HSP60 was down-regulated, and overexpression of Hsp60  led to decreased apoptosis (Qiu 
et al., 2008). There is no consistent effect of Hsp60 expression on prognosis between or 
even within cancer subtypes (Chaiyarit et al., 1999; Kimura et al., 1993; Lebret et al., 2003; 
Schneider et al., 1999; Thomas et al., 2005).  
Mortalin is a member of the Hsp70 family and, like Hsp60, is a chaperone protein found 
primarily in the mitochondria but also in other cellular locations such as the plasma 
membrane, endoplasmic reticulum, cytoplasmic vesicles and the cytosol (Ran et al., 2000; 
Singh et al., 1997). Some members of the Hsp70 family of proteins have been shown to 
bind tubulin (Gache et al., 2005; Sanchez et al., 1994; Williams and Nelsen, 1997) and 
mortalin is known to bind the microtubule protein RHAMM (receptor for hyaluronan 
mediated motility) (Kuwabara et al., 2006). Mortalin expression is elevated in many, but 
not all, cancer cells and tissues (Dundas et al., 2005; Wadhwa et al., 2006). Dundas et al. 
showed that mortalin is over-expressed in colorectal tumours. High levels of mortalin 
correlated with poor prognosis independent of Dukes stage (Dundas et al., 2005).  
The final part of this discussion will focus on the final four proteins which were over-
represented in the cytoskeletal fraction of SW480/lamA cells: tranglutaminase 2, β-actin, 
actinin α4 and vimentin. 
β-actin is one of six different actin proteins and is one of the two non-muscle cytoskeletal 
actins (Vandekerckhove and Weber, 1978). Actin proteins are vital for cells to be able to 
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move, divide and maintain their shape and they are found as globular G-actin monomers or 
filamentous F-actin. All known forms of migration require the reorganisation of the actin 
cytoskeleton. It is widely known that migration occurs through actin polymerisation at the 
leading edge of the cell and contraction at the sides and rear of the cell, generated by actin-
myosin filaments. β-actin is present at the leading edge of the cell and in actin bundles such 
as stress fibres, filopodia and at cell-to-cell contacts (Dugina et al., 2009; Hoock et al., 
1991). Depletion of β-actin by siRNA causes fibroblasts to move more slowly than controls 
(Dugina et al., 2009). It appears that the links between actin polymerisation, cell motility 
and metastasis are complex. Over-expression of β-actin in myoblasts caused increased cell 
motility, although this did not result from an increase in the rate of actin polymerisation 
(Peckham et al., 2001). However, an increase in the F:G actin ratio was found in the cytosol 
of three metastatic colon adenocarcinoma cell lines compared to a non-metastatic control, 
suggesting actin polymerisation is increased in metastatic cells (Nowak et al., 2002). In 
invasive carcinoma cells from mammary tumours, the genes coding for genes that regulate 
β-actin polymerisation, such as the cofilin capping protein and Arp2/3 pathways were up-
regulated (Wang et al., 2004).  
Actinin α4 is an F-actin cross-linking protein and a member of the spectrin gene superfamily 
(Honda et al., 1998). It also acts as a nucleocytoplasmic shuttling molecule and may be 
involved in regulation of gene expression (Kumeta et al., 2010). Actinin α4 is known to be 
associated with invasion and metastasis in many cancers, including CRC (Honda et al., 1998; 
Honda et al., 2005; Kikuchi et al., 2008; Yamamoto et al., 2009). Actinin α4 is enriched at 
the leading edges of invasive cells (Honda et al., 1998) and has been shown to increase cell 
motility in CRC (Honda et al., 2005). Down-regulation of actinin α4 reduces cell motility in 
glioblastoma and lung fibroblasts (Sen et al., 2009; Shao et al., 2010a). In cells stimulated 
with EGF, actinin α4 is phosphorylated and dissociated from actin filaments (Shao et al., 
2010b). High total or cytoplasmic expression of actinin α4 is significantly associated with 
poor survival in breast, pancreatic and ovarian cancer (Honda et al., 1998; Kikuchi et al., 
2008; Yamamoto et al., 2007).  
Tissue transglutaminase (tTG, TG2) is a ubiquitously expressed multifunctional protein. It 
has both intracellular and extracellular functions, and can be found localised to the cytosol, 
plasma membrane, nucleus or ECM. TG2 contains a Ca2+ regulated transamidase active 
site and cross-links proteins through catalysing the formation of a ε-(γ-glutamyl) lysine 
isopeptide bond. TG2 is thought to play a role in the organisation of the cytoskeleton, as 
actin, α-actinin, tubulin, myosin, cofilin and Hsp27 protein 1 are all TG2 substrates (Nemes 
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et al., 1997; Orru et al., 2003; Puszkin and Raghuraman, 1985; Robinson et al., 2007). TG2 is 
also known to co-localise with stress fibres in human umbilical vein endothelial cells 
(Chowdhury et al., 1997). Interestingly, TG2 substrates identified in colon cancer cells 
include EF-1α, EF-1γ, Hsp60 and members of the Hsp70 family (Orru et al., 2003). 
TG2 expression is associated with increased cell adhesion an TG2 is known to bind 
fibronectin and has been shown to be an adhesion co-receptor of β1 and β3 integrins 
(Akimov et al., 2000; Cai et al., 1991; Gaudry et al., 1999; Gentile et al., 1992; Jones et al., 
1997). TG2 is involved in wound healing (Verderio et al., 2004) and down-regulation of TG2 
causes a significant decrease in migration and adhesion of monocytic cells on fibronectin 
(Akimov and Belkin, 2001). TG2 is also an activator of RhoA, which is involved in 
cytoskeletal rearrangement, a process required for cell migration (Ridley and Hall, 1992; 
Singh et al., 2003b).  
Increased expression of TG2 has been demonstrated in many types of tumours and cancer 
cells when compared to normal counterparts and expression of TG2 in colorectal cancer, 
breast cancer, malignant melanoma and ovarian carcinoma was higher in metastatic 
tumours than in primary tumours (Fok et al., 2006; Hwang et al., 2008; Mehta et al., 2004; 
Miyoshi et al., 2010; Verma et al., 2006). Down-regulation of TG2 by siRNA was shown to 
inhibit metastasis (Hwang et al., 2008; Verma et al., 2008). TG2 activity and expression is 
sometimes found to be lower in tumour tissues than normal tissues (Barnes et al., 1985; 
Birckbichler et al., 2000). Expression of TG2 in cancer cells is often associated with 
decreased prognosis (Hwang et al., 2008; Miyoshi et al., 2010) however intra-tumoural 
injection with TG2 was shown to increase survival (Jones et al., 2006). Colorectal cancer 
patients with high expression of TG2 have a poorer rate of overall survival than those with 
low TG2 expression (P = 0.001) (Miyoshi et al., 2010). The effect of TG2 expression 
therefore may depend on the type and stage of the cancer, or on the cellular localisation of 
TG2 (Mehta et al., 2010). 
One substrate of TG2 that was also over-represented in the SW480/lamA cytoskeletal 
fraction is vimentin (Clement et al., 1998; Gupta et al., 2007). Vimentin is a type III 
intermediate filament protein and a marker of mesenchymal cells, which organises many 
proteins involved with cell adhesion, signalling and migration. Vimentin polymers are 
motile and highly dynamic and there is subunit exchange between the different forms, 
which include non-filamentous particles, short filaments known as ‘squiggles’ and long 
‘mature’ intermediate filaments (Chou et al., 2007). Our results demonstrate that there is 
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more insoluble vimentin in SW480/lamA cells compared to control cells, which could reflect 
the organisation of the different vimentin forms in these cells.  
Vimentin regulates the function of integrins, which are transmembrane cell adhesion 
receptors. Integrins connect the ECM to the actin cytoskeleton and convert signals from the 
ECM into cellular responses such as changes in cell morphology, proliferation and migration 
(Brakebusch and Fassler, 2003). Fibroblasts derived from vimentin null mice show defects 
in cell migration (Eckes et al., 1998) and down-regulation of vimentin expression in SW480 
cells results in impaired migration and invasion (McInroy and Maatta, 2007). Vimentin 
expression was higher in CRC when compared to normal tissue, along with β-actin and 
Hsp60 (Alfonso et al., 2005). Expression of vimentin in cancers has been linked to enhanced 
invasiveness and aggressiveness of cancers (Nagaraja et al., 2006; Singh et al., 2003a; 
Zajchowski et al., 2001). Vimentin expression in the tumour stroma of CRC was associated 
with poor prognosis (Ngan et al., 2007).  
It is possible that the changes observed in the cytoskeleton are a result of TG2 cross-linking 
actin, vimentin and -actinin to other cytoskeleton proteins. The under-representation of 
chaperonin proteins in the cytoskeletal fraction may also be explained by altered regulation 
of the cross-linking of these proteins to the cytoskeleton by TG2. The reduced association, 
particularly of B23, within the cytoskeleton might alter the balance between stress fibre 
formation and other forms of filamentous actin, a hallmark of invasive cells (Miettinen et 
al., 1994; Zavadil et al., 2001).  
Another process which might be involved in the observed changes is the epithelial-
mesenchymal transition (EMT) as vimentin, TG2 and actin are known to be involved in EMT. 
EMT is a well-known process in development and wound healing, in which epithelial cells 
convert to mesenchymal cells. Epithelial cells are tightly packed cells which line body 
cavities and surfaces and are connected by adherens junctions, tight junctions and 
desmosomes; mesenchymal cells are highly mobile and invasive with an elongated 
morphology and front end-back end polarity. EMT also occurs in cancer, and provides a 
mechanism by which tumour cells can leave the primary tumour and metastasise. 
Molecules that induce EMT in development are also known to induce EMT in cancer, such 
as TGF-β, Wnt and Snail/Slug (Cui et al., 1996; Huber et al., 2005; Kim et al., 2002; Savagner 
et al., 1997; Zavadil and Bottinger, 2005). The hallmarks of EMT are downregulation of 
epithelial markers such as E-cadherin, upregulation of mesenchymal markers, typically 
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vimentin or fibronectin, increased cell migration and invasion and a fibroblast-like cell 
morphology. 
TG2 expression was shown to induce an epithelial-mesenchymal transition (EMT) in ovarian 
cancer cells (Shao et al., 2009) leading to increased cell invasiveness and metastasis. TG2 
was also shown to induce EMT in mammary epithelial cells (Kumar et al., 2010). In these 
studies, expression of TG2 caused the loss of E-cadherin and up-regulation of mesenchymal 
markers such as vimentin, fibronectin and N-cadherin, and transcriptional repressors such 
as Snail1, Slug, Zeb1 and Zeb2.  
Remodelling of the actin cytoskeleton is a pre-requisite for EMT, whereby intercellular 
junctions are dissociated and cortical actin is reorganised into actin stress fibres (Miettinen 
et al., 1994; Zavadil et al., 2001). In EMT, TGFβ targets guanine nucleotide exchange 
factors, which activate Rho GTPases, which lead to formation of actin stress fibres 
(Bhowmick et al., 2001; Ridley and Hall, 1992; Shen et al., 2001). Actin filaments in stress 
fibres are held together by α-actinin (Lazarides and Burridge, 1975). There is no information 
in the published literature about the role of actinin α4 in EMT of cancer cells, however it 
may have a role to play in this process as it is known that α-actinin is up-regulated in mouse 
mammary gland epithelial cells in response to TGFβ (Xie et al., 2003). 
In the following chapters we will investigate expression of genes and proteins to explore 
further the possible mechanisms, including EMT, by which the colon carcinoma cells over-
expressing lamin A become more motile.  
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CHAPTER THREE   
The identification of a network of changes in 
gene expression induced by over-expression of 
lamin A 
3.1. Introduction 
Cancer cells progress from normal to transformed to metastatic as a result of many genetic 
alterations (Hanahan and Weinberg, 2000). Understanding the motility of cancer cells is 
important in order to improve diagnosis and prognosis of cancer and to develop 
therapeutic approaches to control metastasis. In the previous chapter, changes in the 
cytoskeleton and its associated proteins were investigated when lamin A was over-
expressed in colon carcinoma cells. To further elucidate the mechanism leading to 
increased cell motility in these cells, we decided to study the results of a DNA microarray 
analysis comparing genome-wide expression levels of genes in SW480/lamA and 
SW480/cntl cells. Our aim was to use bioinformatic approaches to find groups of genes 
with common functions which were differentially expressed in these cells and to highlight 
potential candidates for future analysis. 
Over the last two decades, genome-wide gene expression profiling has become an 
invaluable tool in understanding cancer initiation and progression. DNA microarrays are the 
most commonly used method for large scale whole genome experiments as expression 
levels of genes across the entire human genome can be quantified in a single experiment. 
Applications of DNA microarrays include the identification of diagnostic and prognostic 
biomarkers, therapeutic targets, genetic signatures of tumours and responses to 
chemotherapy (Beane et al., 2009; Heller, 2002).  
In this study, the Affymetrix GeneChip® Human Genome U133 (HG-U133) Plus 2.0 Array 
was used, which allows the analysis of the entire human genome. On this microarray, each 
gene or sequence is represented by a probe set comprising eleven probe pairs, which are 
25 bases long and span a target sequence of around 600 bases. The probe pairs comprise 
Perfect Match (PM) and Mismatch (MM) probes and contain identical oligonucleotide 
sequences, except for the central base in the MM probe which is mismatched. The MM 
probes are used as a control for non-specific hybridisation and the eleven probe pairs 
provide independent measurements for every transcript. Probe sets corresponding to 
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constitutively expressed human maintenance genes are present on the microarray, to be 
used as normalisation controls (http://www.ohsu.edu/xd/research/research-cores/gmsr 
/project-design/array-technology/affymetrix-genechip-arrays.cfm). 
Results produced from microarray experiments present challenges for data analysis, as it is 
difficult to identify the relevant biological processes from the large quantity of information 
generated.  Hence, it is necessary to use applications that can give an overview of the 
biological processes implicated in the dataset and collate the data into clusters of known 
biological function. IPA® (Ingenuity® Systems, www.ingenuity.com) is a web-based software 
application which can be used to analyse data from experiments such as microarrays and 
metabolomic and proteomic experiments. The IPA software contains the Ingenuity® 
Knowledge Base, a database of biological interactions derived from millions of individually 
modelled relationships between proteins, genes, complexes, cells, tissues, drugs, and 
diseases. The database is curated by content and modelling experts, and contains data 
from over 200,000 peer-reviewed publications (Calvano et al., 2005). From this 
information, a molecular network, known as an ‘interactome’, has been generated, in 
which molecules are linked due to known direct physical, transcriptional and enzymatic 
interactions. The interactome allows new experimental data to be examined in the context 
of existing knowledge of genome-wide interactions. In this study, IPA was used to construct 
interaction networks highlighting the biological processes that are over-represented in the 
microarray data.  
Microarray datasets should be validated by an alternative quantitative method of 
measuring gene expression, in order to have confidence in the datasets. Real time Q-PCR 
(Chiang et al., 1996; Gibson et al., 1996; Heid et al., 1996; Higuchi et al., 1993) is the gold 
standard technique for quantitative transcriptome analysis and is a method commonly 
used to validate microarray data. It allows gene expression to be quantified precisely, even 
from very small starting amounts of cDNA. 
In real time Q-PCR, nucleic acid sequences are simultaneously amplified and quantified 
throughout the PCR reaction. A thermocycler is used to measure molecules that give a 
fluorescent signal as a result of probe hydrolysis (TaqMan, Applied Biosystems); probe 
hybridisation (LightCycler, Roche); hairpin probe hybridisation (LUX, Invitrogen); hairpin-
loop hybridisation (Molecular Beacons, Sigma) or binding to double stranded DNA (SYBR 
Green) (VanGuilder et al., 2008).  In this study, SYBR green detection was chosen due to the 
expertise in our lab and its relative cost and ease of use. SYBR green-based detection is not 
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sequence specific and thus the presence of primer-dimers and amplification errors will give 
erroneous fluorescence readings. Hence, primers were checked carefully for sequence 
specificity and a lack of self-complementarity. In a real time Q-PCR reaction, the 
fluorescence signal is measured during the exponential amplification phase. CT (cycle 
threshold) numbers are generated which denote the amplification cycle at which the 
fluorescent signal exceeds a threshold above the background fluorescence (baseline). 
Therefore, the higher the CT value, the lower the gene expression.  
Q-PCR data can be analysed by absolute quantification, through calculating the number of 
copies of a specific RNA, or relative quantification, through comparing the gene expression 
in two or more samples. In this study I used relative quantification as I wanted to compare 
gene expression in SW480/lamA and SW480/cntl cells. I used the 2-∆∆CT method (Livak and 
Schmittgen, 2001) as this is the most common method for relative quantification of real 
time Q-PCR results. This method calculates the fold change in expression based on the CT 
values of the two samples to be compared, normalised to an endogenous control gene 
which is expressed at a constant level in each sample.  
In summary, it was hoped that IPA-based analysis of microarray data comparing gene 
expression in SW480/lamA and SW480/cntl cells and validation by Q-PCR would shed light 
on the mechanisms underlying the increased cell motility seen in colon carcinoma cells 
over-expressing lamin A.  
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3.2. Materials and Methods 
3.2.1. Microarray 
The microarray experiment was performed by Dr. N. Willis (Durham University) and Dr. H. 
Peters (Newcastle University). Briefly, SW480/lamA and SW480/cntl cells were cultured as 
described in Section 2.2.2. Total RNA was extracted from cells at 70-80% confluency with 
TRI Reagent™, according to the manufacturer's instructions. Genome-wide microarray 
analysis was performed using a Human Genome U133 Plus 2.0 high density oligonucleotide 
Affymetrix GeneChip Array (Affymetrix, Santa Clara, CA, USA). 
3.2.2. Analysis of microarray dataset 
The microarray dataset analysis was a collaboration with Dr. D. Swan, Newcastle University. 
*.CEL (Cell Intensity) files containing the results of the intensity calculations on the pixel 
values from the microarray experiment were loaded into GeneSpring GX10 (Agilent).  The 
data was processed with the MAS5 algorithm (Hubbell et al., 2002) to produce Present (if 
the transcript was detected), Marginal (if the transcript was at the limit of detection) and 
Absent (if the transcript was undetected) flag data for the probesets. Probesets with 1 or 
more Present or Marginal calls were selected for further analysis and Affymetrix control 
probesets were removed. The data was renormalized using GCRMA (Guanine Cytosine 
Robust Multi-Array Analysis)(Wu et al., 2003) to produce intensity values for the probesets. 
Probesets were considered differentially expressed if there was a fold change of greater 
than 2 between genes from SW480/lamA cells and SW480/cntl cells. 
The data set was then uploaded into Ingenuity Pathways Analysis (IPA) to compute 
functional analysis of probesets. Each identifier was mapped to its corresponding object in 
the Ingenuity Pathways Knowledge Base. A cut-off of 2.5 fold was set to identify genes 
whose expression was significantly differentially regulated. These Network Eligible 
molecules were overlaid onto a global molecular network developed from information 
contained in the Ingenuity Pathways Knowledge Base. Networks of Network Eligible 
Molecules were then algorithmically generated based on their connectivity. IPA analysis 
was performed using standard settings to examine significance against biological functions 
and disease and canonical pathways (using Fischer Exact tests and a p value of <0.05). The 
interaction networks produced indicate literature-curated interactions with other 
molecules. Each network was given a score, calculated by IPA according to the number of 
Network Eligible Molecules in the network, the network’s size, the total number of 
Network Eligible Molecules analysed and the total number of molecules in IPA’s knowledge 
base that could be included in networks (www.ingenuity.com). The network score is based 
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on the hypergeometric distribution and is calculated using a right-tailed Fisher’s Exact Test, 
with the score being the negative log of the p-value. This score is used to rank the 
networks. 
3.2.3. Molecular biology 
To prevent RNase degradation, all molecular biology techniques were carried out in RNase-
free conditions. RNase Away spray (Fisher Scientific, Loughborough, UK) was used to clean 
surfaces. Ethanol was of molecular biology grade and RNase-free pipette tips and nuclease-
free water (Ambion, Austin, TX, USA) were used. The validation of the microarray data 
using Q-PCR was carried out in collaboration with Miss. D. Battle, Durham University.  
3.2.3.1. Primer Design 
The expression levels of thirteen genes from the microarray dataset were assessed by Q-
PCR analysis to validate the microarray dataset and GAPDH was used as the endogenous 
control gene.  
Affymetrix Probe Set IDs corresponding to genes of interest were identified from the 
microarray dataset which contained the results for genes with an expression change of at 
least two fold when comparing expression in SW80/cntl and SW480/lamA cell lines. A 
NetAffx™ Query (http://www.affymetrix.com/analysis/index.affx) was performed for each 
Probe Set ID to determine the target sequence and relevant RefSeq transcript IDs. The 
Probe Set IDs were found to detect all splice variants of BMP4, COL18A1, EIF4E, IGF2 and 
ZEB1. Only one splice variant of EGFR (NM_005228) was detected. All splice variants of FN1 
except NM_054034 were detected and the remaining genes (AREG, CDH1, EREG, SERPINE1, 
SNAI2 and TGFBI) are not alternatively spliced.  
The PrimerBank database (Spandidos et al., 2010; Wang and Seed, 2003) was then used to 
search for Q-PCR primers corresponding to the genes of interest, taking into account (if 
relevant) which transcript variants were detected in the microarray analysis. PrimerBank is 
a public database containing over 300,000 mouse and human primer pairs for PCR analysis, 
designed by a computer algorithm. The primers are designed to meet the following criteria 
(Wang and Seed, 2003):  
a) Primers should be 19-23 nucleotides in length, which is long enough to be gene-specific, 
but minimises the potential for primers to cross-react 
b) GC contents (35-65%) should be similar to guarantee uniform priming 
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c) ΔG threshold value of -9 kcal/mol for the last five residues at the 3’ end, to minimise 
non-specific primer extension 
d) Tm values of between 60-63
oC such that they will function at a high annealing 
temperature of 60oC which reduces non-specific amplification 
e) Amplicons of 150-350bp (or 100-800bp if necessary) for maximum PCR efficiency 
f) Minimised primer cross-reactivity by rejection of primers containing non-unique 15mers 
and rejection of primers with a BLAST score of less than 30 
g) Rejection of primers that would lead to secondary structures forming in the target or 
primer, to maximise PCR efficiency. 
h) Rejection of primers that would form primer dimers – those that contain four residues at 
the 3’ end, which can be found in the complementary sequence - as this can lead to 
reduced PCR yield because free primers are low.  
N.B. The primers used to detect CDH1 were not taken from the PrimerBank database, but 
had been used previously in our laboratory. 
Primer pairs were analysed using Gene Runner (©Hastings Software Inc.) to check for 
possible secondary structure formation between and within primer pairs. Primers were 
occasionally optimised by removing one or two nucleotides from the start or end of the 
sequence, or adding an extra nucleotide to the end of the sequence. The final primer 
sequences used in this chapter are detailed in Table 3.1. 50nmol primers were synthesised 
by Invitrogen. Primers were diluted to produce a 10μmole working solution.   
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Table 3.1: Primer Sequences used in Q-PCR analysis 
 
3.2.3.2. RNA extraction  
SW480/lamA and SW480/cntl cells were grown to 70% confluency and RNA was isolated 
according to the RNeasy mini kit (Qiagen) protocol. Briefly, cells grown in T75 cell culture 
flasks were washed in versene, trypsinised and centrifuged as described in Section 2.2.2. 
Cells were resuspended and washed in 4ml PBS before centrifugation at 200g for 10 
minutes (Eppendorf 5810R). After the supernatant was removed, cells were snap frozen in 
liquid nitrogen and stored at -80oC. When required, cell pellets were thawed and 
resuspended in 600µl Buffer RLT. The lysates were homogenised by vortexing for 1 minute. 
600µl 70% ethanol (molecular biology grade) was added to each homogenised lysate and 
pipette mixed. The samples were transferred to an RNeasy spin column in a 2ml collection 
tube and centrifuged for 15s at 8,000g. 700µl Buffer RW1 was added to the spin column 
and centrifuged for 15s at 8,000g. 500µl Buffer RPE was then added to the spin column and 
centrifuged for 15s at 8,000g before another 500µl Buffer RPE was added to the spin 
column and centrifuged for 2 minutes at 8,000g to dry the spin column membrane. The 
spin column was then placed in a new 2ml collection tube and centrifuged at 16,000g for 1 
minute to minimise any carryover of buffer RPE. The spin column was placed in a new 
Gene Forward Primer Sequence Reverse Primer Sequence 
AREG CCCAAAACAAGACGGAAAGTGA GCTGACATTTGCATGTTACTG 
BMP4 TGGTCTTGAGTATCCTGAGCG CTGAGGTTAAAGAGGAAACGA 
CDH1 TCTTCCCCGCCCTGCC CTAGCAGCTTCGGAACCGC 
COL18A1 GGCTGGCCTACGTCTTTGG CGGATGTGGAACAGCAGTGAG 
EGFR AAGGAAATCCTCGATGAAGCCT TGTCTTTGTGTTCCCGGACATA 
EIF4E AGGATGGTATTGAGCCTATGTGG CACAGAAGTGTCTCTAGCCAAAA 
EREG GCTCTGACATGAATGGCTATTGT TGTTCACATCGGACACCAGTAT 
FN1 GGCCTGGAACCGGGAACCGA AGGGTGGGTGACGAAAGGGGT 
GAPDH CATGAGAAGTATGACAACAGCCT AGTCCTTCCACGATACCAAAGT 
IGF2 CCTCCAGTTCGTCTGTGGG CACGTCCCTCTCGGACTTG 
SERPINE1 CATCCCCCATCCTACGTG CCCCATAGGGTGAGAAAACC 
SNAI2 ATACCACAACCAGAGATCCTCA GACTCACTCGCCCCAAAGATG 
TGFBI CACTCTCAAACCTTTACGAGACC CGTTGCTAGGGGCGAAGATG 
ZEB1 GATGATGAATGCGAGTCAGATGC ACAGCAGTGTCTTGTTGTTGTAG 
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1.5ml collection tube and 30µl RNase-free water was added. The sample was centrifuged at 
10,000rpm for 1 minute to elute the RNA. Purified RNA was stored at -80oC. 
3.2.3.3. Quantitation and purity of RNA 
A NanoDrop spectrophotometer (Thermo Fisher Scientific, UK) was used to assess the 
concentration and purity of RNA, according to the manufacturer’s instructions. 1µl of 
sample was loaded onto the optical pedestal and the absorbance at 260nm and 280nm and 
the concentration of RNA was calculated. The A260:A280 ratio was used to assess RNA purity, 
as a value of 1.7-2.0 indicated a pure sample.   
3.2.3.4. cDNA synthesis 
cDNA synthesis was performed using the iScript cDNA synthesis kit (BioRad), according to 
the manufacturer’s instructions. Briefly, 4µl 5x iScript buffer, 1µl iScript reverse 
transcriptase and 11µl nuclease-free water were added to 2µg of isolated RNA in 0.5ml PCR 
tubes. The reaction mixtures were incubated at 25oC for 5 minutes, 42oC for 30 minutes 
and then 85oC for 5 minutes to heat inactivate the reverse transcriptase. 80µl RNAse-free 
water was added to the synthesised cDNA such that the final concentration of cDNA was 
20ng/µl. Aliquots were stored at -80oC. 
3.2.3.5. Testing Q-PCR primers 
The 2-∆∆CT method is based on the assumption that the amplification efficiencies of the gene 
of interest and endogenous control gene (in this study, GAPDH) are approximately equal 
(Livak and Schmittgen, 2001). To assess the efficiency of the amplicons, a Q-PCR 
experiment was performed to analyse the CT values produced from a cDNA dilution series. 
This dilution series included cDNA concentrations ranging from 0.1 – 100ng.  
Q- PCR was carried out in MicroAmp® optical 96 well reaction plates (Applied Biosystems). 
1.5µl cDNA, 9µl DNase/RNase-free water, 12.5µl Fast SYBR ®Green Master Mix (Applied 
Biosystems), 1µl forward primer (1000μmole) and 1µl reverse primer (1000μmole) were 
added to each well. A no template control (containing no cDNA) was run for each primer 
used. MicroAmp® optical adhesive film (Applied Biosystems) was placed on the top of the 
96 well reaction plate to reduce well-well contamination and evaporation. The plate was 
spun down in a bench-top centrifuge until any bubbles had been removed. A 7500 Fast 
Real-Time PCR System (Applied Biosciences) was used to perform Q-PCR. Samples were 
denatured at 95oC for 20 seconds, before 40 cycles of melting for 3 seconds at 95oC 
followed by annealing and extending at 60oC for 30 seconds. This was followed by a melt 
curve stage in which the samples were heated to 95oC for 15 seconds, cooled to 60oC for 1 
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minute and subjected to a slow continuous temperature increase to 95oC, before being 
cooled to 65oC for 15 seconds. The baseline and threshold values were detected 
automatically, and checked manually. The baseline should be wide enough to eliminate the 
background fluorescence from the early cycles of amplification but should not overlap the 
exponential growth region of the amplification curve. The threshold should be as close as 
possible to the base of the exponential phase, but above the baseline. 
Graphs were plotted displaying log10[cDNA] on the X axis and CT values on the Y axis. 
Primers were acceptable for use in Q-PCR experiments if the gradient of the graph was 
between -3 and -3.6, as this means the efficiency of the genes is similar enough for the 2-
∆∆Ct
 calculation to be valid. A gradient of -3.3 represents an efficiency of 100%. 
3.2.3.6. Q- PCR  
Once the efficiency of the primers had been assessed, Q-PCR was carried out with as 
described above with 30ng (1.5µl) cDNA added to each experimental well. A no template 
control containing no cDNA was also run for each primer used. Three technical replicates 
were performed in each plate, and three biological replicates were run in separate plates. 
The CT values produced were used to calculate relative changes in gene expression using 
the 2-∆∆CT method (Livak and Schmittgen, 2001), where: 
∆∆CT = (CT,GOI – CT, GAPDH)SW480/lamA - (CT,GOI – CT, GAPDH)SW480/cntl 
The upper and lower error limits were calculated as follows: 
Lower error limit = 2-(mean ∆∆CT + SE) 
Upper error limit = 2-(mean ∆∆CT - SE) 
The standard error of the mean (SE) was calculated as follows, where n = number of 
biological replicates: 
SE = standard deviation of mean ∆CT / √n 
A two-tailed student t test was used to determine whether or not there was a statistically 
significant difference between gene expression in SW480/lamA and SW480/cntl cells for 
each gene studied. 
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3.3. Results 
3.3.1. Microarray analysis reveals changes in gene expression 
between SW480/lamA and SW480/cntl cells 
To understand the genome-wide transcriptional responses to over-expression of lamin A in 
SW480 colon carcinoma cells, a microarray experiment was performed using Human 
Genome U133 Plus 2.0 high density oligonucleotide Affymetrix GeneChip Arrays 
(Affymetrix, Santa Clara, CA, USA) to compare gene expression in SW480/lamA and 
SW480/cntl cells. 1211 probesets were considered to be differentially expressed as there 
was a fold change of greater than 2 between expression of genes from SW480/lamA cells 
and SW480/cntl cells.  
3.3.2. Analysis of microarray data using IPA 
To identify significant biological processes perturbed in response to over-expression of 
lamin A, we used IPA to examine our data in the context of existing knowledge of genome-
wide interactions. The microarray data set containing probesets showing greater than 2.5 
fold differential expression between genes from SW480/lamA cells and SW480/cntl cells 
was uploaded into IPA, which built interaction networks using the Ingenuity Knowledge 
Base. Genes that were not part of the dataset but that were biologically relevant to the 
network were added by IPA to give a total of approximately 35 molecules in each network. 
The algorithm used to create the networks ensures that as many genes from the dataset 
are included as is possible. The interaction networks produced (Figures 3.1-3.2; Appendix) 
display individual molecules as nodes connected by edges representing the relationships 
between the nodes. Scores (discussed in Section 3.2.2) calculated by IPA were used to rank 
the networks, where scores of 2 or higher have a p value of at least 0.01. Network 1 (Tables 
3.2-3.4) contains 35 genes, therefore a score of 44 reveals that there is a 1 in 1x1044 chance 
that a network containing at least the same number of Network Eligible Molecules will be 
picked by chance when randomly selecting 35 genes from the IPA knowledge base. The 
scores ranged from 44 (Network 1) to 11 (Network 10), which suggests that every network 
is linked to biological processes which are affected when lamin A is over-expressed in colon 
cancer cells. 
Of the highest scoring ten networks identified (Table 3.5), three were linked to molecules 
involved in cancer and three were linked to cell movement, and Network 1, the most 
significant network, was linked to cancer, cellular movement and cellular growth and 
proliferation. Figure 3.3 shows known interactions between the genes in Network 1, 
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derived from information contained in the Ingenuity Knowledge Base. The genes implicated 
in this network and the known interactions between them may give insight into the 
mechanisms involved in the change in motility seen when lamin A is expressed in SW480 
colon carcinoma cells.  
In vivo, biological pathways interact with each other rather than functioning independently. 
To explore the relationships between the networks, molecules that were common to two 
or more networks were identified (Figure 3.4). Ten genes were found to be common to two 
or more networks, four of which were derived from the microarray dataset, but six of 
which were added by IPA. Seven of the networks were found to form a large cluster, 
including networks linked to cancer (Networks 1, 3 and 7), cellular movement (Networks 1 
and 7), cellular growth and proliferation (Networks 1, 3 and 4) and cell-cell signalling and 
interaction/cell signalling (Networks 4, 5 and 8). Networks 3, 4 and 7 formed the centre of 
this cluster, as each had links to three other networks. Networks 2 and 10 had ACTN2 in 
common. Although network 9 had no genes in common with other networks, it contained 
genes linked to cellular movement, akin to networks 1 and 7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Network 1 produced by IPA 
Affymetrix microarray data comparing SW480/cntl and SW480/lamA cell lines was analysed 
using IPA. Interaction networks were produced from probesets displaying greater than 2.5 fold 
differential expression and show known literature curated interactions with other molecules. 
The networks were analysed for significance against known biological functions. Networks are 
ranked by their ‘Score’, which is calculated by IPA and described in more detail in Section 3.2.2. 
The network with the highest score, ‘Network 1’, is shown in this figure. 
The number of ‘Focus molecules’ indicates the number of genes in each network that were 
present in the microarray probe set. These genes are circled in the diagrams: genes in red 
circles were up-regulated in SW480/lamA when compared to SW480/cntl and genes with blue 
circles were down-regulated. 
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Network Shapes                 Relationships 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.2: The types of molecules and interactions represented by shapes and arrows 
in IPA Networks 
The shape surrounding the gene name denotes the type of molecule that the gene encodes. 
Lines (known as edges) that link genes indicate known interactions and a dotted line 
indicates an inferred or indirect interaction. The arrowheads indicate directionality and 
lines without an arrowhead refer to a binding interaction. Curved arrows designate self-
regulation.  
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Table 3.2: Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
AKAP11 3.18 A kinase (PRKA) anchor protein 11 
AREG 5.22 amphiregulin 
BRCA2 2.29, 2.93 breast cancer 2, early onset 
CDC42EP5 3.43 CDC42 effector protein (Rho GTPase binding) 5 
CHI3L1 2.56, 4.65 chitinase 3-like 1 (cartilage glycoprotein-39) 
CKAP2 2.78 cytoskeleton associated protein 2 
DKK1 6.3 dickkopf homolog 1 (Xenopus laevis) 
EGFR 2.13, 2.99  epidermal growth factor receptor  
EIF4E 3.15 eukaryotic translation initiation factor 4E 
EMP1 6.40, 8.84, 9.47 epithelial membrane protein 1 
EREG 5.73 epiregulin 
ETS1 2.77, 3.61 
v-ets erythroblastosis virus E26 oncogene homolog 1 
(avian) 
FN1 
3.31, 3.77, 
3.93, 4.01 
fibronectin 1 
FOSL1 4.04 FOS-like antigen 1 
IGF2BP1 2.68 insulin-like growth factor 2 mRNA binding protein 1 
IL6R 3.82, 3.97 interleukin 6 receptor 
MET 2.81 met proto-oncogene (hepatocyte growth factor receptor) 
MIA 4.95 melanoma inhibitory activity 
MSX1 3.54 msh homeobox 1 
NRP1 2.75 neuropilin 1 
SERPINE1 3.81 serpin peptidase inhibitor, clade E, member 1 
SNAI2 4.05 snail homolog 2 (Drosophila) 
UPP1 2.78 uridine phosphorylase 1 
   
Table 3.3: Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
BMP4 7.19 bone morphogenetic protein 4 
CDH1 3.43 cadherin 1, type 1, E-cadherin (epithelial) 
CHGA 4.8 chromogranin A (parathyroid secretory protein 1) 
COL18A1 2.7 collagen, type XVIII, alpha 1 
IGFBP3 2.79, 2.92 insulin-like growth factor binding protein 3 
IGF2 8.61 insulin-like growth factor 2 (somatomedin A) 
INSIG1 2.27, 2.41, 2.81 insulin induced gene 1 
MSX2 2.23, 2.89 msh homeobox 2 
   
Table 3.4: Genes added by IPA 
Symbol   Entrez Gene Name 
ADAM17   ADAM metallopeptidase domain 17 
TFF3   trefoil factor 3 (intestinal) 
TJP1   tight junction protein 1 (zona occludens 1) 
EPHB2   EPH receptor B2 
Tables 3.2-3.4 – Genes included in Network 1  
These tables display the genes included in Network 1, whether they were present in the 
microarray dataset or added by IPA and the fold changes revealed by the microarray analysis.  
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Network Top Functions Score 
Focus 
Molecules 
1 
Cancer, 
Cellular Movement, 
Cellular Growth and Proliferation 
44 31 
2 
Cell-To-Cell Signalling and Interaction, 
Cellular Assembly and Organization, 
Nervous System Development and Function 
20 19 
3 
Cancer, 
Cellular Growth and Proliferation, 
Cell Death 
16 16 
4 
Cellular Growth and Proliferation, 
Cell-To-Cell Signalling and Interaction, 
Cellular Function and Maintenance 
14 15 
5 
Cell Signalling, 
Small Molecule Biochemistry, 
Immunological Disease 
14 15 
6 
Lipid Metabolism, 
Small Molecule Biochemistry, 
Molecular Transport 
14 15 
7 
Cellular Movement, 
Connective Tissue Development and Function, Cancer 
14 14 
8 
Cell-To-Cell Signalling and Interaction, 
Haematological System Development and Function, 
Immune Cell Trafficking 
11 13 
9 
Cell Death, 
Cellular Movement, 
Cell Cycle 
11 13 
10 
Neurological Disease, 
Psychological Disorders, 
Cell-To-Cell Signalling and Interaction 
11 13 
 
Table 3.5: IPA Networks 1-10 
This table displays the top functions of the genes included in Networks 1-10, the network scores 
and the number of focus molecules in each Network.  
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Figure 3.3: Interactions between Networks 1-10 
This diagram shows which genes feature in more than one Network. Each Network has between 
0-5 genes in common with other Networks. Genes in bold type are those present in the 
microarray dataset; those in normal type are genes added by IPA to complete the networks.  
 
Further analysis of the IPA-generated networks indicated that two molecules previously 
considered to be implicated in the mechanism by which over-expression of lamin A in colon 
carcinoma cells leads to an increase in cell motility were present in Networks 1-10. TGM2 is 
present in Network 5, which links together molecules involved in Cell Signalling, Small 
Molecule Biochemistry and Immunological Disease. PLS3 is in Network 10, which contains 
molecules linked to Neurological Disease, Psychological Disorders and Cell-To-Cell Signalling 
and Interaction. 
3.3.3. Validation of microarray data using Q-PCR 
As discussed in the introduction to this chapter, real time Q-PCR is the gold standard 
technique for validation of microarray data sets. It is particularly important to validate the 
microarray dataset in this particular study, as although eleven technical replicates were 
incorporated into each probeset, no biological replicates were investigated. Eleven genes 
were selected for real time Q-PCR analysis, which were nodes in Network 1 (AREG, BMP4, 
CDH1, COL18A1, EGFR, EIF4E, EREG, FN1, IGF2, SERPINE1 and SNAI2) that connected to 
between two and nine other genes in the network.  
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The 2-∆∆CT method, used to quantify the relative expression change between samples, is 
based on the assumption that the amplification efficiencies of the gene of interest and 
endogenous control gene are approximately equal. To assess the efficiency of the 
amplicons, a Q-PCR experiment was performed to analyse the CT values produced from a 
cDNA dilution series. This dilution series included cDNA concentrations ranging from 0.1 – 
100ng. Graphs were plotted displaying log10[cDNA] on the X axis and CT values on the Y 
axis. A gradient of -3.3 represents an efficiency of 100%. All the primers tested were 
acceptable for use in Q-PCR experiments because the gradient of the graphs were between 
-3 and -3.6, which means the efficiencies of the genes were similar enough for the 2-∆∆Ct 
calculation to be valid.  
As SYBR Green binds all double stranded DNA, it was important to perform melt curve 
analysis to confirm the integrity of the PCR product. After PCR cycling, the temperature was 
raised slowly from 65oC to 95oC and the 7500 Software v2.0.5 (Applied Biosystems) plotted 
graphs of the derivative reporter (–Rn’) against temperature (oC). The increase in 
temperature causes PCR products to denature, which leads to a decrease in fluorescence. 
In these graphs, a single peak represents the decreased fluorescence at the melting point 
of the PCR products. The presence of additional peaks can indicate that primer-dimers or 
non-specific products are formed. An extra peak was occasionally seen in ‘no template 
control’ experiments, where no cDNA was added. However, we are confident that primer-
dimers and non-specific products did not influence our data, as only single peaks were 
found in graphs representing experiments containing cDNA. A representative melt curve 
graph is shown in Figure 3.4. 
Due to the large amounts of data produced from the Q-PCR experiments, all the 
amplification plots produced are not shown; instead a representative amplification plot is 
shown in Figure 3.4. The combined data showing the relative expression of all 13 genes 
analysed in SW480/lamA and SW480/cntl cells, from three biological replicates, each with 
three technical replicates, can be seen in Figure 3.5.  
The amplification plot in Figure 3.4 detailing the amplification of EREG in the SW480/lamA 
and SW480/cntl cell lines shows the progression of the real time Q-PCR reaction. ΔRn is 
plotted on the Y-axis and cycle number is plotted on the X-axis. ΔRn is calculated using the 
following equation: 
ΔRn = (ROX™ fluorescence / SYBR Green fluorescence) - baseline 
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Figure 3.4: Representative graphs generated from real time Q-PCR experiments 
Both graphs are taken from the real time Q-PCR analysis of EREG expression in SW480/lamA 
and SW480/cntl cells and are representative of other graphs generated in the experiment. 
A Melt curve displaying single peaks which correspond to the point at which the PCR 
product has melted. The purple line indicates the ‘no template control’. 
B A real time Q-PCR amplification plot showing the changes in SYBR green fluorescence 
during the reaction. The red, yellow and green lines represent the technical replicates from 
the SW480/lamA sample and the blue and purple lines represent the technical replicates 
from the SW480/cntl sample.  
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ROX™ is a passive reference dye present in the SYBR green mastermix that provides an 
internal fluorescence reference to which the SYBR green signal can be normalised. The 
baseline is defined by the initial cycles of QPCR in which there is little change in 
fluorescence. From this graph, the CT values can be determined, which denote the cycle 
number at which the amplification of a PCR product is first detected above the background 
fluorescence, passing the threshold. The threshold is a level of ΔRn that is above the 
baseline but low enough to be within the exponential growth region on the amplification 
plot.  The higher the starting amount of target, the lower the CT value. From the graphs in 
Figure 3.4, it can be seen that EREG expression is higher in SW480/lamA cells than in 
SW480/cntl cells, as the SW480/lamA sample has a lower CT value.  
Figure 3.5 shows the differences in expression of selected genes when comparing 
SW480/lamA and SW480/cntl cells. Of the genes present in Network 1, eight changes in 
gene expression identified in the microarray analysis were confirmed by Q-PCR (BMP4, 
CDH1, COL18A1, EGFR, EIF4E, FN1, IGF2, and SERPINE1), two changes in gene expression 
identified in the microarray analysis were not statistically significant (AREG and EREG) and 
Q-PCR analysis did not confirm the change in gene expression of SNAI2 identified in the 
microarray analysis (Figure 3.6). As over 70% of the genes investigated confirmed the 
change in expression identified in the microarray analysis, it was concluded that there was 
enough evidence from the QPCR experiment to have confidence in the microarray data. 
 
 
 
 
 
Figure 3.5: Quantitative real time PCR shows changes in gene expression between 
SW480/lamA and SW480/cntl cells 
Q-PCR was carried out in 96 well plates with 30ng (1.5µl) cDNA added to each experimental 
well. A no template control (containing no cDNA) was also run for each primer used. Three 
technical replicates were performed in each plate, and three-five biological replicates were run 
in separate plates. The CT values produced were used to calculate relative changes in gene 
expression using the 2-∆∆CT method (Livak and Schmittgen, 2001), with GAPDH as the 
normalisation control gene. 
A two-tailed student t test was used to determine whether or not there was a statistically 
significant difference between gene expression in SW480/lamA and SW480/cntl cells for each 
gene studied (* = p<0.05, ** = p<0.01, *** = p<0.005).  
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Figure 3.6: Validation of microarray data by real time Q-PCR 
This graph shows the relative fold change of gene expression in SW480/lamA cells when 
compared to SW480/cntl cells. The dark grey bars represent the real time Q-PCR data, and the 
grey bars represent the microarray data. Statistical significance of real time Q-PCR data, 
determined by a two-tailed student t test, is denoted by asterisks (* = p<0.05, ** = p<0.01, *** = 
p<0.005). 
 
3.3.4. Epithelial Mesenchymal Transition  
In the previous chapter, it was noted that several of the proteins highlighted in the 2D DIGE 
results are involved in EMT. To discover whether EMT is a significant process implicated in 
the changes in gene expression between SW480/lamA and SW480/cntl, gene lists 
generated from the microarray data were compared to gene lists linked to EMT generated 
by IPA - ‘Epithelial-Mesenchymal Transition of Epithelial Cells’ (Table 3.6) and ‘Epithelial-
Mesenchymal Transition of Cells’ (Table 3.7). There was a statistically significant overlap 
between the IPA-generated ‘Epithelial-Mesenchymal Transition of Epithelial Cells’ list and 
the microarray-generated 2.5 fold change list (p=2.16x10-2) and the 2 fold change list 
(p=6.73x10-3). Statistical significance was determined by a Fisher’s exact (hypergeometric) 
test within IPA against the reference set of ‘all genes’. There was also a statistically 
significant overlap between the IPA-generated ‘Epithelial-Mesenchymal Transition of Cells’ 
list and the microarray-generated 2.5 fold change list (p=7.12x10-2) and the 2 fold change 
list (p=1.35x10-3).  
Expression levels of two genes (ZEB1 and TGFBI) which were present in the microarray 
dataset and known to be linked to TGFβ were also analysed by Q-PCR.  ZEB1, which was 
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found to be 2.25 fold up-regulated in SW480/lamA cells compared to the control cells in 
the microarray experiment, was chosen because like SNAI2, it is a repressor of E-cadherin, 
and has been shown to induce EMT in tumour cells (Eger et al., 2005). TGFBI, one of the 
genes from Network 9, was selected because it is known to promote metastasis when 
overexpressed in SW480 cells (Ma et al., 2008) and because it is induced by TGFβ, an 
inducer of EMT (Cui et al., 1996; Skonier et al., 1992). TGFBI was up-regulated 4.3 fold in 
SW480/lamA cells compared to the control cells in the microarray experiment.  
Q-PCR analysis revealed that TGFBI was statistically significantly up-regulated in 
SW480/lamA compared to SW480/cntl cells, verifying the microarray data (Figures 3.5 and 
3.6). ZEB1 was also up-regulated in the cells over-expressing lamin A, consistent with the 
microarray data, but the differences determined by Q-PCR were not statistically significant. 
 
 
Table 3.6: Identities of genes in the IPA ‘Epithelial-Mesenchymal Transition of Epithelial 
Cells’ list and the fold changes of the genes present in the microarray dataset  
The microarray 2 and 2.5 fold change datasets were searched for genes which appear in the IPA 
‘Epithelial-Mesenchymal Transition of Epithelial Cells’ list and the fold changes between 
SW480/cntl and SW480/lamA cells were recorded. 
  
Molecule Fold change Up/down regulated in 
SW480/lamA compared to 
SW480/cntl 
BMP7   
CDC42   
CDH1 3.43 down 
EGF   
LEF1 2.07 up 
MST1R   
S100A4   
SMAD3   
SNAI1   
SNAI2 4.05 up 
TGFB1   
TWIST1   
ZEB1 2.25 up 
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Molecule Fold change 
Up/down regulated in 
SW480/lamA compared to 
SW480/cntl 
ABL1   
AKT1   
AKT2   
BMP7   
CAV1   
CDC42   
CDH1 3.43 down 
EGF   
FGF1   
FOXC2   
FOXO1   
GSC   
HNF4A   
HNRNPAB   
ID1   
IGF1R 2.12 down 
IRS1 2.37 up 
JAG1   
KLF8   
LEF1 2.07 up 
MIR200A (includes EG:406983)   
MIR200B (includes EG:406984)   
MIR200C (includes EG:406985)   
MST1R   
NFYB   
PAX3   
PLAU   
PLAUR 2.39, 2.72, 2.73 up 
PP1   
PTPN14   
S100A4   
SMAD3   
SMAD4   
SNAI1   
SNAI2 4.05 up 
SP1   
TGFB1   
TGFB3   
TWIST1   
ZEB1 2.25 up 
ZEB2   
 
Table 3.7: Identities of genes in the IPA ‘Epithelial-Mesenchymal Transition of Cells’ list 
and the fold changes of the genes present in the microarray dataset  
The microarray 2 and 2.5 fold change datasets were searched for genes which appear in the IPA 
‘Epithelial-Mesenchymal Transition of Cells’ list and the fold changes between SW480/cntl and 
SW480/lamA cells were recorded.  
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3.3.5. Comparison of 2D DIGE data with microarray data 
The microarray data was then interrogated to discover if any of the genes encoding the 
twelve proteins identified in the 2D DIGE analysis comparing detergent/ high salt resistant 
N/CSK from SW480/lamA and SW480/cntl cells (Section 2.3.8) were present. TGM2 
expression was higher in SW480/lamA compared to control cells, with a 2.65 fold change in 
expression. HSPD1 expression was lower in SW480/lamA cells compared to control cells, 
with a fold change of 2.60. In these cases, higher expression of the gene in SW480/lamA 
cells correlated with increased association of the protein with the cytoskeleton, and vice 
versa. The 2D DIGE data revealed that TGM2 was over-represented in the cytoskeletal 
fraction of SW480/lamA cells compared to control cells, with a 3.3-3.5 fold change, and 
HSPD1 protein expression was under-represented in the cytoskeletal fraction of 
SW480/lamA cells, with a 1.5 fold change. 
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3.4. Discussion 
3.4.1. Validation of microarray results 
We have previously shown that over-expression of lamin A in colon cancer cells leads to 
increased cell motility and a poor prognosis for patients. In this chapter, a genome-wide 
expression study was analysed in order to identify genes and pathways that are affected by 
lamin A expression. Expression of lamin A led to large-scale changes in gene expression, as 
over 1200 probesets were differentially expressed. Further analysis with IPA revealed that 
many of the genes highlighted were known to have functions in cell migration and EMT. 
Q-PCR expression data for 9 out of 13 genes examined correlated closely with data from 
the microarray, and showed statistically significant differences in gene expression. This 
indicated that data obtained from the microarray analysis could reliably be used as the 
basis for further experiments.  
Of the four genes investigated that did not have reproducible changes in gene expression 
when examined by microarray and Q-PCR analysis, three (AREG, EREG and ZEB1) which 
were differentially expressed in the microarray analysis showed no significant difference in 
gene expression in Q-PCR experiments and SNAI2 expression was significantly lower in 
SW480/lamA cells in Q-PCR experiments, contrary to the results of the microarray analysis. 
There are a number of possible reasons for the variability in our data. 
Firstly, it is possible that there are genuine biological differences in the cells, as the RNA 
samples for the microarray and the QPCR experiments, although isolated from the same 
cell line, were isolated many years apart. Many colorectal cancer cells are genetically 
unstable, and the SW480 cell line in particular is known to be chromosomally unstable 
(Camps et al., 2005; Lengauer et al., 1997; Ribas et al., 2003). Hence, there may be 
differences between RNA isolated for the microarray experiment, when the cell lines were 
first established compared to the RNA recently isolated for the Q-PCR analysis. 
Differences in expression of SNAI2 and ZEB1 may be due to variability of transcription 
factor expression throughout EMT. It is thought that EMT may consist of discrete phases, 
with differences in gene expression occurring during transition between the different 
stages of EMT (Savagner et al., 1997; Vetter et al., 2009). Some studies have also shown 
that several transcription factors, including Twist and Zeb1, are upregulated following loss 
of E-cadherin. It is thought that this creates a feed-forward loop of E-cadherin repression 
which may lead to stabilisation of the mesenchymal state in EMT (Onder et al., 2008). 
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Hence, transcription factors such as Snail may initiate the repression of epithelial genes, 
whereas other transcription factors such as Zeb1 may act later in EMT to prolong the 
repression (Guaita et al., 2002; Peinado et al., 2007).  
Regulation of the expression levels of Snai2 and Zeb1 is complex and is controlled by a 
number of different factors which may be responsible for the differences in expression 
between the microarray and Q-PCR data: E2A-HLF and Mitf regulate SNAI2 (Inukai et al., 
1999; Sanchez-Martin et al., 2002) and IGF-1, Snail1 and Twist regulate Zeb1 (Dave et al., 
2011; Graham et al., 2008).  Also, Snai2 expression is not always accompanied by down-
regulation of CDH1 (Savagner et al., 1997; Uchikado et al., 2011) and TG2-induced EMT 
showed down-regulation of both CDH1 and SNAI2 (Kumar et al., 2010) so it is not 
necessarily inconsistent that both SNAI2 and CDH1 are down-regulated in cells expressing 
lamin A.  
The proteins encoded by AREG and EREG, amphiregulin (AR) and epiregulin (EPI), are 
members of the epidermal growth factor family which can bind the epidermal growth 
factor receptor (EGFR) and are known to stimulate proliferation of some cell types, but 
inhibit growth of others (Plowman et al., 1990; Toyoda et al., 1995). Expression of EPI and 
AR can be regulated by toll-like receptor 4 (TLR4) (Hsu et al., 2010), which was found to be 
up-regulated by 2.09 in SW480/lamA cells in the microarray analysis. It is possible that no 
significant changes in EPI and AR expression were found in the Q-PCR analysis because 
TLR4 or another protein which regulates EPI and AR was not significantly changed in 
expression in the cells at the time of RNA extraction for Q-PCR analysis.  
The microarray chip contains internal controls, whereby some genes have more than one 
corresponding probeset. AREG and EREG both had two corresponding probesets, where 
one probeset showed up-regulation of the gene, whereas the other probeset did not. ZEB1 
had four corresponding probesets, three of which were up-regulated by 1.29, 1.49 and 2.25 
fold respectively, and one of which showed no change. SNAI2 was only represented by one 
probeset. Therefore some of the non-reproducible changes in gene expression may due to 
problems such as errors in hybridisation efficiency in the microarray experiment. 
3.4.2. Expression of lamin A in colon carcinoma cells causes 
changes in expression of genes linked to cell motility and EMT 
Genes highlighted in the microarray dataset were clustered into networks by IPA on the 
basis of the known functions of their gene products. The ten most significant networks 
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produced all had highly significant scores of at least 11, indicating that each of these 
networks is linked to biological processes which are affected when lamin A is over-
expressed in colon cancer cells. The most significant network, Network 1, had a score of 44 
and contained 31 genes from the microarray dataset and 4 genes which were added by IPA. 
This network linked together molecules involved in cancer, cellular movement and cellular 
growth and proliferation.  
A-type lamins are known to regulate cell proliferation, as normal and tumour cells with low 
expression levels of A-type lamins display high proliferative capacity (Broers et al., 1997; 
Rober et al., 1989; Van Berlo et al., 2005; Venables et al., 2001). However, we have 
previously shown that there is no difference in cell proliferation between SW480/lamA and 
SW480/cntl cells (Willis et al., 2008). Hence, I have concentrated on exploring the links 
between the genes of Network 1 and cell motility. 
The aim of this chapter was to use IPA to highlight genes that might be involved in the 
mechanism that causes increased cell motility when lamin A is over-expressed in colon 
carcinoma cells. Therefore, it is extremely interesting that Network 1 includes genes linked 
to cell motility and that there is a statistically significant overlap between IPA lists of genes 
linked to EMT and the microarray dataset. It can be postulated that expression of lamin A 
in colorectal cancer cells causes an increase in cell motility through inducing an epithelial-
mesenchymal transition. 
Many of the genes in Network 1 encode proteins which are known to induce EMT or EMT-
like responses, including SNAI2 (Hajra et al., 2002; Savagner et al., 1997), BMP4 (Hamada et 
al., 2007; Molloy et al., 2008), MSX2 (Hamada et al., 2007; Satoh et al., 2008), EIF4E (Ghosh 
et al., 2009) and EGFR (Lo et al., 2007).  
One of the hallmarks of EMT is down-regulation of the cell adhesion molecule E-cadherin. 
Loss of E-cadherin expression is one of the most common alterations in cancer cells and 
abolition of E-cadherin function is a critical step in the acquisition of invasive properties. 
The gene that encodes E-cadherin, CDH1, is one of the nodes found in Network 1, and was 
found to be down-regulated in SW480/lamA cells in both microarray and Q-PCR analysis. 
This is particularly interesting because our lab has previously shown that the increased cell 
motility of SW480/lamA cells is in part due to up-regulation of the actin bundling protein T-
plastin, which causes down-regulation of E-cadherin (Willis et al., 2008). The gene for T-
plastin, PLS3, which the microarray showed to be up-regulated by 19.06 in SW480/lamA 
cells, is in Network 10 which contains molecules linked to Neurological Disease, 
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Psychological Disorders and Cell-To-Cell Signalling and Interaction. Plastins control the 
organisation of the actin cytoskeleton through crosslinking actin filaments into tight 
bundles. Expression of L-plastin, an isoform of T-plastin, has been linked to increased 
invasiveness in cancer (Al Tanoury et al., 2010; Klemke et al., 2007). T-plastin expression is 
increased in cisplatin-resistant cancer cells, in comparison to cisplatin-sensitive cells 
(Hisano et al., 1996), which suggests that T-plastin may be up-regulated in more aggressive 
tumours. No links have yet been reported between T-plastin and EMT. 
A number of proteins encoded by genes in Network 1 are involved in cell adhesion in 
addition to E-cadherin, including fibronectin, SERPINE1, MIA and CHGA. CHGA 
(chromogranin A) and SERPINE1 modulate cell adhesion and can exhibit either pro- or anti-
adhesive activity (Durand et al., 2004; Gasparri et al., 1997). Both fibronectin and MIA are 
involved in cell-matrix attachments. Fibronectin is a ligand for many members of the 
integrin family, which link the ECM with the cytoskeleton. MIA is a protein expressed in 
primary and metastatic malignant melanomas but not in normal tissue (Blesch et al., 1994; 
Bosserhoff et al., 1996) which promotes metastasis through the regulation of cell-matrix 
attachments. It binds to fibronectin and laminin, preventing cells from binding the ECM, 
leading to invasion and metastasis (Bosserhoff et al., 1998). 
Along with down-regulation of E-cadherin and changes in cell adhesion, EMT involves up-
regulation of mesenchymal markers, extensive reorganisation of the actin and intermediate 
filament cytoskeleton and increased cell motility. We observed that many genes in 
Network 1 were linked to these processes: 
A number of the genes in Network 1 encode proteins known to be associated with the 
cytoskeleton, including IGFBP1, CDC42EP5 and CKAP2. CDC42 effector protein 5 is a CDC42 
binding protein that induces the assembly of actin filaments, leading to changes in cell 
shape (Hirsch et al., 2001). In fibroblasts, ectopic expression of CDC42EP5 led to loss of 
stress fibres and extension of protrusive lamellipodia (Joberty et al., 1999). IGF2BP1 binds 
β-actin mRNA, preventing its translation until the complex reaches the periphery of the cell 
(Huttelmaier et al., 2005; Ross et al., 1997), localizing it to sites of active actin 
polymerisation, where it modulates cell migration. Cytoskeleton-associated protein 2 is 
known to associate with the microtubule-organising centre and microtubules (Bae et al., 
2003; Maouche-Chretien et al., 1998; Seki and Fang, 2007). SERPINE1 and fibronectin 
expression and EGFR transactivation are sensitive to disruption of the cytoskeleton 
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(Providence et al., 1999; Samarakoon et al., 2009; Samarakoon and Higgins, 2002; Varedi et 
al., 1997).  
One of the main processes linked to the proteins encoded by the genes in Network 1 is 
cellular motility. FN1, EIF4E, NRP1 and EGFR, which were up-regulated in the microarray 
dataset are known to encode proteins which are expressed in highly motile and invasive 
cancer cells. Fibronectin is a typical mesenchymal marker and has been shown to promote 
cancer cell migration and invasion (Meng et al., 2009; Shibata et al., 1997). Down-
regulation of fibronectin in SPC-A-1sci lung cancer cells caused decreased metastasis both 
in vitro and in vivo (Jia et al., 2010). eIF4E, a component of the translation initiation 
complex, is essential for pseudopod protrusion and tumour cell migration and invasion 
(Shankar et al., 2010). Knockdown of eIF4E in metastatic cells results in an MET and 
reduced actin cytoskeleton dynamics (Shankar et al., 2010). NRP1 is up-regulated in 
metastatic cells compared to non-metastatic cell lines and tumours (Miao et al., 2000). 
Over-expression of EGFR is linked to increased cell motility, invasion and metastasis (Kruger 
and Reddy, 2003; Thomas et al., 2003; Verbeek et al., 1998). SERPINE1, which was also up-
regulated, has both pro- and anti- migration and invasion roles in cancer, depending on its 
level of expression, the composition of the ECM and expression levels of associated 
proteins (Dellas and Loskutoff, 2005; Durand et al., 2004). Decreased EMP1, which was 
down-regulated in our microarray dataset, is known to be correlated with lymph node 
metastasis in patients with oral squamous cell carcinoma (Zhang et al., 2011).  
It is possible that expression levels of lamin A influence TGFβ-mediated EMT. A-type lamins 
are known to be involved in regulating gene activity downstream of TGFβ, as A-type lamins 
modulate responses to TGFβ signalling in mesenchymal cells through regulation of 
transcription factors such as pRB and SMADs (Van Berlo et al., 2005). MAN1, a lamin A-
interacting protein, is also known to regulate TGFβ signalling through binding to R-Smads 
(Lin et al., 2005; Osada et al., 2003).  
Many of the genes in Network 1 are linked to TGFβ signalling. BMP4 is a member of the 
TGFβ superfamily. SERPINE1 and SNAI2 are up-regulated by TGFβ and AREG is 
downregulated by TGFβ (Akiyoshi et al., 2001; Choi et al., 2007; Joseph et al., 2009). eIF4E 
is linked to TGFβ-mediated EMT, as TGFβ activates mTOR, inducing the phosphorylation of 
4E-BP1, which causes dissociation of eIF4E from 4E-BP1, increasing protein synthesis (Hay 
and Sonenberg, 2004; Lamouille and Derynck, 2007).  
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It should be noted that the IPA analysis did not highlight EMT in Networks 1-10. Taking this 
into consideration along with the finding that the changes in SNAI2, ZEB1, AREG and EREG 
expression were inconsistent, it is possible that the changes seen in our system represent a 
novel pathway that is similar to EMT but not a classical EMT.   
3.4.3. Conclusion 
In conclusion, our data indicate that lamin A expression in colon carcinoma cells may cause 
an EMT-like response resulting in cells with a more aggressive phenotype, leading to poor 
survival for the patient.  This is a novel finding, as currently nothing is published about the 
relationship between lamin A expression and EMT. The differences between SW480/lamA 
and SW480/cntl cell lines may be mediated through the TGFβ signalling pathway, changes 
in the organisation of the cytoskeleton or by increasing the level of transcription factors. 
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CHAPTER FOUR  
The effects of siRNA knockdown of lamin A on 
gene and protein expression and cell motility  
 
4.1. Introduction 
In the previous chapter we showed that lamin A expression in colon carcinoma cells 
increases cell motility and causes an EMT-like process most likely through activating a 
predicted pathway (Network 1) that may be controlled by TGFβ signalling. Here, I test this 
hypothesis by using siRNA to knockdown lamin A and subsequently to investigate which 
genes in Network 1 change in response.  
In Chapter 3 it was postulated that expression levels of lamin A may influence TGFβ-
mediated signalling, as A-type lamins are known to be involved in regulating gene activity 
downstream of TGFβ.  A-type lamins modulate responses to TGFβ signalling in mouse 
embryonic fibroblasts through regulation of transcription factors such as pRB and SMADs 
(Van Berlo et al., 2005; Worman, 2006).  
The four genes initially selected for analysis were CDH1, FN1, TGFBI and TGM2 as their 
expression is known to be regulated by TGFβ (Cui et al., 1996; Ignotz and Massague, 1986; 
Shin et al., 2008; Skonier et al., 1992; Xu et al., 2009). CDH1 and FN1 were both present in 
Network 1 and have previously been implicated in cell motility changes during metastasis 
(Meng et al., 2009; Perl et al., 1998; Shibata et al., 1997; Willis et al., 2008). TGFBI was 
identified as being differentially expressed in the microarray analysis (Chapter 3) and TG2 
was highlighted in the 2D DIGE analysis (Chapter 2).  
Expression levels of SNAI2 and ZEB1, which are both also regulated by TGFβ, were also 
analysed because whilst they were shown to be upregulated in SW480/lamA cells in the 
microarray analysis this was not confirmed in the QPCR analysis. It is thought that EMT may 
consist of discrete phases, each with different gene expression profiles (Savagner et al., 
1997; Vetter et al., 2009), whereby transcription factors such as Snail initiate the repression 
of epithelial genes, whereas other transcription factors such as Zeb1 act later in EMT to 
prolong the repression (Guaita et al., 2002; Peinado et al., 2007). Therefore, it is possible 
that expression levels of SNAI2 and ZEB1 differ throughout the EMT response, warranting 
further study. 
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There are many different ways in which TGFβ can induce EMT in cancer cells: through 
SMAD-dependent pathways and through SMAD-independent pathways which involve 
activation of signalling systems such as Ras/MAP kinase, Wnt/β-catenin, PI3K/AKT, NF-κB, 
Rho/ROCK, Jagged/Notch, and MDM2/p53 (Tian et al., 2011). 
In EMT, TGFβ can induce expression of Snail and ZEB families of transcription factors which 
then activate expression of mesenchymal genes such as fibronectin and repress expression 
of epithelial markers such as E-cadherin (Medici et al., 2008; Xu et al., 2009). TGFBI is also 
induced by TGFβ (Cui et al., 1996; Skonier et al., 1992) and is known to promote metastasis 
when overexpressed in SW480 cells (Ma et al., 2008).  
In a recent paper, TG2 was shown to induce EMT, causing increased expression of E-
cadherin repressors such as Zeb1, downregulation of E-cadherin and upregulation of 
fibronectin (Kumar et al., 2010). TG2 was found to be required for TGFβ-induced EMT, and 
is thought to be a downstream effector of TGFβ (Kumar et al., 2010). It was also found that 
TG2 expression conferred a stem-cell like phenotype along with induction of EMT (Kumar 
et al., 2010).  
Therefore, it was hypothesised that knockdown of lamin A by siRNA would lead to an MET 
in which decreased expression of TGM2 and TGFBI was followed by decreased expression 
of SNAI2 and ZEB1, which would cause increased expression of CDH1 and decreased 
expression of FN1. Finally, it was expected that the changes in gene expression would lead 
to a decrease in cell motility compared to control cells. 
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4.2. Materials and Methods 
4.2.1. siRNA knockdown 
4.2.1.1. siRNA sequences used 
The Silencer® Select Custom Designed siRNA (Ambion) sequences targeted sequences in 
exons 11 or 12 of LMNA, and were therefore specific for lamin A but not lamin C (Table 
4.1). Silencer® Select Negative Control #1 siRNA (si-c) was used as a negative control. 
Table 4.1: siRNA sequences targeting lamin A 
Name ID Sequence (5’-3’) 
Si-1 s238117 Sense: UCAUCUAUCUCAAUCCUAAtt 
Antisense: UUAGGAUUGAGAUAGAUGAga 
Si-2 s238118 Sense: GGCCUGCUGUGAUUCCACUtt 
Antisense: AGUGGAAUCACAGCAGGCCaa 
 
4.2.1.2. siRNA transfection in T-25 tissue culture flasks 
24 hours before transfection, SW480/lamA cells were seeded at a density of                                                                                                                                                                                                                                                                                                          
2.5x105 cells per flask. Cell media was changed immediately preceding transfection, and L-
15 media containing FBS but no antibiotics was added. Cells were treated with a 
transfection mixture containing 400μl serum-free L-15 medium, 20μl Oligofectamine 
reagent (Invitrogen) and 30μl Lamin A siRNA [20μM] (ID#s238117 or #s238118, Ambion) or 
scrambled siRNA [20μM] (Ambion). Media was changed after 24 hours. Cells were 
processed for protein or RNA extraction between 24 and 48 hours post-transfection. 
4.2.1.3. siRNA transfection in 6 well plates 
In the experiments shown in Figure 4.3, cells were seeded at a density of 1.0x105 cells per 
well 24 hours before transfection. In all other experiments, cells were seeded at a density 
of 4.0x105 cells per well 24 hours before transfection. Cell media was changed immediately 
preceding transfection, and L-15 media containing FBS but no antibiotics was added. Cells 
were treated with a transfection mixture containing 200μl serum-free L-15 medium, 10μl 
Oligofectamine reagent (Invitrogen) and 10μl Lamin A siRNA [20μM] (ID#s238117 Ambion), 
10μl scrambled siRNA [20μM] (Ambion) or 10μl nuclease free water. Media was changed 
after 24 hours. Cells were processed for protein/RNA extraction or wounding assays 
between 24 and 120 hours post-transfection. 
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4.2.2. Wounding assays  
Differences in cell motility were measured using scratch wound assays. SW480/lamA cells 
were seeded at 4.0x105 cells per well in a 6 well plate and transfected with siRNA as 
described in Section 4.2.1. After either 72 or 96 hours, the cell media was removed and 
wounds were made using a 10µl pipette tip (Star Lab, UK). The cell media was changed two 
times to remove floating cells. The wound area was visualized using a live cell imaging 
phase contrast microscope (Zeiss) at X10 magnification, and photographs of the cells were 
taken in confluent areas. Images were captured every 15minutes for 24 hours in identical 
wound locations. Three wound locations were chosen per well. 
The width of the wound at the start (0hr) and end (24hr) of the experiment was measured 
six times for each wound at 100µm intervals using Axiovision Rel. 4.8 (Zeiss). The mean 
distance the cells moved in 24hours was calculated and standard errors were calculated 
from the biological replicates. A paired student t-test was used to test for statistical 
significance. 
Photographs of the cells were taken with the live cell imaging phase contrast microscope 
(Zeiss) at X10 magnification before the wounding assay started, in order to compare the 
morphology of the cells. 
4.2.3. Q-PCR 
Q-PCR was carried out as described in Section 3.2.3. RNA was isolated from the cells at 36, 
48, 60, 72, 84 and 96 hours post-transfection. Primers specific for CDH1, FN1, SNAI2, TGFBI 
and ZEB1, described in Section 3.2.3, were used in Q-PCR analysis. Primers were also 
designed to target TGM2, with the following sequences: forward primer sequence: 
AGCGTTCCTCTTTGCATCCTC and reverse primer sequence: GTAGCTGTTGATAACTGGCTCC.  
 
4.2.4. One dimensional SDS-PAGE and immunoblotting 
1D SDS-PAGE and immunoblotting were performed as described in Section 2.2.5. The 
mouse polyclonal anti-TGFBI antibody (ab89062) was sourced from Abcam and was used at 
a dilution of 1:250.  
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4.3. Results 
 
4.3.1. Selection of siRNA construct for efficient down-regulation 
of lamin A  
It was first necessary to investigate the efficiency of the siRNA constructs in knocking down 
expression of lamin A in SW480/cntl cells. The cells were transfected with two different 
siRNA constructs and a scrambled negative control siRNA. Cells were harvested 24, 36 and 
48 hours after transfection and the efficiency of knockdown was analysed through 
immunoblotting (Figure 4.1).  
siRNA ID s238117 (si-1) was much more effective at knocking down lamin A than siRNA ID 
s238118 (si-2) (Figure 4.1). si-1 knocked down lamin A by over 60% after 48hours. Neither 
of the siRNAs knocked down GFP-lamin A expression at the timepoints assayed. At some 
timepoints GFP-lamin A and/or endogenous lamin A expression was higher in control cells 
than in si-lamin A treated cells. To ensure that the scrambled siRNA control did not have 
any effect on expression of lamin A, control transfections were performed using water 
(NTC) instead of siRNA (Figure 4.2 A). Expression of lamin A was assessed at 48, 72 and 96 
hours after transfection. No difference was seen between expression of lamin A in the 
scrambled siRNA control and the NTC, demonstrating that si-control is a suitable control. 
As knockdown of lamin A was highest 48hrs after transfection, expression of lamin A was 
assessed at 24 hour time points up to 120 hours post-transfection (Figure 4.2 B). si-1 was 
shown to consistently knock down endogenous lamin A at 24, 48, 72, 96 and 120 hour time 
points, and endogenous lamin A was knocked down by over 95% at 120 hours post-
transfection (Figure 4.2 B,D).  
GFP-lamin A was knocked down by over 50% at the 24 and 120 hour timepoints (Figure 4.2 
B,D), whereas expression in si-cntl cells was approximately the same, or higher, at the 48-
96 hour timepoints.  
These experiments show that si-1 can efficiently knockdown endogenous lamin A for at 
least 120 hours post-transfection, and that GFP-laminA expression is also reduced at 120 
hours post-transfection. si-1 was therefore used in further experiments, and is henceforth 
referred to as si-laminA.  
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Figure 4.1: Analysis of different siRNA oligonucleotides shows that si-1 is more effective 
than si-2 at knocking down lamin A expression 
A Immunoblot of whole cell extracts from SW480/lam A cells transfected with lamin A siRNA ID 
s238117 (si-1), ID s238118 (si-2) or scrambled negative control (si-c), resolved on a 10% SDS-
PAGE gel and probed with Jol2 antibody. Actin was used as a loading control.  Cell pellets were 
harvested at 24, 36 and 48 hours post transfection with siRNA. 
B Densitometric analysis of endogenous lamin A expression at each time point in cells 
transfected with si-1 or si-2, relative to si-c. Images were taken with Fujifilm Intelligent Dark 
Box II and relative densities were measured with Image J software. 
 
C Densitometric analysis of GFP-lamin A expression at each time point in cells transfected with 
si-1 or si-2, relative to si-c as described above. 
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Figure 4.2: SW480/lamA cells transfected with lamin A siRNA show reduced lamin A 
expression when compared to control cells 
A Immunoblot of whole cell extracts from SW480/lam A cells transfected with si-laminA ID 
s238117 (si-l), scrambled negative control siRNA (si-c) or no si-RNA (NTC), resolved on a 
10% SDS-PAGE gel and probed with Jol2 antibody. Actin was used as a loading control.  Cell 
pellets were harvested at 48, 72 and 96 hours post transfection with siRNA. 
B Immunoblot of whole cell extracts from SW480/lam A cells transfected with si-laminA ID 
s238117 (si-l) or scrambled negative control siRNA (si-c), resolved on a 10% SDS-PAGE gel 
and probed with Jol2 antibody. Actin was used as a loading control. Cell pellets were 
harvested at 24, 48, 72, 96 and 120 hours post transfection with siRNA. 
C Densitometric analysis of endogenous lamin A expression in SW480/lamA cells transfected 
with si-lamin A compared to those transfected with si-control. Images were taken with 
Fujifilm Intelligent Dark Box II and relative densities were measured with Image J software. 
D Densitometric analysis of GFP-lamin A expression in SW480/lamA cells transfected with si-
lamin A compared to those transfected with si-control, as described above 
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4.3.2. Down-regulation of lamin A by siRNA transfection causes 
decreased cell motility 
Scratch wound assays were used to investigate the effect of knockdown of lamin A on cell 
motility. Cells were seeded in 6 well plates and were transfected with either si-laminA or si-
control 24 hours after seeding. Cells reached 100% confluency at 72 hours post-
transfection. Scratches were made either 72 hours or 96 hours post-transfection, and the 
distance moved by cells in 24 hours was calculated from phase-contrast images (Figure 
4.3). Three scratches were made in each well, enabling at least three technical replicates 
and three biological replicates of each experimental condition to be analysed per plate. 
There was no statistically significant difference between si-control and si-lamin A cell 
motility between 72 and 96 hours post siRNA transfection. However, there was a 
statistically significant difference between the distance moved by si-control and si-lamin A 
cells between 96 and 120 hours post siRNA transfection (p<0.001) whereby si-control cells 
moved 1.3 times further than si-lamin A cells. 
 
 
Figure 4.3: SW480/lamA cells transfected with lamin A siRNA show reduced cell motility 
when compared to control cells 
The mean distance moved by cells in 24 hours as calculated from phase-contrast images. In 
each experiment, three locations were chosen for each of three biological replicates and images 
were taken every 15 minutes for 24 hours. Error bars represent the standard error calculated 
from the biological replicates.  
 
There was no statistically significant difference between si-control and si-lamin A cell motility 
measured between 72-96 hours post siRNA transfection. However, there was a statistically 
significant difference between the distance moved by si-control and si-lamin A cells between 96 
and 120 hours post siRNA transfection (p<0.001; ****). Si-control cells moved 1.3 times further 
than si-lamin A cells. 
 
 
 
 
**** 
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4.3.3. Down-regulation of lamin A by siRNA transfection causes 
changes in gene expression over time 
We next wanted to investigate whether or not changes in expression of genes implicated in 
cell motility in general, or more specifically in EMT, occurred between the time at which 
knockdown of lamin A was first observed, and the change in cell motility seen at 96 hours 
post-transfection. To do this, SW480/lamA cells were seeded in 6 well plates and 
transfected with either si-laminA or si-control 24 hours after seeding. Cells were processed 
for RNA extraction every 12 hours between the 60 hour and 96 hour time points. To 
confirm knockdown of lamin A, cells were processed for protein extraction every 24 hours 
between the 24 hour and 120 hour time points. To confirm the change in motility, a scratch 
wound assay was performed between 96 and 120 hours post-transfection. The whole 
experiment was repeated independently three times. 
Knockdown of endogenous lamin A in si-laminA transfected SW480/lamA cells could be 
seen at all timepoints from 24-120 hours and the band for lamin A in the immunoblot was 
barely visible by 120 hours (Figure 4.2B). GFP-lamin A expression was also reduced by 60% 
in si-lamin A cells at the 120 hour timepoint. The scratch wound assay (Figure 4.4 B,C) 
confirmed that si-laminA transfected cells were less motile than si-control transfected cells 
(p<0.0005), as si-cntl cells moved 40% further than si-laminA cells.  
Changes in expression of CDH1, FN1, SNAI2, TGFBI, TGM2 and ZEB1 over time were 
determined by Q-PCR, using the RNA isolated from si-laminA and si-control treated 
SW480/lamA cells (Figure 4.5). Data was obtained from three independent RNA extractions 
and three technical replicates for each gene at each time point.  
There was often large variation between samples (see error bars in Figure 4.5A), resulting 
in few results that were statistically significant (Table 4.2). However, statistically significant 
differences in expression between SW480/lamA cells transfected with si-lamin A and si-
control were seen at 72hr (TGFBI), 84hr (SNAI2, TGFBI) and 96hr (ZEB1) post-transcription.  
TGFBI expression was consistently lower in si-lamin A transfected cells. The difference was 
statistically significant at the 72hr (p<0.05) and 84hr (p<0.005) timepoints. This is 
consistent with the microarray and QPCR data, in which TGFBI expression was up-regulated 
in SW480/lamA cells. We would expect TGFBI expression to be reduced in SW480/lamA 
cells transfected with si-lamin A which show reduced cell motility, as TGFBI is known to 
promote metastasis when overexpressed in SW480 cells (Ma et al., 2008). 
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Figure 4.4: siRNA knockdown of lamin A causes decreased cell motility in SW480 
colorectal cancer cells 
A Representative phase-contrast images of the start and end time points of the cell wounding 
assay. Cells were grown in 6-well plates and wounded at 96 hours post-transfection with si-
lamin A or si-cntl. Scale bars = 50μm. 
B The mean distance moved by cells in 24 hours was calculated from the phase-contrast images. 
In each experiment, four locations were chosen for each of three biological replicates and 
images were taken every 15 minutes for 24 hours. The experiment was performed on three 
separate occasions. Error bars represent the standard error calculated from the nine biological 
replicates performed for each siRNA type. Si-cntl cells moved 40% further than si-laminA cells 
(p<0.0005; *****). 
 
 
 
 
 
 
 
 
Figure 4.5: siRNA knockdown of lamin A causes changes in gene expression in SW480 
colorectal cancer cells over time 
A Quantitative real time PCR was used to measure the expression of CDH1, FN1, SNAI2, TGFBI, 
TGM2 and ZEB1 at 60, 72, 84 and 96 hours post siRNA transfection. The data was analysed using 
the ddCt method, wherein expression levels were normalised to GAPDH.  Biological triplicates 
were analysed and technical triplicates were performed for each sample. Error bars show 
standard errors of biological replicates. * = p<0.05, *** = p<0.005 
B As above, however, in this graph expression levels of each gene in si-laminA treated cells are 
shown as relative to those in si-control treated cells. Relative differences in gene expression 
were measured using the log10 of the mean 2-ddCt. * = p<0.05, *** = p<0.005 
***** 
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Table 4.2: P values for the differences in gene expression between si-lamin A and si-cntl 
treated SW480/lamA cells 
  
 
 
 
P values calculated using a 1 sample T test, showing the statistical significance of the difference 
in expression levels of target genes measured in SW480/lamA cells treated with si-lamin A or 
si-cntl. 
 
There were no statistically significant differences found in FN1 expression, however, FN1 
expression was lower in si-lamin A treated cells at the 96hr timepoint with a p value of 
0.055, which was almost statistically significant. We would expect FN1 expression to be 
lower in si-lamin A treated cells, as FN1 expression was increased in SW480/lamA cells in 
the microarray and Q-PCR data.  
In previous experiments, levels of expression of SNAI2 were not consistent, as expression 
was higher in SW480/lamA cells in the microarray, but lower in SW480/lamA cells in the 
QPCR data. In this experiment, expression levels of SNAI2 were not significantly different at 
most of the timepoints assayed, however SNAI2 expression was downregulated in si-lamin 
A cells at the 84hr timepoint (p<0.05).  
In the microarray experiment, ZEB1 expression was higher in SW480/lamA cells; however 
no statistically significant changes were seen in ZEB1 expression when comparing 
SW480/lamA and SW480/cntl cells using QPCR. Expression levels of ZEB1 were not 
significantly different in cells transfected with si-lamin A and si-control at most of the 
timepoints assayed, however ZEB1 expression was upregulated in si-lamin A cells at the 
96hr timepoint (p<0.05). This is inconsistent with the findings from the microarray 
experiment.  
As TG2 is known to induce EMT, was up-regulated 2.64 fold in SW480/lamA cells in the 
microarray experiment, and was shown to be overrepresented in the cytoskeletal fraction 
of SW480/lamA cells, we hypothesised that TGM2 would be down-regulated in cells 
transfected with si-lamin A. However, contrary to our expectations, TGM2 expression levels 
were not significantly different.  
 
CDH1 FN1 SNAI2 TGFBI TGM2 ZEB1 
60hr 0.107 0.599 0.337 0.151 0.153 0.901 
72hr 0.137 0.265 0.933 0.048 0.244 0.681 
84hr 0.746 0.544 0.047 0.003 0.965 0.306 
96hr 0.188 0.055 0.662 0.244 0.812 0.023 
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4.3.4. The effect of down-regulation of lamin A by siRNA 
transfection on TGFBI protein expression over time 
Lastly, we wanted to investigate whether changes in expression of TGFBI occurred between 
transfection of siRNA causing a knockdown of lamin A, and the change in cell motility 
measured between 96-120 hours post-transfection. Immunoblots were used to assay the 
expression of TGFBI every 24 hours between 48-120hours post-transfection with either si-
lamin A or si-control. It is apparent that expression levels of TGFBI in both si-laminA and si-
control transfected cells increase over time, as the cells become more confluent. 
Expression of TGFBI was approximately equal compared to control cells between 48-120 
hours after transfection (Figure 4.6).  
 
 
                 
 
 
 
 
 
 
 
 
 
Figure 4.6: The effect of siRNA knockdown of lamin A on expression of TGFBI 
A Immunoblot of whole cell extracts from SW480/lam A cells transfected with si-laminA or si-
control resolved on a 10% SDS-PAGE gel and probed with anti-TGFBI antibody. Actin was used 
as a loading control. Cell pellets were harvested at 48, 72, 96 and 120 hours post transfection 
with siRNA. 
B Densitometric analysis of TGFBI expression in SW480/lamA cells transfected with si-lamin A 
compared to those transfected with si-control. Images were taken with Fujifilm Intelligent Dark 
Box II and relative densities were measured with Image J software. Error bars represent 
standard error of three biological replicates. 
A 
B 
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4.4. Discussion 
In this chapter siRNA was used to downregulate expression of lamin A and GFP-lamin A to 
confirm that the motility changes shown in Chapter 2 were a direct consequence of 
expression of lamin A, and to assess the effect of downregulation of lamin A on gene and 
protein expression over time.  
Knockdown of endogenous lamin A was highly successful, with a decrease in protein 
expression evident from 24 hours after transfection and over 95% reduction in expression 
by 120 hours after transfection. Expression of GFP-lamin A was reduced by over 50% 120 
hours after transfection. The wound closure rate was not significantly slower in si-lamin A 
treated cells compared to control cells 72-96 hours after transfection, however si-lamin A 
cells moved over 40% more slowly than control cells when assayed 96-120 hours post-
transfection. These findings confirm our previous finding that upregulation of lamin A in 
SW480 CRC cells causes increased cell motility.  
To test the hypothesis that knockdown of lamin A would lead to changes in expression of 
TGFβ-regulated genes previously identified in this investigation, we analysed the 
expression of CDH1, FN1, TGFBI, SNAI2, TGM2 and ZEB1 at 12 hour timepoints after the 
knockdown of lamin A and before the observed change in cell motility. We hypothesised 
that siRNA knockdown of lamin A would lead to an MET in which decreased expression of 
TGM2 and TGFBI would be followed by decreased expression of SNAI2 and ZEB1 and 
subsequent increased expression of CDH1 and decreased expression of FN1.  
In partial accordance with this hypothesis, there was decreased expression of TGFBI at the 
72hr (p<0.05) and 84hr (p<0.005) timepoints and decreased SNAI2 expression at the 84hr 
timepoint (p<0.05) in si-lamin A transfected cells compared to control cells.  
Although the decrease in cell motility in cells transfected with si-lamin A compared to 
control cells was extremely reproducible (p<0.0005), when assaying gene expression using 
Q-PCR there was often large variation between the three replicate samples, resulting in few 
results that were statistically significant. Increasing the number of biological replicates may 
give a more accurate representation of the changes occurring in the cells and may increase 
the number of statistically significant changes seen.  
Unexpectedly, ZEB1 expression was higher in si-lamin A cells 96hrs after transfection 
(p<0.05). Expression levels of ZEB1 in SW480/lamA cells have been inconsistent throughout 
this study. In the microarray experiment, ZEB1 expression was higher in SW480/lamA cells, 
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yet no statistically significant changes were seen in ZEB1 expression when comparing 
SW480/lamA and SW480/cntl cells using QPCR. It is possible that changes in ZEB1 
expression occur predominantly at the leading edge of the cell. Invasive cells that have 
undergone EMT are typically found at the invasion front of CRCs, whereas the central cells 
of the tumour have more characteristics of epithelial cells (Brabletz et al., 2001; Hlubek et 
al., 2007). Repressors of E-cadherin such as ZEB1 have been shown to be highly expressed 
and E-cadherin expression reduced at the invasive front of cancers (Hlubek et al., 2007; 
Huszar et al., 2010; Spaderna et al., 2006). Migrating cells at the invasive front of a tumour 
contain membrane protrusions that form a leading edge. Some proteins such as GPR56, 
APC and phospho-β-catenin have been shown to accumulate at the leading edge of 
migrating cells (Faux et al., 2010; Shashidhar et al., 2005). The change in expression of ZEB1 
and other genes of interest may therefore be seen most predominantly in the protein 
expression at the leading edge of the cell. Future experiments will include examining the 
expression and distribution of the proteins encoded by the genes of interest. 
The results suggest that a change in total expression levels of TGM2, CDH1 and FN1 is not 
required to mediate the effects of lamin A expression on cell motility. However, these 
genes may regulate lamin A-mediated cell motility through changes in the levels of TG2, E-
cadherin and fibronectin protein expression, or in the distribution of these proteins within 
the cell. It is also possible that expression of these genes is regulated by lamin A expression 
but does not have an effect on cell motility in the SW480 cell line.  
The most significant change in gene expression was that of TGFBI, which was consistently 
lower in si-lamin A transfected cells compared to control cells. This is consistent with the 
microarray and QPCR data, in which TGFBI expression was up-regulated in SW480/lamA 
cells and with previous studies, in which TGFBI was shown to promote metastasis when 
overexpressed in SW480 cells (Ma et al., 2008). However, expression of TGFBI protein was 
approximately equal compared to control cells between 48-120 hours post-transfection.  
Expression levels of TGFBI protein in both si-laminA and si-control transfected cells 
increased over time, as the cells became more confluent. It is possible that the effect of the 
density of cells on TGFBI expression is masking any differences between TGFBI expression 
in SW480/lamA and SW480/cntl cells. TGFBI expression has been shown to be density 
dependent in human corneal epithelial cells (Wang et al., 2002); however in this study the 
transcript levels reduced as the cell density increased. Expression levels of proteins 
encoded by some of the other genes investigated in this study, such as CDH1 and SNAI2, 
are also known to be affected by cell density. Levels of E-cadherin increase as the cell 
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density increases (Maeda et al., 2005) and Snai2 has been shown to regulate E-cadherin in 
SW480 cells in a cell density dependent manner (Conacci-Sorrell et al., 2003). However, it 
must be noted that the effects of cell density on protein expression may not affect 
comparisons between si-lamin A and si-control transfected cells, as all the cells were at 
equal density at each timepoint assayed.  
TGFBI encodes an extracellular matrix protein which is induced by TGFβ and is ubiquitously 
expressed in most normal human tissues, apart from in the brain (Skonier et al., 1992; 
Thapa et al., 2007; Zhao et al., 2002). It associates with many other ECM proteins including 
fibronectin, integrins and collagens (Bae et al., 2002; Billings et al., 2002). TGFBI is thought 
to mediate cell motility and adhesion through its interaction with integrins (Bae et al., 
2002; Kim et al., 2003). Reduced expression of TGFBI has been found in some human 
cancer cell lines and tumours (Calaf et al., 2008; Zhao et al., 2006; Zhao et al., 2002) and 
elevated expression has been found in some colorectal tumour samples (Agrawal et al., 
2002; Buckhaults et al., 2001; Kitahara et al., 2001; Notterman et al., 2001). Like TGFβ, the 
function of TGFBI in cancer cells is complex, as TGFBI can either promote cancer 
progression or act as a tumour suppressor (Ma et al., 2008; Zhang et al., 2009). 
Interestingly, the untransfected SW480 cell line contains very low levels of TGFBI protein, 
whereas the cell line SW620, derived from a lymph node metastasis from the same patient, 
expresses much higher levels of TGFBI protein (Leibovitz et al., 1976; Ma et al., 2008).  
SNAI2 expression was also decreased 84 hours after transfection (p<0.05) in si-lamin A 
transfected cells compared to control cells. Snai2 is a member of the Snail family of zinc 
transcription factors. It is a well known inducer of EMT (Hajra et al., 2002; Savagner et al., 
1997), a downstream mediator of TGFβ (Choi et al., 2007; Joseph et al., 2009) and is known 
to promote cell motility and invasion in cancer cells (Joseph et al., 2009; Katafiasz et al., 
2011). The relationship between expression of lamin A and expression of SNAI2 has not 
been consistent in this study. In the microarray experiment, SNAI2 was found to be 4.05 
fold up-regulated in SW480/lamA cells compared to control cells, however SNAI2 
expression was significantly lower in SW480/lamA cells as assessed by Q-PCR.  
As has been suggested for ZEB1, the change in expression of SNAI2 and TGFBI may be seen 
predominantly in a change of Snai2 and TGFBI protein expression at the leading edge of the 
cell. Future experiments using immunofluorescence in combination with wounding assays 
will seek to test this hypothesis. 
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The data suggest that knockdown of lamin A forms in SW480/lamA cells leads to a decrease 
in expression of TGFBI and SNAI2, followed by a decrease in cell motility. It is unclear from 
the data gathered so far whether or not this change in cell motility is caused by an MET. 
The observed decrease in cell motility may be also caused in part by other genes in 
Network1 that we did not assess, or by other signalling systems regulated by TGFβ. In 
future experiments, I would examine expression of the remaining genes in Network 1 after 
siRNA knockdown of lamin A. Nothing is yet known about a potential link between TGFBI 
and SNAI2 expression. Further experiments are required to assess if TGFBI and SNAI2 are 
directly causing the change in cell motility. This could be achieved by measuring the rate of 
cell motility after either overexpressing the genes in SW480/cntl cells or using siRNA to 
knockdown gene expression in SW480/lamA cells.  
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CHAPTER FIVE   
General Discussion 
5.1 Background and aims of thesis 
Lamins are multifunctional proteins that are often aberrantly expressed in tumours. Many 
studies show lamin A/C to be down-regulated in tumour cells, but expression is also 
frequently increased or up-regulated (Foster et al., 2010). Often expression levels vary 
dramatically even within cancer subtypes; for example, in CRC and basal cell carcinomas, A-
type lamin expression can be positive, reduced or negative (Moss et al., 1999; Tilli et al., 
2003; Venables et al., 2001; Willis et al., 2008).  
Expression of lamin A in CRC cells promotes increased cell motility (Willis et al., 2008). In 
wounding assays, wound closure was significantly faster in CRC cells transfected with GFP–
lamin A compared with control cells transfected with GFP alone. The same study revealed 
that patients with CRC tumours expressing A-type lamins were almost twice as likely to die 
from their disease compared with clinicopathologically identical patients whose tumours 
were negative for expression of A-type lamins (Willis et al., 2008). A-type lamins are 
therefore potential biomarkers for poor prognosis in CRC.  
The central aim of this thesis was to investigate the mechanisms by which over-expression 
of lamin A in CRC cells causes increased cell motility, leading to a poor prognosis for 
patients. The findings of Willis et al. suggest that lamin A may influence cell motility 
through the regulation of actin dynamics and cell adhesion, as GFP-lamin A expression was 
shown to control a pathway in which up-regulated expression of the actin bundling protein 
T plastin led to down-regulated expression of the cell adhesion molecule E-cadherin (Willis 
et al., 2008). My aim was to investigate these findings further by using both quantitative 
proteomics and genomics. As initial approaches, a proteomic study was used to assess the 
organisation of the cytoskeleton, and a microarray experiment was used to examine 
genome wide changes induced in response to lamin A over-expression.  
5.2 Over-expression of lamin A causes changes in the 
organisation of the cytoskeleton 
To investigate cytoskeletal organisation in this study, it was necessary to use a highly 
reproducible procedure to isolate the cytoskeleton for analysis with 2D DIGE so that 
quantitative comparisons could be made. To do this, I optimised a biochemical 
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fractionation protocol for the preparation of cytoskeletal fractions, and this technique was 
shown to produce extremely reproducible profiles of protein expression in 2D gels. This 
protocol has been shared with investigators in Spain who wish to analyse the cytoskeleton 
in their work, and has recently been published (Foster et al., 2011). This protocol should 
therefore be a useful tool for those who wish to investigate aspects of the cytoskeleton. 
This study is the first to use quantitative proteomics to investigate changes linked to cancer 
cell motility in a cytoskeletal fraction. Using 2D DIGE, 64 protein spots showed changes in 
representation within the cytoskeleton of SW480/lamA cells compared to SW480/cntl cells, 
and there was a large enough amount of protein in 29 of these spots for them to be 
identified using mass spectrometry. In future experiments, to identify the remaining 
proteins in this fraction, we could use SILAC (stable isotope labelling with amino acids in 
cell culture) technology, which is thought to provide highly sensitive detection of protein 
changes (Boisvert and Lamond, 2010; Ong et al., 2002). In this procedure, cells of interest 
would be labelled with amino acids containing stable isotopes such as deuterium or 13C, 
and comparisons would be made with control cells containing non-labelled amino acids.  
The majority of proteins identified in the 2D DIGE investigation were either components/ 
cross-linkers of the cytoskeleton, protein chaperones or translation initiation/elongation 
factors. The finding that tissue transglutaminase (TG2) was highly over-represented in the 
cytoskeleton fraction of SW480/lamA cells is very interesting, as TG2 may cause some of 
the changes in protein association with the cytoskeleton found in these cells. TG2 forms 
intramolecular and intermolecular crosslinks by catalysing the formation of ε-(γ-glutamyl) 
lysine isopeptide bonds between proteins. Many of the proteins identified in this study, 
such as actin, α-actinin, EF-1α, EF-1γ, Hsp60 and members of the Hsp70 family are known 
to be TG2 substrates, and other substrates include the cytoskeletal proteins tubulin, 
myosin and cofilin (Nemes et al., 1997; Orru et al., 2003; Puszkin and Raghuraman, 1985; 
Robinson et al., 2007). The changes observed in the cytoskeleton may be a result of TG2 
crosslinking actin, vimentin and α-actinin to other cytoskeleton proteins. The under-
representation of chaperonin proteins in the cytoskeletal fraction may also be explained by 
altered regulation of the cross-linking of these proteins to the cytoskeleton by TG2. Further 
experiments to determine the differences between TG2 crosslinking activity in 
SW480/lamA and SW480/cntl cells would be very informative. Affinity isolation combined 
with SILAC technology could be used to identify TG2 binding partners and to assess any 
differences between the cell types. Double-immunofluorescence staining could also be 
used to visualise potential TG2 co-localisation with proteins of interest in CRC cells. 
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Five translation initiation/elongation factors, many of which have known roles in cancer, 
were shown to be over or under-represented in the cytoskeletal fraction of SW480/lamA 
cells. This may reflect an association between transcriptional machinery and the 
cytoskeleton or nuclear matrix. Future work should focus on using immunofluorescence to 
visualise the intracellular distribution of these proteins and to assess their association with 
different cytoskeletal proteins.  
To further elucidate the mechanism leading to increased cell motility in these cells, IPA was 
used to analyse a genome-wide DNA microarray experiment which compared gene 
expression in SW480/lamA and SW480/cntl cells. Over-expression of lamin A led to large 
scale changes in gene expression; over 1200 probesets were differentially expressed. The 
most significant interaction network identified by IPA highlighted genes linked to cancer, 
cellular movement and cellular growth and proliferation. This network had a highly 
significant score of 44 and 31 out of the 35 genes included were taken from the microarray 
dataset. To validate the microarray data, expression of a subset of eight out of eleven 
Network 1 genes examined was independently confirmed using Q-PCR. This network 
therefore contained over 30 genes which may be involved in the mechanism that causes 
increased cell motility in cells over-expressing lamin A.  
The data from the genomic and proteomic studies, coupled with the finding that expression 
of lamin A causes increased expression of the actin bundling protein T-plastin (Willis et al., 
2008), suggest that lamin A expression causes changes in the organisation of the actin 
cytoskeleton. Different forms of filamentous actin are found in cells, including stress fibres 
comprising contractile bundles of actin typically held together by α-actinin, actin 
meshworks in the cell cortex and lamellipodia and highly oriented, polarised cables in 
filopodia. In the proteomics study, cells over-expressing lamin A were found to have higher 
levels of insoluble β-actin and increased association of the actin cross-linking protein α-
actinin with the cytoskeleton compared to control cells. A number of the genes in Network 
1 also encode proteins known to be associated with the actin cytoskeleton, including 
IGF2BP1 and CDC42EP5. CDC42 effector protein 5 induces the assembly of actin filaments 
(Hirsch et al., 2001) and ectopic expression of CDC42EP5 in fibroblasts has been shown to 
cause loss of stress fibres and extension of protrusive lamellipodia (Joberty et al., 1999). 
IGF2BP1 binds β-actin mRNA, localizing it to sites of active actin polymerisation, where it 
modulates cell migration (Huttelmaier et al., 2005; Ross et al., 1997).  
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The reduced association of chaperonin proteins, particularly of nucleophosmin, within the 
cytoskeleton might alter the balance between different forms of actin. Nucleophosmin is 
thought to mediate changes in actin cytoskeleton dynamics, as increased expression of 
nucleophosmin has been shown to lead to decreased stress fibre formation (Sandsmark et 
al., 2007). EMT induced by TGFβ results in the reorganisation of cortical actin into 
longitudinal stress fibres (Miettinen et al., 1994; Piek et al., 1999; Zavadil et al., 2001). In 
EMT, TGFβ targets guanine nucleotide exchange factors, which activate Rho GTPases, 
which lead to formation of actin stress fibres (Bhowmick et al., 2001; Ridley and Hall, 1992; 
Shen et al., 2001). TG2 is also known to co-localise with stress fibres in human umbilical 
vein endothelial cells (Chowdhury et al., 1997). It would be interesting to investigate the 
structure of actin filaments in SW480/lamA and SW480/cntl cells using 
immunofluorescence with fluorescently tagged phalloidin, a toxin that binds to filamentous 
actin.  
5.3 Over-expression of lamin A in CRC cells may cause an 
epithelial-mesenchymal transition  
It was postulated that the observed change in cell motility may arise through an EMT or an 
EMT-like process, as Network 1 contained genes encoding epithelial markers such as CDH1 
which were down-regulated and mesenchymal markers such as FN1 which were up-
regulated in SW480/lamA cells. There was also found to be a statistically significant overlap 
between IPA lists of genes linked to EMT and the microarray dataset. Three of the proteins 
identified in the 2D DIGE experiment are known to be involved with this process: vimentin 
is a typical mesenchymal marker (Ivaska, 2011), TG2 is known to induce EMT (Kumar et al., 
2010; Shao et al., 2009) and rearrangement of the actin cytoskeleton is a hallmark of EMT 
(Yilmaz and Christofori, 2009). Many of the genes in Network 1 encode proteins which are 
known to induce EMT or EMT-like responses, including SNAI2 (Hajra et al., 2002; Savagner 
et al., 1997), BMP4 (Hamada et al., 2007; Molloy et al., 2008), MSX2 (Hamada et al., 2007; 
Satoh et al., 2008), EIF4E (Ghosh et al., 2009) and EGFR (Lo et al., 2007).  
It is possible that expression levels of lamin A influence TGFβ-mediated EMT. A-type lamins 
are known to be involved in regulating gene activity downstream of TGFβ, as A-type lamins 
modulate responses to TGFβ signalling in mesenchymal cells through regulation of 
transcription factors such as pRB and SMADs (Van Berlo et al., 2005). MAN1, a lamin A-
interacting protein, is also known to regulate TGFβ signalling through binding to R-Smads 
(Lin et al., 2005; Osada et al., 2003).  
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Many of the genes highlighted in Network 1 and in the 2D DIGE analysis are linked to TGFβ 
signalling. BMP4 is a member of the TGFβ superfamily. SERPINE1 and SNAI2 are up-
regulated by TGFβ and AREG is downregulated by TGFβ (Akiyoshi et al., 2001; Choi et al., 
2007; Joseph et al., 2009). eIF4E is linked to TGFβ-mediated EMT, as TGFβ activates mTOR, 
inducing the phosphorylation of 4E-BP1, which causes dissociation of EIF4E from 4E-BP1, 
increasing protein synthesis (Hay and Sonenberg, 2004; Lamouille and Derynck, 2007). 
TGFβ and TG2 interact cooperatively, as TG2 expression is regulated by TGFβ and TG2 is 
involved in the ECM storage and activation of latent TGFβ (LTGFβ) (Kojima et al., 1993; 
Ritter and Davies, 1998; Telci et al., 2009; Verderio et al., 1999). BMP4 is also involved in 
regulation of TG2 gene expression (Ritter and Davies, 1998). 
Currently there are no published findings about the relationship between lamin A 
expression and EMT, therefore the suggestion that lamin A may cause an EMT or an EMT-
like process is novel.  
5.4 siRNA knockdown of lamin A leads to down-regulation of 
TGFBI and SNAI2 expression followed by reduced cell motility 
In the final chapter of this thesis, the effect of siRNA knock down of lamin A on genes 
involved in TGFβ signalling was investigated. The aim was to understand which of the genes 
known to be regulated by lamin A expression are responsible for causing the changes in cell 
motility. 
Transfection of si-lamin A resulted in a reduction of endogenous lamin A expression by over 
95% and a reduction of GFP-lamin A expression by over 50% by 120 hours after 
transfection. Cells transfected with si-lamin A were less motile than control cells, 
confirming that the increased cell motility shown in Chapter 2 was a direct consequence of 
the over-expression of lamin A. Reduced cell motility in si-lamin A transfected cells was 
preceded by decreased expression of TGFBI and SNAI2. These findings are consistent with 
the microarray and QPCR data, in which TGFBI expression was up-regulated in SW480/lamA 
cells and with previous studies, in which TGFBI was shown to promote metastasis when 
overexpressed in SW480 cells (Ma et al., 2008). However, expression of TGFBI protein was 
similar in si-lamin A and si-control cells between 48-120 hours post-transfection. As 
migrating cells at the invasive front of a tumour have been shown have different protein 
expression compared to the cells away from the invasive front (Hlubek et al., 2007; Huszar 
et al., 2010; Spaderna et al., 2006), it is possible that changes in expression of SNAI2 and 
TGFBI may be seen predominantly in a change of Snai2 and TGFBI protein expression at the 
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leading edge of the cell. Future experiments using immunofluorescence in combination 
with wounding assays will seek to test this hypothesis. 
TGFBI is induced by TGFβ (Skonier et al., 1992) and is thought to mediate cell motility and 
adhesion through its interaction with integrins (Bae et al., 2002; Kim et al., 2003). Its 
expression is reduced in some cancer cell lines and tumours and elevated in others 
(Agrawal et al., 2002; Buckhaults et al., 2001; Calaf et al., 2008; Kitahara et al., 2001; 
Notterman et al., 2001; Zhao et al., 2006; Zhao et al., 2002). TGFBI can either act as a 
tumour suppressor or a promoter of cancer progression (Ma et al., 2008; Zhang et al., 
2009). Interestingly, the untransfected SW480 cell line contains very low levels of TGFBI 
protein, whereas its metastatic counterpart SW620 expresses much higher levels of TGFBI 
protein (Leibovitz et al., 1976; Ma et al., 2008).  
Snai2 is a member of the Snail family of zinc transcription factors. Also known as Slug, it is a 
well known inducer of EMT (Hajra et al., 2002; Savagner et al., 1997), a downstream 
mediator of TGFβ (Choi et al., 2007; Joseph et al., 2009) and is known to promote cell 
motility and invasion in cancer cells (Joseph et al., 2009; Katafiasz et al., 2011). In the 
microarray experiment, SNAI2 was found to be 4.05 fold up-regulated in SW480/lamA cells 
compared to control cells, however SNAI2 expression was significantly lower in 
SW480/lamA cells as assessed by Q-PCR. 
In future experiments, to assess whether TGFBI and SNAI2 are directly causing the change 
in cell motility, the genes could be overexpressed in SW480/cntl cells or knocked down in 
SW480/lamA cells followed by assessment of cell motility using wounding assays. As the 
expression levels of genes using Q-PCR were very variable between replicates in this 
experiment, it would also be useful to repeat the assessment of gene expression with a 
larger number of biological repeats. This may give a more accurate representation of the 
changes occurring in the cells. 
5.5 Conclusions 
It is unclear from the data gathered so far whether or not the change in cell motility 
induced by lamin A over-expression is caused by an EMT. It should be noted that the IPA 
analysis did not highlight EMT in Networks 1-10 and changes in microarray and Q-PCR 
assessments of expression of SNAI2, ZEB1, AREG and EREG were inconsistent. In Chapter 4, 
no significant differences were seen in CDH1, FN1 or TGM2 expression between 60-96 
hours post transfection with si-laminA and ZEB1 expression was unexpectedly higher 96 
hours after transfection.  
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It is possible that the changes seen in our system represent a novel pathway that is similar 
to EMT but not a classical EMT.  Many of the genes and proteins identified in this thesis are 
known to affect cell motility. FN1, EIF4E, NRP1, EGFR and SERPINE1, which were all 
upregulated in SW480/lamA cells, all encode proteins which have been found to be 
expressed in highly motile and invasive cancer cells (Chazaud et al., 2002; Miao et al., 2000; 
Shankar et al., 2010; Shibata et al., 1997; Verbeek et al., 1998). Decreased expression levels 
of EMP1, which was downregulated in SW480/lamA cells, are known to correlate with 
metastatic cells (Zhang et al., 2011). Inhibition of nucleophosmin shuttling can cause 
increased cell motility (Sandsmark et al., 2007) and elevated Hsp60 levels correlate with 
high occurrence of lymph node metastases in large bowel carcinomas (Cappello et al., 
2005a). Actinin α4 is enriched at the leading edges of invasive cells (Honda et al., 1998) and 
has been shown to increase cell motility in CRC (Honda et al., 2005). Down-regulation of 
actinin α4 reduces cell motility in glioblastoma and lung fibroblasts (Sen et al., 2009; Shao 
et al., 2010a). 
Experiments following on from this study should focus on identifying which genes and 
proteins are required for increased cell motility to occur following over-expression of lamin 
A in CRC cells. The data in this thesis is an excellent resource for work in this area, as the 
proteomics study revealed 13 proteins and Network 1 contains 35 genes which may be 
necessary in this process. Networks 2-10 were also all shown by IPA to be statistically 
significant, indicating that these networks would also be a valuable resource for future 
work. Both TGFB1 and TGFBI are present in Networks 1-10: TGFB1 is a node in Network 7 
and TGFBI is present in Network 9. As both Networks 7 and 9 are linked to cellular motility, 
these would be ideal starting points for future work. In addition, components of the 
canonical and non-canonical TGFβ pathways should be studied. siRNA knockdown of 
proteins of interest followed by wounding assays will be vital to assess the effect of 
individual proteins on cell motility. It is hoped that a mechanism will eventually be 
discovered which describes the order of events which follow a change in expression of 
lamin A, leading to a change in cell motility.  Once the mechanism has been revealed, other 
cancer cell lines and tumours should be examined, to discover if the findings are applicable 
to tumours originating from other locations.  
A number of the proteins and genes identified in this study, including EF-1δ, mortalin, 
Hsp60, actinin α4, TG2, E-cadherin, Snai2 and vimentin are known to be linked to cancer 
prognosis. It would be interesting to assess the effect of expression of these proteins on 
prognosis of CRC.  This could be done using a tissue bank such as the Netherlands Cohort 
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Study on Diet and Cancer (NLCS), a prospective cohort study which contains tissue samples 
linked to clinicopathological data. There is also another tissue array bank, located in 
Western Australia, which is larger than the NLCS and contains several thousand tissue 
samples. This databank could be used to assess the use of proteins of interest as predictive 
markers to determine whether expression of these proteins influences the response of 
tumours to adjuvant therapies. Expression of TGFBI, for example, has already shown to be 
associated with response to chemotherapy in lung cancer (Irigoyen et al., 2010). Although 
lamin A is already known to be a prognostic biomarker for CRC, it would be more useful to 
identify a panel of biomarkers which could be used as a prognostic tool for CRC. A panel of 
biomarkers would be expected to allow clinicians to make more accurate predictions of 
prognosis compared to predictions based on the current Dukes and TNM classification 
systems or a single biomarker.  
In conclusion, the data described in this thesis suggest that expression of lamin A in CRC 
cells causes changes in the organisation of the actin cytoskeleton and in TGF-β signalling, 
potentially involving an epithelial to mesenchymal transition, leading to increased cell 
motility and an increased risk of death from cancer. 
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Appendix  
Network diagrams 2-10 produced by IPA 
Affymetrix microarray data comparing RNA from SW480/cntl and SW480/lamA cell lines 
was analysed using IPA. Interaction networks were produced from probesets displaying 
greater than 2.5 fold differential expression and show known literature curated 
interactions with other molecules. The networks were analysed for significance against 
known biological functions. Networks are ranked by their ‘Score’, which is calculated by 
IPA, and takes into account the number of network eligible molecules in the network, its 
size, the total number of network eligible molecules analysed and the total number of 
molecules in the knowledge base. 
The number of ‘Focus molecules’ indicates the number of genes in each network that were 
present in the microarray probeset. These genes are circled in the diagrams: genes in red 
circles were up-regulated in SW480/lamA when compared to SW480/cntl and genes with 
blue circles were down-regulated. Each network clustered together genes with particular 
functions: 
Network 2: Cell-To-Cell Signalling and Interaction, Cellular Assembly and Organization, 
Nervous System Development and Function 
Network 3: Cancer, Cellular Growth and Proliferation, Cell Death 
Network 4: Cellular Growth and Proliferation, Cell-To-Cell Signalling and Interaction, 
Cellular Function and Maintenance   
Network 5:  Cell Signalling, Small Molecule Biochemistry, Immunological Disease 
Network 6: Lipid Metabolism, Small Molecule Biochemistry, Molecular Transport 
Network 7: Cellular Movement, Connective Tissue Development and Function, Cancer 
Network 8: Cell-To-Cell Signalling and Interaction, Haematological System Development 
and Function, Immune Cell Trafficking 
Network 9: Cell Death, Cellular Movement, Cell Cycle 
Network 10: Neurological Disease, Psychological Disorders, Cell-To-Cell Signalling and 
Interaction  
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Network 2 
Cell-To-Cell Signalling and Interaction,  
Cellular Assembly and Organisation,  
Nervous System Development and 
Function 
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
136 
 
Network 2: Cell-To-Cell Signalling and Interaction, Cellular Assembly and Organization, 
Nervous System Development and Function   
Score: 20  Focus molecules: 19  
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ETV1 8.59 ets variant gene 1 
KRT13 11.3 keratin 13 
NT5E 
4.84, 6.48, 
11.28, 26.97 
5'-nucleotidase, ecto (CD73) 
PTPRG 5.19 protein tyrosine phosphatase, receptor type, G 
S100P 7.61 S100 calcium binding protein P 
SLC39A8 2.38, 4.25 solute carrier family 39 (zinc transporter), member 8 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ASCL2 2.98 achaete-scute complex homolog 2 (Drosophila) 
BSN 2.76 bassoon (presynaptic cytomatrix protein) 
GDA 3.09, 30.96 guanine deaminase 
GPR64 4.08 G protein-coupled receptor 64 
HBA1 
2.77, 2.85, 2.85, 
3.02, 3.50, 3.96 
hemoglobin, alpha 1 
IFITM1 4.94, 6.38 interferon induced transmembrane protein 1 (9-27) 
INHBB 2.99 inhibin, beta B 
SERPINA3 2.63 serpin peptidase inhibitor, clade A, member 3 
SNAP25 
4.49, 7.66, 
10.44 
synaptosomal-associated protein, 25kDa 
STON2 2.51 stonin2 
SYP 2.78 synaptophysin 
SYT1 2.43, 2.88 synaptotagmin I 
TRIM9 2.65 tripartite motif-containing 9 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
ACTN2 actinin, alpha 2 
APP amyloid beta (A4) precursor protein 
ATAD2 ATPase family, AAA domain containing 2 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 
CTSD cathepsin D 
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
ESR1 estrogen receptor 1 
KLK2 kallikrein-related peptidase 2 
KLK3 kallikrein-related peptidase 3 
MAPT microtubule-associated protein tau 
MLL2 myeloid/lymphoid or mixed-lineage leukemia 2 
NCOA3 nuclear receptor coactivator 3 
PCLO piccolo (presynaptic cytomatrix protein) 
SNAPIN SNAP-associated protein 
SYT2 synaptotagmin II 
VAMP2 vesicle-associated membrane protein 2 (synaptobrevin 2) 
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Network 3: 
Cancer, 
Cellular Growth and Proliferation, 
Cell Death
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Network 3: Cancer, Cellular Growth and Proliferation, Cell Death  
 Score: 16 Focus molecules: 16  
 
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ABL2 2.65, 3.07 v-abl Abelson murine leukemia viral oncogene homolog 2  
AKAP12 7.47, 9.11, 12.86 A kinase (PRKA) anchor protein (gravin) 12 
DUSP5 4.16 dual specificity phosphatase 5 
EGR3 3.6 early growth response 3 
EIF4E 3.15 eukaryotic translation initiation factor 4E 
GPER 45.56 G protein-coupled estrogen receptor 1 
LATS2 4.17, 4.51 LATS, large tumor suppressor, homolog 2 (Drosophila) 
NFIB 2.02, 3.99, 5.61 nuclear factor I/B 
PLAUR 2.39, 2.72, 2.73 plasminogen activator, urokinase receptor 
RFC3 2.43, 2.51 replication factor C (activator 1) 3, 38kDa 
ROBO1 4.84 
roundabout, axon guidance receptor, homolog 1 
(Drosophila) 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
COL18A1 2.7 collagen, type XVIII, alpha 1 
FGF9 2.76 fibroblast growth factor 9 (glia-activating factor) 
NUPR1 3.48 nuclear protein 1 
SCN3B 6.63, 11.39 sodium channel, voltage-gated, type III, beta 
TRA@ 3.26 T cell receptor alpha locus 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
ANXA1 annexin A1 
BCL2L1 BCL2-like 1 
BRCA1 breast cancer 1, early onset 
BRD2 bromodomain containing 2 
CDKN2A cyclin-dependent kinase inhibitor 2A 
CSF1 colony stimulating factor 1 (macrophage) 
E2F1 E2F transcription factor 1 
HIF1A hypoxia inducible factor 1, alpha subunit 
MAPK1 mitogen-activated protein kinase 1 
MAPK3 mitogen-activated protein kinase 3 
PRL prolactin 
PTK2 PTK2 protein tyrosine kinase 2 
RAD17 RAD17 homolog (S. pombe) 
RELA 
v-rel reticuloendotheliosis viral oncogene homolog A 
(avian) 
RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1 
S100A4 S100 calcium binding protein A4 
SIVA1 SIVA1, apoptosis-inducing factor 
TNFRSF18 tumor necrosis factor receptor superfamily, member 18 
TP53 tumor protein p53 
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Network 4: 
Cellular Growth and Proliferation, 
Cell-To-Cell Signalling and Interaction, 
Cellular Function and Maintenance
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Network 4: Cellular Growth and Proliferation, Cell-To-Cell Signalling and Interaction, 
Cellular Function and Maintenance   
Score: 14  Focus Molecules: 15  
 
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ABCA1 2.58, 2.96 ATP-binding cassette, sub-family A (ABC1), member 1 
CCND2 3.12, 5.19 cyclin D2 
DUSP6 2.98, 2.99, 3.36 dual specificity phosphatase 6 
MGST1 2.36, 2.81, 3.64 microsomal glutathione S-transferase 1 
SAA1 3.29, 6.66 serum amyloid A1  
TPST1 2.98 tyrosylprotein sulfotransferase 1 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ALDH1A3 4.87 aldehyde dehydrogenase 1 family, member A3 
CEBPD 2.58 CCAAT/enhancer binding protein (C/EBP), delta 
CHGB 11.5 chromogranin B (secretogranin 1) 
CLDN11 2.85 claudin 11 (oligodendrocyte transmembrane protein) 
CLEC11A 3.04, 3.73 C-type lectin domain family 11, member A 
PSMB9 2.58 
proteasome (prosome, macropain) subunit, beta type, 9 
(large multifunctional peptidase 2) 
SLPI 2.51 secretory leukocyte peptidase inhibitor 
TNFRSF11B 3.76, 4.30 
tumor necrosis factor receptor superfamily, member 11b 
(osteoprotegerin) 
ZNF365 4.09 zinc finger protein 365 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
AEBP1 AE binding protein 1 
ANXA1 annexin A1 
CCR5 chemokine (C-C motif) receptor 5 
CD47 CD47 molecule 
CTSF cathepsin F 
HMGB1 high-mobility group box 1 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
ITGAM integrin, alpha M  
LGALS3 lectin, galactoside-binding, soluble, 3 
LIF 
leukemia inhibitory factor (cholinergic differentiation 
factor) 
MIF 
macrophage migration inhibitory factor (glycosylation-
inhibiting factor) 
MUC1 mucin 1, cell surface associated 
MUC5AC mucin 5AC, oligomeric mucus/gel-forming 
NR1H2 nuclear receptor subfamily 1, group H, member 2 
NR1H3 nuclear receptor subfamily 1, group H, member 3 
PTPRC protein tyrosine phosphatase, receptor type, C 
RUNX2 runt-related transcription factor 2 
SCARB1 scavenger receptor class B, member 1 
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Network 5: 
Cell Signalling, 
Small Molecule Biochemistry, 
Immunological Disease 
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Network 5:  Cell Signalling, Small Molecule Biochemistry, Immunological Disease 
Score: 14 Focus Molecules: 15 
 
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
HMGA2 4.1 high mobility group AT-hook 2 
KALRN 2.87 kalirin, RhoGEF kinase 
MAOA 6.22, 8.07, 12.08 monoamine oxidase A 
RIN2 28 Ras and Rab interactor 2 
RPS6KA2 2.51 ribosomal protein S6 kinase, 90kDa, polypeptide 2 
SLC7A7 2.69 
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 7 
SOCS3 2.73 suppressor of cytokine signaling 3 
TGM2 2.65 
transglutaminase 2 (C polypeptide, protein-glutamine-
gamma-glutamyltransferase) 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ARNTL2 2.69 aryl hydrocarbon receptor nuclear translocator-like 2 
CHN2 2.79 chimerin (chimaerin) 2 
HSP90B1 2.69 heat shock protein 90kDa beta (Grp94), member 1 
LNPEP 2.37, 2.58 leucyl/cystinyl aminopeptidase 
PCM1 3.09 pericentriolar material 1 
RORA 2.24 RAR-related orphan receptor A 
STMN3 2.66 stathmin-like 3 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
CCR5 chemokine (C-C motif) receptor 5 
CD86 CD86 molecule 
FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) 
IL3 interleukin 3 (colony-stimulating factor, multiple) 
IL13 interleukin 13 
IL21 interleukin 21 
IL1RN interleukin 1 receptor antagonist 
IL23A interleukin 23, alpha subunit p19 
IRF1 interferon regulatory factor 1 
JAK1 Janus kinase 1 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 
NEK2 NIMA (never in mitosis gene a)-related kinase 2 
NOS2 nitric oxide synthase 2, inducible 
PRKCD protein kinase C, delta 
RIPK2 receptor-interacting serine-threonine kinase 2 
SOCS1 suppressor of cytokine signaling 1 
STAT3 signal transducer and activator of transcription 3 
TLR2 toll-like receptor 2 
TNFRSF1B tumor necrosis factor receptor superfamily, member 1B 
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 
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Network 6 
Lipid Metabolism, 
Small Molecule Biochemistry, 
Molecular Transport
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Network 6: Lipid Metabolism, Small Molecule Biochemistry, Molecular Transport  
Score: 14      Focus Molecules: 15  
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ACSL5 2.67, 3.66 acyl-CoA synthetase long-chain family member 5 
CCR7 3.83 chemokine (C-C motif) receptor 7 
ELOVL6 2.5, 2.93 ELOVL family member 6, elongation of long chain fatty acids 
GJB2 20.67 gap junction protein, beta 2, 26kDa 
LRCH1 2.62 
leucine-rich repeats and calponin homology (CH) domain 
containing 1 
NR2F2 2.98 nuclear receptor subfamily 2, group F, member 2 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
ABCA2 2.55 ATP-binding cassette, sub-family A (ABC1), member 2 
CD24 
2.96, 3.36, 
5.89, 6.32, 
7.00, 7.02  
CD24 molecule 
DSC2 2.94 desmocollin 2 
DYNC2LI1 2.5 dynein, cytoplasmic 2, light intermediate chain 1 
EPHX1 3.18 epoxide hydrolase 1, microsomal (xenobiotic) 
GPR155 4.82, 5.04 G protein-coupled receptor 155 
LEPR 2.83 leptin receptor 
MAFB 2.25, 3.91 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
B (avian) 
TTPA 3.57 tocopherol (alpha) transfer protein 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
ACOX1 acyl-CoA oxidase 1, palmitoyl 
ADFP perilipin 2 
APOM apolipoprotein M 
CYB5A cytochrome b5 type A 
DBI 
diazepam binding inhibitor (GABA receptor modulator, acyl-
CoA binding protein) 
EHHADH enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase 
FOXA2 forkhead box A2 
HNF4A hepatocyte nuclear factor 4, alpha 
IL4 interleukin 4 
INS1 forkhead box M1 
LEP leptin 
PDE3B phosphodiesterase 3B, cGMP-inhibited 
PMCH pro-melanin-concentrating hormone 
SC4MOL sterol-C4-methyl oxidase-like 
SC5DL sterol-C5-desaturase-like 
SCD2 stearoyl-CoA desaturase 5 
SREBF1 sterol regulatory element binding transcription factor 1 
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) 
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) 
ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 
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Network 7 
Cellular Movement, 
Connective Tissue  
Development and Function, 
Cancer
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Network 7: Cellular Movement, Connective Tissue Development and Function, Cancer  
Score: 14      Focus Molecules: 14  
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
BMP2K 
2.11, 3.17, 
4.95 
BMP2 inducible kinase 
CENPE 3.26 centromere protein E, 312kDa 
DZIP3 3.25 DAZ interacting protein 3, zinc finger 
ELK3 3.89 ELK3, ETS-domain protein (SRF accessory protein 2) 
LCN2 2.72 lipocalin 2 
LTBP2 3.89, 4.34 latent transforming growth factor beta binding protein 2 
PALLD 2.32, 2.56 palladin, cytoskeletal associated protein 
PDLIM4 4.04 PDZ and LIM domain 4 
PLAUR 
2.39, 2.72, 
2.73 
plasminogen activator, urokinase receptor 
THSD1 2.92 thrombospondin, type I, domain containing 1  
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
FOLR1 4.69 folate receptor 1 (adult) 
GNAI1 10.03, 12.68 
guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 1 
MFAP2 2.77 microfibrillar-associated protein 2 
NPNT 5.92 nephronectin 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
ASGR2 asialoglycoprotein receptor 2 
BUB1B 
budding uninhibited by benzimidazoles 1 homolog beta 
(yeast) 
CD44 CD44 molecule (Indian blood group) 
CENPF centromere protein F, 350/400kDa (mitosin) 
ERBB2 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
EZR ezrin 
GBE1 glucan (1,4-alpha-), branching enzyme 1 
HNF1A HNF1 homeobox A 
HNF4A hepatocyte nuclear factor 4, alpha 
ITGB1 
integrin, beta 1 (fibronectin receptor, beta polypeptide, 
antigen CD29 includes MDF2, MSK12) 
MCCC1 methylcrotonoyl-CoA carboxylase 1 (alpha) 
MMP9 matrix metallopeptidase 9 
NF2 neurofibromin 2 (merlin) 
PLAU plasminogen activator, urokinase 
TGFB1 transforming growth factor, beta 1 
TNF tumor necrosis factor 
TP53 tumor protein p53 
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Network 8 
Cell-To-Cell Signalling and Interaction, 
Haematological System Development and Function, 
Immune Cell Trafficking 
 
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
148 
 
Network 8: Cell-To-Cell Signalling and Interaction, Haematological System Development 
and Function, Immune Cell Trafficking   
Score: 11    Focus Molecules: 13  
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
GZMB 3.22 granzyme B 
NFATC2 2.61 
Nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2 
PPP3CB 3.2 
protein phosphatase 3 (formerly 2B), catalytic subunit, beta 
isoform 
QKI 
2.16, 2.24, 
2.74, 3.31 
quaking homolog, KH domain RNA binding (mouse) 
RNF128 29.38 ring finger protein 128 
SOCS3 2.73 suppressor of cytokine signaling 3 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
AUTS2 4.16 autism susceptibility candidate 2 
CAMK4 2.98 calcium/calmodulin-dependent protein kinase IV 
FGFR2 2.50, 2.65 fibroblast growth factor receptor 2  
HSPD1 2.6 heat shock 60kDa protein 1 (chaperonin) 
IL16 2.64, 4.28 interleukin 16 (lymphocyte chemoattractant factor) 
KCNC1 4.12 potassium voltage-gated channel, Shaw-related subfamily, 1 
PCSK1 49.8 proprotein convertase subtilisin/kexin type 1 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
ART2A ADP-ribosyltransferase 2a 
BGLAP bone gamma-carboxyglutamate (gla) protein 
CD4 CD4 molecule 
CNR1 cannabinoid receptor 1 (brain) 
ENO1 enolase 1, (alpha) 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 
FGF2 fibroblast growth factor 2 (basic) 
GAL3ST1 galactose-3-O-sulfotransferase 1 
GPNMB glycoprotein (transmembrane) nmb 
HSPG2 heparan sulfate proteoglycan 2 
IDO1 indoleamine 2,3-dioxygenase 1 
IFNB1 interferon, beta 1, fibroblast 
IFNG interferon, gamma 
IFNK interferon, kappa 
ITGA3 integrin, alpha 3 
JAG1 jagged 1 
MBP myelin basic protein 
OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa 
PSMB8 proteasome (prosome, macropain) subunit, beta type, 8  
SELE selectin E 
SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), member 9 
STAT4 signal transducer and activator of transcription 4 
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Network 9 
Cell Death, 
Cellular Movement, 
Cell Cycle  
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Network 9: Cell Death, Cellular Movement, Cell Cycle   
Score: 11     Focus Molecules: 13  
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
HSPH1 
2.48, 2.80, 
2.81 
general transcription factor IIF, polypeptide 2, 30kDa 
LRRN1 3.22 leucine rich repeat neuronal 1 
NGFR 2.98 nerve growth factor receptor (TNFR superfamily, member 16) 
PLAGL1 2.54, 2.62 pleiomorphic adenoma gene-like 1 
RAD18 2.59 RAD18 homolog (S. cerevisiae) 
SMARCA1 2.55 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 1 
TGFBI 4.3 transforming growth factor, beta-induced, 68kDa 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
HMGCS1 2.82, 4.25 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 
LPL 2.89, 3.32 lipoprotein lipase 
LRP2 3.64 low density lipoprotein-related protein 2 
MKNK1 3.15 MAP kinase interacting serine/threonine kinase 1 
NPPB 3.54 natriuretic peptide precursor B 
SEMA3A 3.86 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3A 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
ACTB actin, beta 
ANGPT1 angiopoietin 1 
APOB apolipoprotein B (including Ag(x) antigen) 
BMP6 bone morphogenetic protein 6 
CCNB1 cyclin B1 
CLU clusterin 
GADD45G growth arrest and DNA-damage-inducible, gamma 
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 
HNRNPK heterogeneous nuclear ribonucleoprotein K 
ID2 
inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
NGF nerve growth factor (beta polypeptide) 
NOTCH1 notch 1 
NTF3 neurotrophin 3 
PCBP1 poly(rC) binding protein 1 
PERP PERP, TP53 apoptosis effector 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
SCEL sciellin 
TGTP T-cell specific GTPase 1 
TOP2A topoisomerase (DNA) II alpha 170kDa 
WT1 Wilms tumor 1 
YY1 YY1 transcription factor 
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Network 10 
Neurological Disease, 
Psychological Disorders, 
Cell-To-Cell Signalling and Interaction
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Network 10: Neurological Disease, Psychological Disorders, Cell-To-Cell Signalling and 
Interaction  
Score: 11  Focus Molecules: 13  
Genes up-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
CTTN 2.55 cortactin 
GPR125 3.02 G protein-coupled receptor 125 
MEIS2 3.56 Meis homeobox 2 
PLS3 19.06 plastin 3 (T isoform) 
SACS 3.29 spastic ataxia of Charlevoix-Saguenay (sacsin) 
SLC1A1 2.76 solute carrier family 1, member 1 
   
Genes down-regulated in SW480/lamA cells  
Symbol Fold Change Entrez Gene Name 
BDNF 5.38 brain-derived neurotrophic factor 
GAD1 2.68 glutamate decarboxylase 1 (brain, 67kDa) 
GNAS 4.22 GNAS complex locus 
HUNK 4.16 hormonally upregulated Neu-associated kinase 
MAPRE3 2.75 microtubule-associated protein, RP/EB family, member 3 
NCAM1 3.34 neural cell adhesion molecule 1 
SLC1A3 2.83 
solute carrier family 1 (glial high affinity glutamate 
transporter), member 3 
   
Genes added by IPA 
Symbol   Entrez Gene Name 
ACTN2 actinin, alpha 2 
AR androgen receptor 
ARC activity-regulated cytoskeleton-associated protein 
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 
BCAR1 breast cancer anti-estrogen resistance 1 
CAMK2B calcium/calmodulin-dependent protein kinase II beta 
CAV1 caveolin 1, caveolae protein, 22kDa 
CIT citron (rho-interacting, serine/threonine kinase 21) 
DCTN1 dynactin 1 
DNM2 dynamin 2 
DRD1 dopamine receptor D1 
DRD3 dopamine receptor D3 
GNAO1 
guanine nucleotide binding protein (G protein), alpha 
activating activity polypeptide O 
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 
GRM1 glutamate receptor, metabotropic 1 
HAP1 huntingtin-associated protein 1 
HOMER1 homer homolog 1 (Drosophila) 
HSPA1B heat shock 70kDa protein 1B 
HTT huntingtin 
NEUN RNA binding protein, fox-1 homolog (C. elegans) 3 
NSF N-ethylmaleimide-sensitive factor 
PTPN5 protein tyrosine phosphatase, non-receptor type 5  
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